

WEST Search History

DATE: Monday, March 22, 2004

Hide? Set Name Query **Hit Count**

DB=USPT; PLUR=YES; OP=ADJ

<input type="checkbox"/>	L32	l31 not l10	100
<input type="checkbox"/>	L31	L30 with l1	100
<input type="checkbox"/>	L30	clostrid\$ or neurotoxin	6508

DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

<input type="checkbox"/>	L29	L28 and l15	65
<input type="checkbox"/>	L28	clostrid\$ not l25	2003

DB=PGPB; PLUR=YES; OP=ADJ

<input type="checkbox"/>	L27	US-20030166238-A1.did.	1
--------------------------	-----	------------------------	---

DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

<input type="checkbox"/>	L26	L25 and l15	25
<input type="checkbox"/>	L25	neurotoxin	405
<input type="checkbox"/>	L24	l20 and l21 and l22 and l23	9
<input type="checkbox"/>	L23	endocyt\$6 or transport\$4	354269
<input type="checkbox"/>	L22	cleav\$ or protease or proteinase	41377
<input type="checkbox"/>	L21	bind\$4	389299
<input type="checkbox"/>	L20	L19 or l17	11724
<input type="checkbox"/>	L19	L18 with l15	161
<input type="checkbox"/>	L18	"single chain"	1387
<input type="checkbox"/>	L17	L16 with l15	11675
<input type="checkbox"/>	L16	gene or plasmid or protein	250407
<input type="checkbox"/>	L15	fus\$4 or chimer\$3	225808

DB=USPT; PLUR=YES; OP=ADJ

<input type="checkbox"/>	L14	L13 same l12 same l8 not l10	2
<input type="checkbox"/>	L13	l5 same (l6 or l7)	15844
<input type="checkbox"/>	L12	l1 same l11	4544
<input type="checkbox"/>	L11	"single chain"	10437
<input type="checkbox"/>	L10	L9 and l3	25
<input type="checkbox"/>	L9	l5 same l6 same l7 same l8	35
<input type="checkbox"/>	L8	cleav\$ or protease or proteinase	97654
<input type="checkbox"/>	L7	endocyt\$6	3603
<input type="checkbox"/>	L6	transport\$	420621
<input type="checkbox"/>	L5	bind\$4	338897
<input type="checkbox"/>	L4	bnid\$4	15

<input type="checkbox"/>	L3	l1 with L2	27127
<input type="checkbox"/>	L2	gene or plasmid or protein	174117
<input type="checkbox"/>	L1	fus\$4 or chimer\$3	238926

END OF SEARCH HISTORY

File 155: MEDLINE(R) 1966-2004 Jan W2 (c) format only 2004 The Dialog Corp.

Set Items Description

Ref Items RT Index-term

E1 0 1 FUSION PROTEINS, RECOMBINANT

E2 0 1 FUSION PROTEINS, VIRAL

E3 0 *FUSION PROTEIN

E4 0 1 FUSION REGULATORY PROTEIN 1, HEAVY CHAIN

E5 0 1 FUSION REGULATORY PROTEIN-1

E6 1 FUSIONA

E7 1 FUSIONABILITY

E8 6 FUSIONABLE

E9 1 FUSIONADAS

E10 1 FUSIONADO

E11 4 FUSIONADOS

E12 349 FUSIONAL

S1 39072 'RECOMBINANT FUSION PROTEINS'

S2 28703 NEUROTOX?

S3 126 S1 AND S2

S4 32438 'TOXINS'

S5 480 S1 AND S4

S6 449 S5 NOT S3

S7 328 S6 AND PY<2000

S8 133 KEX OR YSC

S9 0 S7 AND S8

S10 11 S1 AND S8

R1 37428 81 *ENDOPEPTIDASES

R2 37428 X 81 ENDOPEPTIDASES

Ref Items Type RT Index-term

R1 37428 81 *ENDOPEPTIDASES

R2 125 X DC=D8.811.277.656.300. (ENDOPEPTIDASES)

3651 15802233 PMID: 12854151

Inhibition of HBV targeted ribonuclelease enhanced by introduction of linker. Jul 2003

3662 15377227 226.3049 PMID: 1272273

Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. May 2003

3663 15317414 2277.3060 PMID: 12890769

Reversible suppression of glutamatergic neurotransmission of cerebellar granule cells in vivo by genetically manipulated expression of tetanus neurotoxin light chain. Jul 30 2003

3664 15077658 2267.2820 PMID: 12787071

Two serine residues distinctly regulate the rescue function of Humanin, an inhibiting factor of Alzheimer's disease-related neurotoxicity : functional potentiation by isomerization and dimerization. Jun 2003

3665 14856159 22420361 PMID: 12532452

Targeted ribonuclelease can inhibit replication of hepatitis B virus. Feb 2003

3666 14819242 22505330 PMID: 12622404

PTEN regulates Akt kinase activity in hippocampal neurons and increases their sensitivity to glutamate and apoptosis. 2002

3667 14722295 2248.3980 PMID: 12595242

Issue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons. Jan 2003

3668 14682585 22454963 PMID: 12565753

Expression of a functional recombinant Phoenicia nigrovenata toxin active on K⁺ channels. Mar 1 2003

R3 0 X 1' PEPTIDE PEPTIDOHYDROLASES

R4 18851 X 1 PROTEASES

R5 7695 X 1 PROTEINASES

R6 18978 B 107 PEPTIDE HYDROLASES

R7 777 N 3 ACROSIN

R8 433 N 10 ANCROD

R9 468 N 12 ANISTRAPLASE

R10 2467 N 11 ASPARTIC ENDOPEPTIDASES

R11 385 N 11 BATOXOBIN

R12 39 N 5 BRINOLASE

R13 1096 S1 AND S11

S1 37428 'ENDOPEPTIDASES'

S2 9 S11 AND S7

S3 14 30746 MEMBRANE(5N) BIND?

S4 62079 TRANSLOCAT?

S5 63 S13 AND S14 AND S15

S6 72 S15 AND S13 NOT S16

S7 18 S0 S17 NOT SECRET?

S8 19 28490 BOTULIN? OR TETAN?

S9 20 178 S1 AND S19

S10 5 S20 AND S11

Ref Items Index-term

E1 2 AU=FRANCIS ISSAC R

E2 1 AU=FRANCIS J S A M M

E3 161 *AU=FRANCIS J

E4 2 AU=FRANCIS J A

E5 9 AU=FRANCIS J B

E6 8 AU=FRANCIS J C

E7 6 AU=FRANCIS J D

E8 51 AU=FRANCIS J E

E9 1 AU=FRANCIS J F

E10 7 AU=FRANCIS J G

E11 1 AU=FRANCIS J H

E12 5 AU=FRANCIS J J

E13 5 AU=FRANCIS J K

E14 89 AU=FRANCIS J L

E15 1 AU=FRANCIS J LYNN

E16 41 AU=FRANCIS J M

E17 4 AU=FRANCIS J N

E18 1 AU=FRANCIS J P

E19 10 AU=FRANCIS J R

E20 17 AU=FRANCIS J S

E21 4 AU=FRANCIS J T

E22 1 AU=FRANCIS J V

E23 34 AU=FRANCIS J W

E24 1 AU=FRANCIS JACKIE

E25 1 AU=FRANCIS JACQUELINE

E26 3 AU=FRANCIS JAMES

E27 3 AU=FRANCIS JAMES N

E28 2 AU=FRANCIS JANE

E29 4 AU=FRANCIS JANE M

E30 1 AU=FRANCIS JASMINE H

E31 2 AU=FRANCIS JENNELLE

E32 2 AU=FRANCIS JENNIFER

E33 1 AU=FRANCIS JENNIFER D

E34 3 AU=FRANCIS JENNIFER L

E35 1 AU=FRANCIS JEREMY S

E36 2 AU=FRANCIS JOANNA C

E37 9 AU=FRANCIS JOHN L

E38 1 AU=FRANCIS JONATHAN M

E39 3 AU=FRANCIS JONATHAN W

E40 10 AU=FRANCIS JOSEPH

E41 1 AU=FRANCIS JOSEPH P

E42 2 AU=FRANCIS JOSEPH T

E43 1 AU=FRANCIS JOSHUA

E44 1 AU=FRANCIS JUDITH

E45 3 AU=FRANCIS JULIUS

E46 63 AU=FRANCIS K

E47 1 AU=FRANCIS K A

E48 10 AU=FRANCIS K C

S22 221 E3,E23-E26, E28, E31-E32, E40, E43-E45

S23 4 S19 AND S22

3679 14613403 22394042 PMID: 12504596

Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-beta 1 against NMDA-induced necrosis. Dec 2002

3680 14546728 22135753 PMID: 12140255

Plasma membrane targeting of SNAP-25 increases its local concentration and is necessary for SNARE complex formation and regulated exocytosis. Aug 15 2002

3681 14423490 22394087 PMID: 12505422

Activation of GABA(A) receptors by guanidinocreatine: a novel pathophysiological mechanism. Nov 2002

3682 14150739 22278759 PMID: 12391613

Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and camitine. Nov 1 2002

3683 14124312 22317006 PMID: 12430716

HN-1 gp160 proteins and gp160 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain a HN-1-associated dementia. Nov 2002

3684 14109856 2228790 PMID: 12396596

Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Oct 25 2002

3685 13924257 22143702 PMID: 12146278

[Expression and purification of recombinant humanoxin-1 in *Pichia pastoris*] Jan 2002

3686 11972150 99355417 PMID: 10428463

Production of an immunoenzymatic tracer combining a scFv and the acetylcholinesterase of *Bungarus fasciatus* by genetic recombination Jul 16 1999

36/17 11874546 99315188 PMID: 10387025
The functional role of partially charged amino acid side chains in alpha-bungarotoxin revealed by site-directed mutagenesis of a His-tagged recombinant alpha-bungarotoxin. Jun 15 1999

36/18 11773080 99211386 PMID: 10346912
Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dihydrothreitol. May 25 1999

36/19 11773080 99211386 PMID: 10346912
Neurexins are functional alpha-toxin receptors. Mar 1999

36/20 11730254 99167083 PMID: 10009533
Ischemia induces metallothionein III expression in neurons of rat brain. 1999

36/21 11723801 99160489 PMID: 10049679
Recombinant and truncated tetanus neurotoxin light chain cloning, expression, purification, and proteolytic activity. Mar 1999

36/22 11655533 99121035 PMID: 9922260
EmrE, a small *Escherichia coli* multidrug transporter, protects *Saccharomyces cerevisiae* from toxins by sequestration in the vacuole. Feb 1999

36/23 11624177 99057603 PMID: 9938137
cDNA sequence analysis and expression of four long neurotoxin homologues from *Naja naja atra*. Nov 26 1998

36/24 11593846 99026267 PMID: 980860
Comparative transfer of the *Escherichia coli*-*Clostridium perfringens* shuttle vector pJIR1457 to *Clostridium botulinum* type A strains. Nov 1998

36/25 11497567 98387840 PMID: 9717740
Production of an expression system for a synaptobrevin fragment to monitor cleavage by botulinum neurotoxin B. Jul 1998

36/26 11496293 98380521 PMID: 9716688
Ganglioside GT1b as a complementary receptor component for *Clostridium botulinum* neurotoxins. Aug 1998

36/27 11494208 98378355 PMID: 9714553
Functional characterization of mouse nicotinic acetylcholine receptor alpha-subunit: resistance to alpha-bungarotoxin and high sensitivity to acetylcholine. Jul 24 1998

36/28 11387700 98266836 PMID: 9807820
Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. Jun 1998

36/29 11209593 98086179 PMID: 9426210
Transient expression of botulinum neurotoxin C1 light chain differentially inhibits calcium and glucose induced insulin secretion in clonal beta-cells. Dec 8 1997

36/30 11139735 98015419 PMID: 935935
Recombinant SNAP-25 is an effective substrate for *Clostridium botulinum* type A toxin endopeptidase activity in vitro. Oct 1997

36/31 11104455 97404680 PMID: 9261392
Glycoprotein Enr of pestiviruses induces apoptosis in lymphocytes of several species. Sep 1997

36/32 11089093 97444337 PMID: 9299865
A new potassium channel toxin from the sea anemone *Heteractis magnifica*: isolation, cDNA cloning, and functional expression. Sep 23 1997

36/33 11032722 97417717 PMID: 9266675
High-level production and labeling of snake neurotoxins, disulfide-rich proteins. Aug 1997

36/34 11050445 97404680 PMID: 9261392
Glycoprotein Enr of pestiviruses induces apoptosis in lymphocytes of several species. Sep 1997

36/35 11026724 97380307 PMID: 9237097
Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Jun 1997

36/36 10970709 97322809 PMID: 9179299
In vitro folding and functional analysis of an anti-insect selective scorpion depressant neurotoxin produced in *Escherichia coli*. Jun 1997

36/37 10913157 97265242 PMID: 9111179
Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. Apr 1997

36/38 10891577 97243441 PMID: 9118897
DNA fragmentation and prolonged expression of c-fos, c-jun, and hsp70 in kainic acid-induced neuronal cell death in transgenic mice overexpressing human Cu/Zn-superoxide dismutase. Mar 1997

36/39 10851392 97202741 PMID: 9050235
Molecular characteristics of mammalian and insect amino acid transporters: implications for amino acid homeostasis. Jan 1997

36/40 10824716 97175716 PMID: 9023371
Binding of the synaptic vesicle v-SNARE, synaptotagmin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at C-terminal heparin-binding domain. Nov 1996

36/41 10790025 97140301 PMID: 8986782
Insulin-stimulated translocation of GLUT4 glucose transporters requires SNARE-complex proteins. Dec 24 1996

36/42 10667816 97016880 PMID: 8636393
Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. Nov 1996

36/43 10605337 96229225 PMID: 8625526
Effects of chlorotrifluoroethylene oligomer fatty acids on recombinant GABA receptors expressed in *Xenopus* oocytes. Jan 1996

36/44 10436837 96243500 PMID: 871755
Facile production of native-like kappa-bungarotoxin in yeast: an enhanced system for the production of a neuronal nicotinic acetylcholine receptor probe. Feb 1996

36/45 10421671 96228050 PMID: 864768
Botulinum neurotoxin light chains inhibit both Ca(2+)-induced and GTP analogue-induced catecholamine release from permeabilised adrenergic chromaffin cells. May 20 1996

36/46 10357260 96160045 PMID: 8562508
Clinical trials of targeted toxins. Oct 1995

36/47 10356144 96158928 PMID: 8562075
A strongly interacting pair of residues on the contact surface of charybdotoxin and a Shaker K⁺ channel. Jan 1996

36/48 10348836 96151333 PMID: 8599190
Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Oct 1995

36/49 10304915 96106945 PMID: 853563
Expression in *Escherichia coli* and purification of human eosinophil-derived neurotoxin with ribonuclease activity. Oct 1995

36/50 10277824 96074594 PMID: 7488184
cDNA sequence analysis and expression of alpha-bungarotoxin from Taiwan banded krait (*Bungarus multicinctus*). Nov 22 1995

36/51 10271008 96072756 PMID: 7578132
Expression and purification of the light chain of botulinum neurotoxin A: a single mutation abolishes its cleavage of SNAP-25 and neurotoxic after reconstitution with the heavy chain. Nov 21 1995

36/52 10261988 96063533 PMID: 7488136
17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Nov 13 1995

36/53 10224508 96025599 PMID: 7525758
High affinity binding of alpha-ha-toxin to recombinant neurexin I alpha. Oct 13 1995

36/54 10216937 96018129 PMID: 7570631
Cloning and expression of mamba toxins. Apr 1995

36/55 10165737 22168583 PMID: 121801959
Characterization of scorpion alpha-like toxin group using two new toxins from the scorpion *Leiurus quinquestratus hebraeus*. Aug 2002

36/56 10155787 22152946 PMID: 12027804
Cytotoxic potency of cardiotoxin from *Naja spilota*: development of a new cytolytic assay. Aug 15 2002

36/58 10148812 22140034 PMID: 12145198
Carmodulin and lipid binding to synaptobrevin regulates calcium-dependent exocytosis. Aug 1 2002

36/59 10089833 22043136 PMID: 12047391
Refolding of the *Escherichia coli* expressed extracellular domain of alpha 7 nicotinic acetylcholine receptor. Jun 2002

36/60 09954415 21371794 PMID: 11880503
Caspase-3-dependent proteolytic cleavage of protein kinase Cdelta is essential for oxidative stress-mediated dopaminergic cell death a

exposure to methylcyclopentadienyl manganese tricarbonyl. Mar 1 2002

36661 09938303 21850743 PMID: 11861082

A unique approach for high level expression and production of a recombinant cobra neurotoxin in *Escherichia coli*. Apr 11 2002

36662 09809576 21618056 PMID: 11767552

A recombinant scFv/streptavidin-binding peptide fusion protein for the quantitative determination of the scorpion venom neurotoxin. Apr 1 Nov 2001

36663 09803835 21611849 PMID: 1176436

Biologically active sequence (K101) mediates the neurite outgrowth function of the gamma-1 chain of laminin-1. Dec 15 2001

36664 09798253 21606007 PMID: 11738760

Use of fusion protein constructs to generate potent immunotherapy and protection against scorpion toxins. Dec 12 2001

36665 09770747 21575763 PMID: 11719263

Cytochrome c oxidase subunit Vb interacts with human androgen receptor: a potential mechanism for neurotoxicity in spinobulbar muscular atrophy. Oct 1 2001

36666 09689280 21477743 PMID: 11592857

The neuronal calcium sensor protein (NLIP-1) is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer's disease? Oct 2001

36667 09642153 21428356 PMID: 11543986

Properties and interaction of heterologously expressed glutamate decarboxylase isoenzymes GAD(65kDa) and GAD(67kDa) from human brain with ginkgolide and its 5'-phosphate. Sep 13 2001

36668 09626046 21472148 PMID: 11503008

Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor-kappaB (NF-kappaB)-dependent mechanism. Aug 2001

36669 09588916 21372659 PMID: 11478968

Expression of an active recombinant lysine 49 phospholipase A(2) myotoxin as a fusion protein in bacteria. Oct 2001

36670 09580364 21363578 PMID: 11470300

A stoichiometric complex of neuregins and dystroglycan in brain. Jul 23 2001

36671 09572149 21356118 PMID: 11461976

Role of alpha2-macroglobulin in regulating amyloid beta-protein neurotoxicity: protective or detrimental factor? Jul 2001

36672 09490505 21267040 PMID: 1136671

A common exocytotic mechanism mediates axonal and dendrite outgrowth. Jun 1 2001

36673 09439297 21210796 PMID: 11299302

Human immunodeficiency virus type 1 Tat protein decreases cyclic AMP synthesis in rat microglia cultures. Apr 2001

36674 09410039 21176902 PMID: 11281322

Sup35 yeast prion protein as an adapter for production of the Gap-p55 antigen of HIV-1 and the L-chain of botulinum neurotoxin in *Saccharomyces cerevisiae*. Jan-Feb 2001

36675 09352619 21114032 PMID: 11160457

Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. Jan 15 2001

36676 09349876 21111022 PMID: 11178934

Inhibition of neuronal nitric oxide synthase by N-phényl imidazoles. Feb 2001

36677 09237059 21109370 PMID: 11162740

Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. Nov 17 2000

36678 09177907 20483654 PMID: 11027615

The amino acid region 115-119 of amyloidtoxins plays an important role in neurotoxicity. Oct 5 2000

36681 09112657 20411243 PMID: 10964418

Membrane localization and biological activity of SNAP-25 cysteine mutants in insulin-secreting cells. Sep 2000

36682 09002184 20389730 PMID: 10930694

Cloning, expression and evaluation of a recombinant sub-unit vaccine against *Clostridium botulinum* type F toxin. Sep 15 2000

36683 09035114 20324656 PMID: 10873064

Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Jun 2000

36684 09030890 20324939 PMID: 10865133

Measurement of exocytosis by amperometry in adrenal chromaffin cells: effects of clostridial neurotoxins and activation of protein kinase C fusion pore kinetics. May 2000

36685 09002356 20291906 PMID: 10833399

Cloning, expression, and one-step purification of the minimal essential domain of the light chain of botulinum neurotoxin type A. Jun 2000

36686 08856185 20414225 PMID: 10675534

Identification and characterization of functional subunits of *Clostridium botulinum* type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes Feb 11 2000

36687 08853128 2037998 PMID: 10672018

Functional characterization and mechanism of action of recombinant human kynureine 3-hydroxylase. Feb 2000

36688 08835257 20119217 PMID: 10652444

Microglial tissue plasminogen activator (tPA) triggers neuronal apoptosis in vitro. Feb 15 2000

36689 08812762 20095669 PMID: 10630205

Recombinant adenovirus-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Nov 1999

36690 08792663 20074908 PMID: 10616730

An *in vivo* assay for the identification of target proteases which cleave membrane-associated substrates. Dec 17 1999

36691 08787091 20069083 PMID: 10600453

Expression and purification of the *BmK* M1 neurotoxin from the scorpion *Buthus martensi* Karsch. Dec 1999

36692 08789428 20050851 PMID: 10581396

Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Nov 10 1999

36693 087656143 20047427 PMID: 10582602

Botulinum neurotoxin E-insensitive mutants of SN-52 fail to bind VAMP but support exocytosis. Dec 1999

36694 08763553 20044741 PMID: 10574958

Variability among the sites by which curarimimetic toxins bind to torpedo acetylcholine receptor, as revealed by identification of the function residues of alpha2-cobratoxin. Dec 3 1999

36695 08688576 95377281 PMID: 10649153

Recombinant and chemical derivatives of apamin. Implication of post-transcriptional C-terminal amidation of apamin in biological activity. Aug 1995

36696 086601219 95348816 PMID: 7623136

Neurotrophin-4/5 enhances survival of cultured spinal ganglion neurons and protects them from cisplatin neurotoxicity. Jul 1999

36697 08622454 95310981 PMID: 7790908

Kinetic acid-induced neuronal death is associated with DNA damage and a unique immediate-early gene response in *C. elegans* transgenic rats. Jun 1995

36698 08546027 95234326 PMID: 7718248

A mutated acetylcholine receptor subunit causes neuronal degeneration in *C. elegans*. Apr 1995

36699 08525400 95213678 PMID: 7693935

Protection against HIV-1 gp120-induced brain damage by neuronal expression of human amyloid precursor protein. Apr 1 1995

36700 08374166 95062139 PMID: 7526378

Engineering of protein epitopes: a single deletion in a snake toxin generates full binding capacity to a previously unrecognized antibody. Jul 1

36701 08371481 95059454 PMID: 7663473

Structural determinants of the blockade of N-type calcium channels by a peptide neurotoxin. Nov 17 1994

36702 08326562 95014532 PMID: 7929408

Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin anti-transferrin receptor sFv. Oct 26 1994

3/6/103 08303720 94373331 PMID: 752204
Competitive antagonism by phenylglycine derivatives at type I metabotropic glutamate receptors. Jun 1994

3/6/104 08367296 94333571 PMID: 8055534
Production of active, insect-specific scorpion neurotoxin in yeast. Jul 15 1994

3/6/105 08233041 94301998 PMID: 7518082
Engineering a uniquely reactive thio into a cysteine-rich peptide. Apr 1994

3/6/106 08198098 94264020 PMID: 7911329
A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with native heavy chain. Jun 7 1994

3/6/107 08169290 94235190 PMID: 8179845
Structure, function and expression of voltage-dependent sodium channels. Fall/Winter 1993

3/6/108 08143419 94209288 PMID: 8157345
Functional expression and site-directed mutagenesis of a synthetic gene for alpha-bungarotoxin. Apr 15 1994

3/6/109 08093322 94159078 PMID: 8114918
Central nervous system damage produced by expression of the H1-V1 coat protein gp120 in transgenic mice. Jan 13 1994

3/6/110 08001602 94067319 PMID: 8247129
Synaptic vesicle fusion complex contains unc-18 homologue bound to syntaxin. Nov 25 1993

3/6/111 07988762 94051479 PMID: 8233724
Potentiation of N-methyl-D-aspartate-mediated brain injury by a human immunodeficiency virus-1-derived peptide in perinatal rodents. Aug 1993

3/6/112 07924263 93380595 PMID: 8373764
Effects of mutations of Torpedo acetylcholine receptor alpha 1 subunit residues 184-200 on alpha-bungarotoxin binding in a recombinant fusion protein. Sep 21 1993

3/6/113 07724190 93179465 PMID: 8095049
Characterization of a distinct binding site for the prokaryotic chaperone, GroEL, on a human granulocyte ribonuclease. Feb 25 1993

3/6/114 07612655 93066342 PMID: 1438389
Deposition of betaA4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxy-terminal fragment of the Alzheimer amyloid precursor in the brain. Nov 15 1992

3/6/115 07573392 93028327 PMID: 1409549
Insertion of a disulfide-containing neurotoxin into *E. coli* alkaline phosphatase: the hybrid retains both biological activities. Apr 1992

3/6/116 07478566 92342135 PMID: 1635553
Molecular neurotoxicology of trimethyltin: identification of stannin, a novel protein expressed in trimethyltin-sensitive cells. Jul 1992

3/6/117 07386559 92249751 PMID: 1577556
Cloning of a *Clostridium botulinum* type B toxin gene fragment encoding the N-terminus of the heavy chain. Feb 1 1992

3/6/118 07281817 92144640 PMID: 1736594
Substitution of *Torpedo* acetylcholine receptor alpha 1-subunit residues with snake alpha 1- and rat nerve alpha 3-subunit residues in recombinant fusion proteins: effect on alpha-bungarotoxin binding. Feb 11 1992

3/6/119 07265844 92131347 PMID: 1837449
Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. 1991

3/6/120 07165311 92027518 PMID: 1656845
Calcium channel antagonists and human immunodeficiency virus coat protein-mediated neuronal injury. Jul 1991

3/6/121 07131767 91372881 PMID: 1910014
Characterization of the C3 gene of *Clostridium botulinum* types C and D and its expression in *Escherichia coli*. Oct 1 1991

3/6/122 06763034 91002534 PMID: 2207082
Comparison of the toxin binding sites of the nicotinic acetylcholine receptor from *Drosophila* to human. Jul 10 1990

3/6/123 065736929 90365570 PMID: 1366462
Expression and secretion of a functional scorpion insecticidal toxin in cultured mouse cells. Apr 1990

3/6/124 065680484 90306371 PMID: 2365072
A recombinant snake neurotoxin generated by chemical cleavage of a hybrid protein recovers full biological properties. Jun 18 1990

3/6/125 06456371 90083145 PMID: 2697847

Direct expression in *E. coli* of a functionally active protein A—snake toxin fusion protein. Nov 1989

3/6/126 06343017 89339352 PMID: 2670934
Cloning and expression of a synthetic gene for *Cerebella* *lacteus* neurotoxin B-IV. Sep 15 1989

3/7/26 DIALOG(R)File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All rights reserved.

14962293 98380521 PMID: 9712688
Ganglioside GT1b as a complementary receptor component for *Clostridium botulinum* neurotoxins.

Kozaki S, Kamata Y, Watarai S, Nishiki T, Mochida S
Department of Veterinary Science, College of Agriculture, Osaka Prefecture University, Sakai, Osaka, 599-8531, USA.
Microbial pathogenesis (ENGLAND) Aug 1998, 25 (2) p91-9, ISSN 0882-4010 Journal Code: 8606191

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
Clostridium botulinum type B neurotoxin (BoNT/B) recognizes a complex of synaptotagmin II and ganglioside GT1b or GD1a a the high-affinity toxin binding site. Recombinant deletion mutants of synaptotagmin II allowed us to demonstrate that the N-terminal domain including the transmembrane region retains BoNT/B binding activity while the C-terminal domain is not involved in constituting the BoNT/B receptor. BoNT/B binding to reconstituted lipid vesicles containing synaptotagmin II and ganglioside showed that GT1b and GD1a confer the difference in the maximum binding capacity but not in the dissociation constant. The direct binding of GT1b to the deletion mutants revealed that the transmembrane region is required to bind GT1b, suggesting that synaptotagmin II binds to the ceramide portion of gangliosides within the plasma membrane. A monoclonal antibody against GT1b effectively inhibited not only BoNT/B binding to the reconstituted lipid vesicles and brain synaptosomes but also type A BoNT (BoNT/A) binding to brain synaptosomes. In addition, the monoclonal antibody antagonized the action of both BoNT/A and BoNT/B on synaptic transmission of rat superior cervical ganglion neurons. These results suggest that GT1b functions as a component of the receptor complex. Copyright 1998 Academic Press Record Date Created: 19980929 Record Date Complete: 19980929

3/7/61 DIALOG(R)File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All rights reserved.

09383803 2185043 PMID: 11661082

A unique approach for high level expression and production of a recombinant cobra neurotoxin in *Escherichia coli*.
Wang, Jing Liu, Xu Kangsen
School of Life Science, University of Science and Technology of China, Hefei, Anhui province, People's Republic of China.
ybwang@ustc.edu.cn

Journal of biotechnology (Netherlands) Apr 11 2002, 94 (3) p235-44, ISSN 0168-1656 Journal Code: 8411927
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

In this report, we describe a simple approach to produce a large quantity of a recombinant cobra neurotoxin containing four disulfide bonds. A cDNA encoding the toxin was fused, in frame, to the carboxy terminal of thioredoxin via a linker sequence encoding two amino acids, Asp+Pro. Due to the presence of thioredoxin, a soluble form of the fusion protein was expressed in a compartment sensitive to osmotic pressure, in *Escherichia coli*. The fusion protein was released into the solution with low ionic strength under an osmotic shock treatment, and purified in a single step using an ion exchange chromatography column. The purified protein was treated in diluted hydrochloric acid to induce hydrolysis of the protein at the Asp-Pro linker site. Then, the recombinant neurotoxin was purified by gel filtration of the acid-treated sample. When the biological activity of the purified toxin was assayed, it was as potent as the natural toxin. Using this protocol, approximately 1/2 mg of pure recombinant neurotoxin can be produced from one liter of bacterial culture. More importantly, this protocol can be easily used for the production of the toxin at a larger scale with low cost. The approach outlined in this report will be suitable for the other recombinant proteins especially those of the 'three-finger' family. Record Date Created: 20020225 Record Date Complete: 20020517

3/7/117 DIALOG(R)File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All rights reserved.

07386559 92249751 PMID: 1577256

Cloning of a *Clostridium botulinum* type B toxin gene fragment encoding the N-terminus of the heavy chain.

Jung H H, Rhee S D, Yang K H
Department of Life Science, Korea Advanced Institute of Science and Technology, Taejon, Korea.
FEBS microbiology letters (NETHERLANDS) Feb 1 1992, 70 (1) p69-72, ISSN 0378-1097 Journal Code: 7705721
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Two lambda gt11 clones of the toxin gene of *Clostridium botulinum* type B were identified by the monoclonal antibody specific the heavy chain of type B toxin. Neither of the expressed fusion proteins from the lysates of lysogenic *E. coli* Y1089 showed a botulinum toxic activity. One of the clones hybridized to the oligonucleotide probe which was synthesized according to the amino acid sequence of N-terminus of heavy chain. The sequence analysis revealed that highly homologous regions in N-terminus of heavy chain exist among botulinum neurotoxins (type A, B) and tetanus toxin on the amino acid sequence level. Record Date Created: 19920611 Record Date Completed: 19920611

3/7/124 DIALOG(R)File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All rights reserved.

06580484 90306371 PMID: 2365072
A recombinant snake neurotoxin generated by chemical cleavage of a hybrid protein recovers full biological properties.

Recombinant Fusion Proteins --Metabolism--ME: Spectrometry, Substrate Specificity: Tetanus Toxin--biosynthesis--B; Tetanus Toxin--isolation and purification--IP; Tetanus Toxin--metabolism--ME CAS Registry No.: 0 (Membrane Proteins); 0 (Peptide Fragments); 0 (Recombinant Fusion Proteins); 0 (Tetanus Toxin); 0 (vesicle-associated membrane protein) Enzyme No.: EC 3.4.24 (Metalloendopeptidases); EC 3.4.24. (zinc-endopeptidase, tetanus neurotoxin)

Record Date Created: 19990511 Record Date Completed: 19990511

7/6/1 14:67:937 22:55:1921 PMID: 12563791
[Association expression of genes encoding gsf of *Schistosoma japonicum* and enterotoxicigenic *Escherichia coli*] 1999

7/6/2 12:00:058 99452975 PMID: 1052470
Involvement of small GTPases in *Mycoplasma fermentans* membrane lipoproteins-mediated activation of macrophages. Oct 22 1999

7/6/3 11996258 99444608 PMID: 1051320
The transcriptional activator CoR is involved in biosynthesis of the phytotoxin coronatine and binds to the *cmaAB* promoter region in a temperature-dependent manner. Sep 1999

7/6/4 11976922 99421861 PMID: 10491038
IL-2 receptor-targeted cytolytic IL-2/CF fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. Oct 1 1999

7/6/5 11974124 99419014 PMID: 10486072
Neosynthesis and activation of Rho by *Escherichia coli* cytotoxic necrolytic factor (CNF-1) reverse cytopathic effects of ADP-ribosylated Rho. Sep 24 1999

7/6/6 11954727 99399900 PMID: 10470104
Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras *in vitro* and *in vivo*. May-Jun 1999

7/6/7 11942739 99386678 PMID: 10455034
Analysis of agonist function at fusion proteins between the IP prostaglandin receptor and cognate, unnatural and chimaeric G-proteins. Sep 1 1999

7/6/8 11919266 99362664 PMID: 10430949
The Xanthomonas *Hip* type III system secretes proteins from plant and mammalian bacterial pathogens. Aug 3 1999

7/6/9 11914297 99357644 PMID: 10422035
Activation process of cypieran-specific insecticidal protein produced by *Bacillus thuringiensis* subsp. *israelensis*. Aug 1999

7/6/10 11905255 99346356 PMID: 10419539
Yersinia enterocolitica type III secretion. On the role of SycE in targeting YopE into HeLa cells. Jul 30 1999

7/6/11 11905231 99348332 PMID: 10419515
Ion channel activity of the BH3 only Bcl-2 family member, Bid. Jul 30 1999

7/6/12 1189702 99340543 PMID: 10411728
The 5' region of cmtf harbours a translational regulatory mechanism for CNF1 synthesis and encodes the cell-binding domain of the toxin. Jul 1999

7/6/13 11887991 99330177 PMID: 10403383
Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway. Jun 18 1999

7/6/14 11882159 99323920 PMID: 10393809
Rsp157p, the budding yeast homolog of amphiphysin, colocalizes with actin patches. Aug 1999

7/6/15 11865823 99307182 PMID: 10377103
Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity. Jul 1 1999

7/6/16 11862205 99303467 PMID: 10376974
An anti-CD3 single-chain Fv selected by phage display and fused to *Pseudomonas exotoxin A* (K1-4[scFv]-ETA) is a potent immunotoxin against a Hodgkin-derived cell line. Jun 1999

7/6/17 11853388 99294094 PMID: 10367674
Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma. Jan-Feb 1999

7/6/18 11847433 99288230 PMID: 10336877
High-level expression and purification of the recombinant diphtheria toxin DTGM for PHASE I clinical trials. Jun 1999

7/6/19 11815887 99255637 PMID: 10322014
Direct interaction of the EpsL and EpsM proteins of the general secretion apparatus in *Vibrio cholerae*. May 1999

7/6/20 11814001 99253640 PMID: 10321723
Cloning and cytotoxicity of fusion proteins of EG and angiogenin. 1999

7/6/23 1175824 99214180 PMID: 10196187
A novel cytotoxin from *Clostridium difficile* serogroup F is a functional hybrid between two other large clostridial cytotoxins. Apr 16 1999

A new series of pET-derived vectors for high efficiency expression of *Pseudomonas exotoxin*-based fusion proteins. Mar 18 1999

7/6/24 1177897 99210155 PMID: 10195780
Novel modifications to the C-terminus of LTB that facilitate site-directed chemical coupling of antigens and the development of LTB as a carrier for mucosal vaccines. Mar 17 1999

7/6/25 11753374 99196933 PMID: 10095114
Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Apr 1999

7/6/26 11753200 99190538 PMID: 10089877
Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin perfringens. Nov 1 1998

7/6/27 11753179 99192697 PMID: 10092217
Crystallization and preliminary X-ray diffraction studies of alpha-toxin from two different strains (NCTC8237 and CER89L43) of *Clostridium* globotetraosyl ceramide fatty acid isoform traffic. Dec 1998

7/6/28 11747339 99189747 PMID: 10089877
Solution structure of Bid, an intracellular amplifier of apoptotic signaling. Mar 5 1999

7/6/29 11747698 99185011 PMID: 10085027
Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Apr 1999

7/6/30 11747681 99184994 PMID: 10085010
An *Arcanobacterium* (*Actinomyces*) pyogenes mutant deficient in production of the pore-forming cytolysin pyolysin has reduced virulence. Apr 1999

7/6/31 11720993 99157583 PMID: 10048023
Expression and properties of an aerobactin-*Clostridium septicum* alpha toxin hybrid protein. Feb 1999

7/6/32 11720819 99157408 PMID: 10047878
Differential activity of cholera toxin and *E. coli* enterotoxin: construction and purification of mutant and hybrid derivatives. Nov 1998

7/6/33 11680321 99115680 PMID: 9914159
The KDEL retrieval system is exploited by *Pseudomonas exotoxin A*, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum. Feb 1999

7/6/34 11680158 99115117 PMID: 9916051
Deamidation of Cdc42 and Rac by *Escherichia coli* cytotoxic necrolytic factor 1: activation of c-Jun N-terminal kinase in HeLa cells. Feb 1999

7/6/35 11672041 99107223 PMID: 9892205
Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Jan 1 1999

7/6/36 11657978 9902760 PMID: 9876933
Stepwise translocation of an active site loop between heat-labile enterotoxins LT-II and LT-I and characterization of the obtained hybrid toxins. Nov 1998

7/6/37 11635815 99059581 PMID: 9852324
Gating of skeletal and cardiac muscle sodium channels in mammalian cells. Jan 15 1999

7/6/38 11626571 99060051 PMID: 9843379
Characterization of membrane translocation by anthrax protective antigen. Nov 10 1998

7/6/39 11606274 99039034 PMID: 9821593
Positive selection vectors to generate fused genes for the expression of his-tagged proteins. Nov 1998

7/6/40 11596318 99028905 PMID: 9812362
Functional interactions between cbp and barD, two homologous conditional killer systems found in the *Escherichia coli* chromosome and in plasmid R1. Nov 1 1998

7/6/41 11563608 98455677 PMID: 9782357
Prokaryotic expression of porcine epidemic diarrhoea virus ORF3. 1998

7/6/42 11546114 98437626 PMID: 9757112

Crystallization of ccdB. Sep 1 1998

7643 11531599 98422764 PMID: 9750370
Bacterial phospholipases. 1998

7644 1152796 98401141 PMID: 973188
Recombinant antibody fragments. Aug 1998

7645 11503002 98387897 PMID: 9719644
Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. Sep 4 1998

7647 11495172 98380400 PMID: 9712803
Actin bacillus *aet*toxins/leukotoxin induces apoptosis in HL-60 cells. Sep 1998

7648 11469999 98355391 PMID: 9687463
Phage display of a biologically active *Bacillus thuringiensis* toxin. Aug 1998

7649 11435654 98318336 PMID: 9656824
Nicotinic agonists competitively antagonize serotonin at mouse 5-HT3 receptors expressed in Xenopus oocytes. May 15 1998

7650 11430324 98312844 PMID: 9656824
Afferent signals to the CNS appear not to condition the modulation of interleukin-1 receptors in the hippocampus. Sep-Dec 1997

7651 11412641 98294443 PMID: 9630987
An *Escherichia coli* hemolysin transport system-based vector for the export of polypeptides: export of Shiga-like toxin II β subunit by *Salmonella typhimurium* *aroA*. Jun 1996

7652 11368068 98248937 PMID: 9587366
Recombinant immunotoxins and chimeric toxins for targeted therapy [in oncology]. Immunotoxines recombinantes et toxines chimériques pour une thérapie ciblée en oncologie. Dec 1997

7653 11350445 98230732 PMID: 9563949
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. May 1 1998

7654 11343319 98223364 PMID: 9563885
Recombinant herculein-Pseudomonas exotoxin fusion proteins: interactions with the herculein receptors and antitumor activity in vivo. Apr 1998

7655 11337192 98217169 PMID: 9558086
Increasing immunogenicity of antigens fused to Ig-binding proteins by cell surface targeting. Apr 15 1998

7656 11325272 98204871 PMID: 9535863
A modular DNA barrier protein based on the structure of diphtheria toxin mediates target cell-specific gene delivery. Apr 10 1998

7657 11310748 98190640 PMID: 9521785
The biochemistry of hemolysin toxin activation: characterization of HlyC, an internal protein acyltransferase. Mar 31 1998

7658 11308636 98187903 PMID: 9529054
The N-terminal part of the enzyme component (C2) of the binary *Clostridium botulinum* C2 toxin interacts with the binding component 2I and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin. Apr 1998

7659 11308445 98187712 PMID: 9528683
Bacillus *l*-*Ps* toxin fusion proteins bind but are not cytotoxic to cells expressing HER4; correlation of EGFR for cytotoxic activity. Mar 5 1998

7660 11301954 98181049 PMID: 9514636
Involvement of glutamic acid residue at position 7 in the formation of the intramolecular disulfide bond of *Escherichia coli* heat-stable enterotoxin I β in vivo. Mar 1998

7661 1129886 98177234 PMID: 9508786
Internalization of a *Bacillus anthracis* protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. Feb 1998

7662 11275533 98154422 PMID: 9493371
Production of a non-toxic site-directed mutant of *Clostridium perfringens* epsilon-toxin which induces protective immunity in mice. Feb 1998

7663 11274724 98153220 PMID: 9485477
Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EG-like domain of herculein beta1. Mar 3 1998

Streptolysin O: a proposed model of allosteric interaction between a pore-forming protein and its target lipid bilayer. Feb 24 1998

7665 11289315 98147722 PMID: 9488398
Chimeric clostridial cytotoxins: identification of the N-terminal region involved in protein substrate recognition. Mar 1998

7666 11288187 98125736 PMID: 946560
Site-directed mutagenesis of *Clostridium difficile* toxin genes. Jan 1998

7667 11233753 98111100 PMID: 9450639
Construction and characterization of versatile cloning vectors for efficient delivery of native foreign proteins to the periplasm of *Escherichia coli*. 1997

7668 11219501 98096837 PMID: 9435018
Site-directed mutagenesis of histidine residues in anthrax toxin lethal factor binding domain reduces toxicity. Dec 1997

7669 11190167 98066714 PMID: 9403010
Getting plant toxins to fuse. Oct 1997

7670 11182550 9805986 PMID: 9395513
Furin-mediated cleavage of *Pseudomonas* exotoxin-3-derived chimeric toxins. Dec 12 1997

7671 11186636 98044819 PMID: 9385562
Bi-functional lacZ alpha-codB genes for selective cloning of PCR products. Nov 1997

7672 11130131 9804523 PMID: 9342362
Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Oct 2 1997

7673 11129676 9803948 PMID: 93423949
Cytotoxicity of anthrax lethal factor microinjected into macrophage cells through Sendai virus envelopes. Feb-Apr 1997

7674 11034612 97388302 PMID: 9247136
Phage display of *Bacillus thuringiensis* CryA(a) insecticidal toxin. Jul 7 1997

7675 11035669 97387249 PMID: 9242895
A recombinant GM-CSF-PE40 ligand toxin is functionally active but not cytotoxic to cells. Jun 1997

7676 11073103 97427938 PMID: 9284126
7677 11072462 97427286 PMID: 9282328
Epitope conservation and immunohistochemical localization of the guanylyltransferase toxin peptide receptor, guanylyl cyclase C. Sep 15 1997

7678 11071892 97426721 PMID: 9287265
Immune modulation and sepsis. Jun 1997

7679 11034612 97388302 PMID: 9247136
Phage display of *Bacillus thuringiensis* CryA(a) insecticidal toxin. Jul 7 1997

7680 11033569 97387249 PMID: 9242395
A recombinant GM-CSF-PE40 ligand toxin is functionally active but not cytotoxic to cells. Jun 1997

7681 11010370 97363719 PMID: 9220012
Molecular localization of the *Escherichia coli* cytotoxic necrotizing factor CNF1 cell-binding and catalytic domains. Jun 1997

7682 10994209 97347435 PMID: 9202074
Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. Jul 1 1997

7683 10983780 97336906 PMID: 919653
Using secondary structure predictions and site-directed mutagenesis to identify and probe the role of potential active site motifs in the RT6 mon(ADP-ribose)laminases. 1997

7684 10982992 97336105 PMID: 9192900
Gln 63 of Rho is deamidated by *Escherichia coli* cytotoxic necrotizing factor-1. Jun 12 1997

7685 10974961 97327728 PMID: 9210405
Construction, expression and characterization of chimaeric toxins containing the ribonuclease toxin restriction: intracellular mechanism of act

Jun 15 1997

7686 10961209 97313862 PMID: 9170263

Cleavage of the synaptobrevin/vesicle-associated membrane protein (VAMP) of the mouse brain by the recombinant light chain of Clostridium botulinum type B toxin. May 15 1997

7/6/87 10920130 9727226 PMID: 9144199
Channel formation by antipoplastic protein Bcl-2. May 13 1997

7/6/88 10920130 9727226 PMID: 914042
Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. Apr 29 1997

7/5/89 10911411 9723433 PMID: 9109408
Characterization and receptor specific toxicity of two diphtheria toxin-related interleukin-3 fusion proteins DAB389-mIL-3 and DAB389-(Gly4Ser)2-mIL-3. Apr 7 1997

7/5/90 10899020 97250967 PMID: 9096650
Intra-tumoral application of a heteroglycine-exotoxin-a fusion protein causes rapid tumor regression without adverse systemic or local effects. Mar 17 1997

7/6/91 10887084 97238939 PMID: 9083117
A mechanism for toxin insertion into membranes is suggested by the crystal structure of the channel-forming domain of colicin E1. Mar 15 1997

7/6/92 10866676 97218154 PMID: 9068615
In vitro effects of a recombinant toxin mSCF-PE40, targeting c-kit receptors ectopically expressed in small cell lung cancers. Feb 26 1997

7/6/93 10853874 97205237 PMID: 9052741
Nucleotide sequence of a gene encoding the novel *Yersinia enterocolitica* heat-stable enterotoxin that includes a pro-region-like sequence in its mature toxin molecule. Feb 1 1997

7/6/95 10836413 97187652 PMID: 9035105
A new class of antigen-specific killer cells. Jan 1997

7/6/96 10819657 97108543 PMID: 8951823
Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin. Nov 1996

7/6/97 10812920 97102795 PMID: 8947035
Homologues of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode *Caenorhabditis elegans*. Nov 15 1996

7/6/98 10803648 97033160 PMID: 8938722
Interaction of Ca(2+)-activated K+-channels with refolded charybdotoxins mutated at a central interaction residue. 1996

7/6/99 10803669 97093081 PMID: 8936643
Molecular and biochemical characterization of a heat-labile cytolytic enterotoxin from *Aeromonas hydrophila*. Nov 1996

7/6/100 10801193 97090993 PMID: 8936601
Use of *Vibrio* spp. for expression of *Escherichia coli* enterotoxin B subunit fusion proteins: purification and characterization of a chimera containing a C-terminal fragment of DNA polymerase from herpes simplex virus type 1. Nov 1996

7/6/101 10795314 97084797 PMID: 8931131
Characterization of a toxin fusion targeted to the interleukin-2 receptor. Oct 1996

7/6/102 10781943 97138224 PMID: 8985250
Potent antitumour activity of a new class of tumour-specific killer cells. Jan 2 1997

7/6/103 10776887 97126817 PMID: 8971711
Comparative analysis of the virulence control systems of *Bordetella pertussis* and *Bordetella bronchiseptica*. Dec 1996

7/6/104 10776116 97126244 PMID: 8971168
Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated *Pseudomonas exotoxin* for therapy of malignant astrocytoma. Dec 15 1996

7/6/105 10759657 97109543 PMID: 8951823
Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin. Nov 1996

Homologues of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode *Caenorhabditis elegans*. Nov 15 1996

7/6/107 10743648 97093160 PMID: 8938722
Interaction of Cx2(+)-activated K+-channels with refolded charybdotoxins mutated at a central interaction residue. 1996

7/6/108 10743569 97093081 PMID: 8938643
Molecular and biochemical characterization of a heat-labile cytolytic enterotoxin from *Aeromonas hydrophila*. Nov 1996

7/6/109 10741193 97090693 PMID: 8936601
Use of *Vibrio* spp. for expression of *Escherichia coli* enterotoxin B subunit fusion proteins: purification and characterization of a chimera containing a C-terminal fragment of DNA polymerase from herpes simplex virus type 1. Nov 1996

7/6/110 10735314 97084797 PMID: 8931131
Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor. Oct 1996

7/6/111 10729076 97078529 PMID: 8919453
Identification and characterization of an extracellular protease activity produced by the marine *Vibrio* sp. 60. Feb 1 1996

7/6/112 10703540 97052810 PMID: 8897439
Recombinant immunotoxins: protein engineering for cancer therapy. Oct 1996

7/6/113 10667118 97016182 PMID: 8862819
Positive selection of recombinant DNA by Cx2B. Aug 1996

7/6/114 10597761 960415308 PMID: 8818275
Construction of new insecticidal *Bacillus thuringiensis* recombinant strains by using the sporulation non-dependent expression system of *cryIIA* and a site specific recombination vector. Jul 18 1996

7/6/115 10591049 96045594 PMID: 8810739
Use of translational fusions to the maltose-binding protein to produce and purify proteins in *Pseudomonas syringae* and assess their activity in vivo. Sep 1996

7/6/116 10579339 960391952 PMID: 8794167
Protein engineering and design for drug delivery. Aug 1996

7/6/117 10575341 963837501 PMID: 8795010
Heparin-binding capacity of the HIV-1 NEF-protein allows one-step purification and biochemical characterization. Jun 1996

7/6/118 10540323 96351741 PMID: 8741987
Studies on the ability of barnase toxins in vitro and in vivo. Jan-Feb 1996

7/6/119 10522249 96333343 PMID: 8757837
Escherichia coli hemolysin mutants with altered target cell specificity. Aug 1996

7/6/120 10516607 96327868 PMID: 8755086
Serodiagnosis of listeriosis based upon detection of antibodies against recombinant truncated forms of listeriolysin O. Jun 1996

7/6/121 10513000 96333624 PMID: 8759196
A recombinant *Escherichia coli* heat-stable enterotoxin b (STb) fusion protein eliciting neutralizing antibodies. Apr 1996

7/6/122 10512619 96332340 PMID: 8710899
Fused polycationic peptide mediates delivery of diphtheria toxin A chain to the cytosol in the presence of anthrax protective antigen. Aug 6 1996

7/6/123 10500026 96310588 PMID: 8740553
The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein. Apr 1996

7/6/124 10489724 96300228 PMID: 8706654
A recombinant insect-specific alpha-toxin of *Buthus occitanus* scorpion confers protection against homologous mammal toxins. Jun 1996

7/6/125 10485192 96294783 PMID: 8688498
Amino acid residues in the pro region of *Escherichia coli* heat-stable enterotoxin I that affect efficiency of translocation across the inner membrane. Jul 1996

7/6/126 10480824 96292047 PMID: 8725098
A continuous epitope from transmissible gastroenteritis virus S protein fused to *E. coli* heat-labile toxin B subunit expressed by attenuated *Salmonella* induces serum and secretory immunity. Mar 1996

7/6/127 10480514 9629937 PMID: 8660841
7/6/106 10752920 97102795 PMID: 8947035

An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma-m chain in RCC cells does not improve sensitivity. Jul 10 1996

7/6/128 10468062 96275213 PMID: 8787077
Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of SR96 sFv-PE40 and heregulin-PE40. 1996

New gene from nine *Bacillus sphaericus* strains encoding highly conserved 35-kilodalton mosquitoicidal toxins. Jun 1996

7/6/130 10428564 96234995 PMID: 8639641
Role of CAS, a human homologue to the yeast chromosome segregation gene CSE1, in toxin and tumor necrosis factor-mediated apoptosis. May 28 1995

7/6/131 10427576 96234003 PMID: 8654560
Translational fusion of heat-labile enterotoxin chain B and beta₂-subunit of human chorionic gonadotropin: periplasmic expression in *Escherichia coli* and its immunogenicity. May 27 1996

7/6/132 10404014 96209978 PMID: 8631856
Target cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel non-viral gene delivery system. May 3 1996

7/6/133 10403262 96209219 PMID: 8633853
Domain III substitution in *Bacillus thuringiensis* delta-endotoxin CytA(N) results in superior toxicity for *Spodoptera exigua* and altered membrane protein recognition. May 1996

7/6/134 10398063 96204514 PMID: 8628234
Analysis of cry1Aa expression in sigE and sigK mutants of *Bacillus thuringiensis*. Apr 10 1996

7/6/135 10398435 96200861 PMID: 8621095
A *Bacillus sphaericus* gene encoding a novel type of mosquitoicidal toxin of 31.8 kDa. Apr 17 1996

7/6/136 10396911 96200113 PMID: 8631720
Plasmid RK2 toxin protein PurE: purification and interaction with the PurD antitoxin protein. Mar 1996

7/6/137 10382592 96187879 PMID: 8609372
Cytotoxicity of KDEL-terminated ricin toxins correlates with distribution of the KDEL receptor in the Golgi. Feb 1996

7/6/138 11373241 96178238 PMID: 8617218
A specific targeting domain in mature exotoxin A is required for its extracellular secretion from *Pseudomonas aeruginosa*. Jan 15 1996

7/6/139 10366229 96167453 PMID: 8608178
IL-2-ricin fusion toxin is selectively cytotoxic in vitro to IL-2 receptor-bearing tumor cells. Nov-Dec 1995

7/6/140 10360272 96163481 PMID: 8575456
Lipid interaction of the 37-kDa and 58-kDa fragments of the *Helicobacter pylori* cytotoxin. Dec 15 1995

7/6/141 10357255 96160040 PMID: 8562903
Targeting diphtheria toxin to growth factor receptors. Oct 1995

7/6/142 10345443 96147920 PMID: 8575044
[Construction and expression of the gene CD4V1V2-PE40, coding for a molecular targeted protein against AIDS] Aug 1995

7/6/143 10332216 96134516 PMID: 8527136
Improved expression of toxic proteins in *E. coli*. Aug 1995

7/6/144 10328564 96130835 PMID: 8594322
Identification by *in vitro* complementation of regions required for cell-invasive activity of *Bordetella pertussis* adenylate cyclase toxin. Sep 1995

7/6/145 10326513 96128870 PMID: 8596120
Disruption of *Neisseria simplex* virus ribonucleotide reductase quaternary structure by peptide inhibitors as a novel approach to antiviral therapy. Oct 1995

7/6/146 10294589 96096516 PMID: 8522171
Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic *Escherichia coli*. Nov 20 1995

7/6/147 10285718 96087571 PMID: 8522489
Experimental therapies in the treatment of cutaneous T-cell lymphoma. Oct 1995

7/6/148 10249633 96051174 PMID: 8527486
A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. 1995

7/6/149 10240727 96044032 PMID: 7592381
A modified two-component regulatory system is involved in temperature-dependent biosynthesis of the *Pseudomonas syringae* phytotoxin coronatine. Nov 1995

7/6/150 10230919 96032221 PMID: 759113
Identification of the essential regions for LukS and H gamma II-specific functions of staphylococcal leukocidin and gamma-hemolysin. Aug 19

7/6/154 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rights reserved.
11976922 99421861 PMID: 10491008
IL-2 receptor-targeted cytolytic IL-2Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice

Zheng X X; Steele A W; Hancock W W; Kawamoto K; Li X C; Nickerson P W; Li Y; Tian Y; Strom T B
Department of Medicine, Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA 02215, USA
Journal Code: 29051717R Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM

Record type: Completed Subfile: AIM; INDEX MEDICUS; ADS/HIV
High affinity IL-2R₅ is present on recently activated but not on resting or memory T cells. Selective targeting of T cells bearing high affinity IL-2R₅ is an attractive therapy for many T cell-dependent cytopathic disease processes. A variety of rodent mAbs directed against the alpha-chain of the IL-2R₅ as well as IL-2 fusion toxins, have been used in animals and humans to achieve selective immunosuppression. Here we report on the development of a novel IL-2R targeting agent, a cytolytic chimeric IL-2Fc fusion protein. This immunoligand binds specifically and with high affinity to IL-2R₅ and is structurally capable of recruiting host Ab-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities. The Ig component ensures an extended circulating t1/2 of 25 h following systemic administration. To subsequently explore the mechanisms of the antidiabetogenic effects of IL-2Fc, we have mutated the Fc_Y binding and complement C1q binding (Fc_Y-) domains of the Fc fragment to render the Fc_Y unable to direct Ab-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities. In a model of passive transfer of diabetes in nonobese diabetic mice, IgY IL-2Fc, but not nonIgY IL-2Fc-, exhibits striking antidiabetogenic effects. Together with the negligible potential of IL-2Fc for immunogenicity, this finding forecasts that cytolytic IL-2Fc may offer a new therapeutic approach for selective targeting of auto and allomorphic T cells.

Tags: Animal; Female; Male; Support, Non-U.S. Govt; Support, U.S. Govt; P.H.S. Descriptors: Cytotoxicity; Immunologic-genes; Diabetes Mellitus; Insulin-Dependent-immunology-IM; *Diabetes Mellitus, Insulin-Dependent--prevention and control-PC; *Gene Therapy; Immunoglobulins, Fc-genes-GE; *Interleukin-2-Genetics-GE; *Receptors, Interleukin-2-Genetics-GE; *Recombinant Fusion Proteins; Immunology--IM; Adoptive Transfusions; Monoclonal-Administration and dosage-AD; Antigens; CD4--Immunology-IM; Diabetics; Mellitus, Insulin-Dependent-pathology-P; Gene Targeting; Half-life; Immunophenotype; CD4--Immunology-IM; Recombinant Fusion Proteins--therapeutic use--TU; Injections, Intraperitoneal; Interleukin-2--therapeutic use--TU; Lymphocyte Depletion; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Recombinant Fusion Proteins; Monoclonal; Antigens CD4-0 (Immunoglobulins, Fc); 0 (Interleukin-2); 0 (Receptors, Interleukin-2); 0 (Recombinant Fusion Proteins)

Record Date Created: 19991021 Record Date Completed: 19991021

7/6/153 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rights reserved.
11887991 99330177 PMID: 10403383
Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway.
Noakes K L; Teissierenc H T; Lord J M; Dunbar P R; Cerundolo V; Roberts L M
Department of Biological Sciences, University of Warwick, Coventry, UK
FEBS letters (NETHERLANDS) Jun 18 1999 ; 453 (1-2) p95-9 ISSN 0014-5793 Journal Code: 0155157
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
Subfile: INDEX MEDICUS
Shiga-like toxin 1 (SLT) from *Escherichia coli* O157:H7 enters mammalian cells by endocytosis from the cell surface to the endoplasmic reticulum before translocating into the cytosol. Here, SLT was engineered at its N- or C-terminus to carry a peptide derived from influenza virus Matrix protein 1 for delivery to major histocompatibility complex (MHC) class I molecules. We show that SLT N-Ma was capable of sensitizing cells for lysis by appropriate cytotoxic T-lymphocytes whilst no killing of SLT-resistant cells was observed. Our results demonstrate that peptide was liberated intracellularly and that retrograde transport of a disarm cytotoxic protein can intersect the MHC class I presentation pathway.

Tags: Support, Non-U.S. Govt Descriptors: Antigen Presentation; *Antigens, Viral-metabolism-ME; *Bacterial Toxins -immunology-M; *Histocompatibility Antigens Class I; *Viral Matrix Proteins--immunology-M; Antigens, Viral-genes; GE Antigens, Viral-immunology-M; Bacterial Toxins -Genetics-GE; Bacterial Toxins -metabolism-ME; Biological Transport Cytotoxicity; Immunologic: Endoplasmic Reticulum-metabolism-ME; Recombinant Fusion Proteins -immunology-M; Recombinant Fusion Proteins -metabolism-ME; Shiga-Like Toxin I; T-Lymphocytes, Cytotoxic-immunology-M; Viral Matrix Proteins-genes-GE; Viral Matrix Proteins-metabolism-ME; CAS Registry No.: 0 (Antigens, Viral); 0 (Bacterial Toxins (Histocompatibility Antigens Class I); 0 (Recombinant Fusion Proteins); 0 (Shiga-Like Toxin I); 0 (Viral Matrix Proteins) (influenza virus membrane protein))
Record Date Created: 19990302 Record Date Completed: 19990802

7/5/17 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rights reserved.
Toxicologic pathology (UNITED STATES) Jan-Feb 1999, 27 (1), p53-7, ISSN 0192-6233 Journal Code: 7905907
Document type: Journal Article; Review; Review; Tutorial Languages: ENGLISH Main Citation Owner: NLM
Record type: Completed Subfile: INDEX MEDICUS

laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20092, USA.

About 12,000 Americans are diagnosed with malignant astrocytoma each year. Despite surgery, radiotherapy, and chemotherapy, the prognosis of these patients remains poor. Targeted toxins based on the identification of novel antigens or receptors provide a promising new approach to treating cancer. We have identified one such cell surface protein in the form of interleukin (IL)-4 receptors (IL-4R) on human malignant astrocytoma. Normal brain tissues from frontal cortex and temporal lobe cortex do not express IL-4R. To target IL-4R, we generated a chimeric fusion protein composed of IL-4 and Pseudomonas exotoxin (IL-4-PE). This toxin is highly cytotoxic to IL-4R-bearing human brain cancer cells. Preclinical toxicologic experiments were performed in mice, rats, and guinea pigs to determine an maximum tolerated dose. Intrathecal administration in cynomolgus monkeys produced high cerebrospinal fluid levels without any central nervous system or other abnormalities. When IL-4-PE was injected into the right frontal cortex of rats, localized necrosis was observed at 1,000 but not < or = 100 microg/ml doses. Intravenous administration of this biologic to monkeys produced reversible grade 3 or grade 4 elevations of hepatic enzymes in a dose-dependent manner. These results indicate that localized administration can produce nontoxic levels of IL-4-PE that may have significant activity against astrocytoma. In vivo experiments with nude mice have demonstrated that IL-4-PE has significant antitumor activity against human glioblastoma tumor model. Intratumor administration of IL-4-PE has been initiated for the treatment of malignant astrocytoma in a phase I clinical trial. (28 Refs.)

Tags: Animal; Human; Descriptors: "Brain Neoplasms-therapy"; "Therapy"; "Interleukin-4-Exotoxins-pharmacology"; "PD"; "Glioblastoma-therapy"; "Therapy"; "Interleukin-4-Exotoxins-pharmacology"; "GE"; "Brain Neoplasms--metabolism"; "ME"; "Drug Design"; "Interleukin-4-therapeutic use"; "TU"; "Recombinant Fusion Proteins--chemical synthesis"; "CS"; "Recombinant Fusion Proteins--chemical synthesis"; "CS"; "Recombinant Fusion Proteins--therapeutic use"; "TU"; "Recombinant Fusion Proteins--pharmacology"; "PD"; "0 (Recombinant Proteins); 0 (Exotoxins); 0 (IL-4-PE40 chimeric protein); 0 (Recombinant Proteins); 0 (Exotoxin A; Pseudomonas aeruginosa)"

Record Date Created: 1990/07/29 Record Date Completed: 1990/07/29

7/15/18 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rights reserved.

High-level expression and purification of the recombinant diphtheria toxin toxin DTGM for PHASE I clinical trials.

Frankel A E; Ramage J; LaRitter A; Feely T; Detalle S; Hall P; Tagge E; Kreitman R; Williamson M; Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. afrankel@wfubmc.edu

Protein expression and purification (UNITED STATES) Jun 1999, 16 (1), p190-201, ISSN 1046-5928 Journal Code: 9101495 Contract/Grant No.: NIH/R01/176738; HR; NHLBI Document type: Clinical Trial; Clinical Trial Phase I; Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

A genetically engineered fusion toxin targeted to acute myeloid leukemic (AML) blasts was designed with the first 388 amino acid residues of diphtheria toxin with an H-M linker fused to human granulocyte-macrophage colony-stimulating factor. The cDNA was subcloned in the pRK bacterial expression plasmid and used to transform BL21 (DE3) Escherichia coli harboring pUBS500 plasmid. Transformants were grown in Superbroth and induced with IPTG. Inclusion bodies were isolated, washed, and denatured in guanidine hydrochloride with dithioerythritol. Recombinant protein was refolded by diluting 100-fold in cold buffer with arginine and oxidized glutathione. After dialysis, purified protein was obtained after anion-exchange, size exclusion on FPLC, and polyminxin B affinity chromatography. The final material was filter sterilized, aseptically vialled, and stored at -80 degrees C. Fifty-four bacterial culture preparations were made and pooled into 27 batches. The final product was characterized by Coomassie Plus protein assay, Coomassie-stained SDS-PAGE, limulus amoebocyte lysate endotoxin assay, human AML HL60 cell cytotoxicity assay, HPLC TSK3000, N-terminal sequencing, E. coli DNA contamination, C57BL6 mouse toxicity, and immunohistochemistry. Yields were 23 mg/liter; bacterial culture of denatured fusion toxin. After refolding and chromatography, final yields were 24 +/- 4% or 5 mg/liter. Yielded product was sterile and 1.7 +/- 0.4 mg/ml in PBS. Purity by SDS-PAGE was 99 +/- 1%. Aggregates by HPLC were <1%. Potency revealed a 24-h IC50 of 2.7 +/- 0.5 microM on HL60 cells. Endotoxin levels were 1 x 10^-6. The N-terminal sequence was confirmed, and E. coli DNA was <113 pg/ml. The LD10 in mice was 110 microg/kg/day x 5. There was no evidence of loss of solubility, proteolysis, aggregation, or loss of potency over 3 months at -80 and -20 degrees C. Further, the drug was stable at 4, 25, and 37 degrees C in human serum for 48 h. Drug reacted only with human monocytes, granulocytes, and myeloid precursors in frozen human tissue sections by immunohistochemistry. The synthesis of this protein drug should be useful for production for clinical phase I/II clinical trials and may be suitable for other diphtheria toxin toxins indicated for clinical development. This is the first report of the setup of a recombinant fusion toxin for clinical trials. Copyright 1999 Academic Press.

*Diphtheria Toxin-therapeutic use-TU: "Granulocyte-Macrophage Colony-Stimulating Factor-isolation and purification-IP"; "Granulocyte-Macrophage Colony-Stimulating Factor-therapeutic use-TU: Acute Disease; Amino Acid Sequence; Base Sequence; DNA; Recombinant-
cophage Colony-Stimulating Factor-therapeutic use-TU: Acute Disease; Amino Acid Sequence; Base Sequence; DNA; Recombinant-
cophage Colony-Stimulating Factor-isolation and purification-IP"; "Recombinant Fusion Protein-therapeutic use-TU: CAS Registry No.: 0 (DNA, Recombinant); 0 (Diphtheria Toxin) 0 (P astmids) 0 (Recombinant Fusion Protein); 83889-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)"

genetics-GE; Diphtheria Toxin--genetics-GE; Drug Evaluation; Preclinical; Escherichia coli--genetics-GE; Gene Expression; Granulocyte-Macrophage Colony-Stimulating Factor--genetics-GE; HL-60 Cells; Lethal-Dose 50; leukemia; Myeloid--drug therapy-; DT; Mice; Microbiology; Molecular Sequence Data; Plasmids--genetics-GE; Recombinant Fusion Proteins--isolation and purification-IP; Recombinant Fusion Proteins--therapeutic use-TU; CAS Registry No.: 0 (DNA, Recombinant); 0 (Diphtheria Toxin) 0 (P astmids) 0 (Recombinant Fusion Protein); 83889-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)

Record Date Created: 1990/07/12 Record Date Completed: 1990/07/12

7/7/20 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rights reserved.

Cloning and cytotoxicity of fusion proteins of EGF and angiogenin.

Yoon J M; Han S H; Kwon O B; Kim S H; Park M H; Kim B K; Department of Microbial Chemistry, College of Pharmacy, Seoul National University, Kwanak-Gu, South Korea.

Life Sciences (ENGLAND) 1999, 64 (16) p1435-45, ISSN 0024-3226 Journal Code: 0375521 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Targeted toxins represent a new approach to specific cytotoxic therapy. Immunotoxins based on plant and microbial toxins are very immunogenic. To develop a targeted therapy that is less immunogenic and easily invades target tissues, four fusion proteins containing human angiogenin targeted by human EGF have been constructed. EGF is a single chain polypeptide, which binds epidermal growth factor receptor (EGFR) and is known to be internalized by endocytosis. Angiogenin has been separately fused either at the amino terminus or the carboxyl terminus of EGF via linkers, giving rise to angiogenin-gly-EGF and angiogenin-(gly)4s EGFR and EGF-angiogenin, EGF-gly-angiogenin, respectively. The fusion proteins were over-expressed in Escherichia coli and purified from periplasmic eluents by affinity chromatography. EGF-angiogenin and EGF-gly-angiogenin maintained receptor-binding activity of angiogenin in a single peptide and actively inhibited growth of human EGFR-positive target cells in culture. They are expected to have a very low immunogenic potential in humans because of their endogenous origin and also to have another potential therapeutic advantage because of their small size. Record Date Created: 1990/05/26 Record Date Completed: 1990/05/26

7/7/21 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rights reserved.

1179440 99238511 PMID: 10220447

Intracellular delivery of an antiviral peptide mediated by the B subunit of Escherichia coli heat-labile enterotoxin.

Loregian A; Papini E; Sain B; Marsden H S; Hirst T R; Pau G; Institute of Microbiology, University of Padua, 35121 Padua, Italy.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Apr 27 1999, 96 (p5221-6, ISSN 0027-8424, Journal Code: 7505876 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

We report an intracellular peptide delivery system capable of targeting specific cellular compartments. In the model system we constructed a chimeric protein consisting of the nontoxic B subunit of Escherichia coli heat-labile enterotoxin (EltB) fused to a 27-mer peptide derived from the DNA polymerase of herpes simplex virus 1. Viral DNA synthesis takes places in the nucleus and requires the interaction with an accessory factor, UL42, encoded by the virus. The peptide, designated Pol, is able to dissociate this interaction. The chimeric protein, EltB-Pol, retained the functional properties of both EltB and peptide components and was shown to inhibit viral DNA polymerase activity in vitro via disruption of the polymerase-UL42 complex. When added to virally infected cells, EltB-Pol had no effect on adenovirus replication but specifically interfered with herpes simplex virus 1 replication with vesicular compartments. The results indicate that the chimeric protein entered through endosomal acidic compartments a that the Pol peptide was cleaved from the chimeric protein before being translocated into the nucleus. The system we describe is suitable for delivery of peptides that specifically disrupt protein-protein interactions and may be developed to target specific cellular compartments. Record Date Created: 1990/06/10 Record Date Completed: 1990/06/10

7/7/23 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rights reserved.

11775824 99214180 PMID: 10196187

A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins.

Chaves-Otero E; Low P; Freer E; Norlin I; Weidmann M; von Etzelaus-Strain C; Thelestaem M; Microbiology and Tumourbiology Center, Karolinska Institutet, S-171 77 Stockholm, Sweden.

Journal of biological chemistry (UNITED STATES) Apr 16 1999, 274 (16) p10466-52, ISSN 0021-9258 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

2985121 Record Date Completed: 1990/06/10 Record Date Created: 1990/06/10

The large clostridial cytotoxins (LCTs) constitute a group of high molecular weight clostridial cytotoxins that inactivate cellular small GTP-binding proteins. We demonstrate that a novel LCT (TcdB-1470) from Clostridium difficile strain 1470 is a functional hybrid between "reference" TcdB-10463 and Clostridium sordellii TcsL-1522. It bound to the same specific receptor as TcdB-10463 but glucosylated the same GTP-binding proteins as TcsL-1522. All three toxins had equal enzymatic potencies but were equally cytotoxic only when microinjected. When applied extracellularly TcdB-1470 and TcdB-10463 were considerably more potent cytotoxins than TcsL-1522. The small GTP-binding protein R-Ras was identified as a target for Tcd-1470 and also for TcsL-1522 but not for Tcd-10463. R-Ras is known to control integrin-extracellular mat

interactions from inside the cell. Its glucosylation may be a major determinant for the cell rounding and detachment induced by the two R-Ras-attacking toxins. In contrast, fibroblasts treated with TocB-10463 were arborized and remained attached, with phosphotyrosine containing structures located at the cell-to-cell contacts and beta2-integrin remaining at the tips of cellular protrusions. These components were absent from cells treated with the R-Ras-inactivating toxins. The novel hybrid toxin will broaden the utility of the LCTs for clarifying the functions of several small GTPases, now including also R-Ras.

Record Date Created: 19990517 Record Date Completed: 19990517

77/29 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

11747698 99185011 PMID: 10985027
Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells.

Singh Y, Klimpel K R, Goel S, Swain P K, Leppla S H

Centre for Biochemical Technology, Delhi 110007, India.

Infection and immunity (UNITED STATES) Apr 1999, 67 (4) p1853-9, ISSN 0019-9567 Journal Code: 0246127

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed
The protective antigen (PA) protein of anthrax toxin binds to a cellular receptor and is cleaved by cell surface furin to produce a 63-kDa fragment (PA63). The receptor-bound PA63 oligomerizes to a heptamer and acts to translocate the catalytic moieties of the toxin, lethal factor (LF) and edema factor (EF), from endosomes to the cytosol. In this report, we used nondenaturing gel electrophoresis to show that each PA63 subunit in the heptamer can bind one LF molecule. Studies using PA immobilized on a plastic surface showed that monomeric PA63 is also able to bind LF. The internalization of PA and LF by cells was studied with radiolabeled and biotinylated proteins. Uptake was relatively slow, with a half-time of 30 min. The number of moles of LF internalized was nearly equal to the number of moles of PA subunit internalized. The essential role of PA oligomerization in LF translocation was shown with PA protein cleaved at residues 313-314. The oligomers formed by these proteins during uptake into cells were not as stable when subjected to heat and detergent as were those formed by native PA. The results show that the structure of the toxin proteins and the kinetics of proteolytic activation, LF binding, and internalization are balanced in a way that allows each PA63 subunit to internalize an LF molecule. This set of proteins has evolved to achieve highly efficient internalization and membrane translocation of the catalytic components, LF and EF. Record Date Created: 19990426 Record Date Completed: 19990426

77/31 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

11720993 99157563 PMID: 10048023
Expression and properties of an aerolysin-Clostridium septicum alpha toxin hybrid protein.

Dep D B, Nelson K L, Lawrence T S, Sellman B R, Tweten R K, Buckley J T

Department of Biochemistry and Microbiology, University of Victoria, BC, Canada.

Molecular microbiology (ENGLAND) Feb 1999, 31 (3) p785-94, ISSN 0950-382X Journal Code: 8712028

Contract/Grant No.: A137657; AI; NIAID Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM

Record type: Completed

Aerolysin is a bacterial channel-forming toxin secreted by *Aeromonas hydrophila*. The alpha toxin produced by *Clostridium septicum* is homologous to the large lobe of aerolysin. However, it does not contain a region corresponding to the small lobe of the Aeromonas toxin, leading us to ask what the function of the small lobe is. We fused the small lobe of aerolysin to alpha toxin, producing a hybrid protein that should structurally resemble aerolysin. Unlike aerolysin, the hybrid was not secreted when expressed in *Aeromonas salmonicida*. The purified hybrid was activated by proteolytic processing in the same way as both parent proteins and, after activation, it formed oligomers that corresponded to the aerolysin heptamer. Like aerolysin, the hybrid was far more active than alpha toxin against human erythrocytes and mouse T lymphocytes. Both aerolysin and the hybrid bound to human glycoprotein, and both were inhibited by preincubation with this erythrocyte glycoprotein, whereas alpha toxin was unaffected. We conclude that aerolysin contains two receptor binding sites, one for glycosyl-phosphatidylinositol-anchored proteins that is located in the large lobe and is also found in alpha toxin, and a second site, located in the small lobe, that binds a surface carbohydrate determinant. Record Date Created: 19990506 Record Date Completed: 19990506

77/32 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

11720819 99157408 PMID: 10047878

Differential activity of cholera toxin and *E. coli* enterotoxin: construction and purification of mutant and hybrid derivatives.

Rodighiero C, Man A T, Lencer W I, Hirst T R

University of Bristol, Department of Pathology and Microbiology, School of Medical Sciences, UK.

Biochemical Society Transactions (ENGLAND) Nov 1998, 26 (4) pS364, ISSN 0300-5127 Journal Code: 7506897

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Record Date Created: 19990413 Record Date Completed: 19990413

77/33 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

116580321 99115980 PMID: 9914159
The KDEL retrieval system is exploited by *Pseudomonas* exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum.

Jackson M E, Simpson J C, Girod A, Pepperkok R, Roberts L M, Lord J M

Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK m@jna.bio.warwick.ac.uk
Journal of cell science (ENGLAND) Feb 1999, 112 (Pt 4) p457-75, ISSN 0021-9533 Journal Code: 052457

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

To investigate the role of the KDEL receptor in the retrieval of protein toxins to the mammalian cell endoplasmic reticulum (ER) lysosome variants containing AARL or KDEL C-terminal tags, or the human KDEL receptor, have been expressed in toxin-treated COS 7 and HeLa cells. Expression of the lysosome variants and the KDEL receptor was confirmed by expressing lysosome-KDEL, which causes a

immunofluorescence. When such cells were challenged with diphtheria toxin (DT) or *Escherichia coli* Shiga-like toxin 1 (SLT-1) there was no observable difference in their sensitivities as compared to cells which did not express these exogenous proteins. In contrast, the cytotoxicity of *Pseudomonas* exotoxin A (PE) is reduced by expressing lysosome-KDEL, which causes a additional KDEL receptors. These data suggest that, in contrast to SLT-1, PE can exploit the KDEL receptor in order to reach ER lumen where it is believed that membrane transfer to the cytosol occurs. This contention was confirmed by microinjecting iVero cells antibodies raised against the cytoplasmically exposed tail of the KDEL receptor. Immunofluorescence confirmed that these antibodies prevented the retrograde transport of the KDEL receptor from the Golgi complex to the ER, and this in turn reduced the cytotoxicity of PE, but not that of SLT-1, to these cells. Record Date Created: 19990720 Record Date Completed: 19980720

77/36 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

11657978 99082760 PMID: 9876933
Stepwise transplantation of an active site loop between heat-labile enterotoxins LT-II and LT-I and characterization of the obtained hybrid toxins.

Fell J K, Platias A A, van den Akker F, Reddy R, Merritt E A, Storm D R, Hol W G

Howard Hughes Medical Institute, Department of Biological Structure, University of Washington, Seattle 98195-7742 USA

Contract/Grant No.: A134501; AI; NIAID Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM

Record type: Completed

Members of the cholera toxin family, including *Escherichia coli* heat-labile enterotoxins LT-I and LT-II, catalyze the covalent modification of intracellular proteins by transfer of ADP-ribose from NAD to a specific arginine of the target protein. The ADP-ribosylating activity of these toxins is located in the A-subunit, for which LT-I and LT-II share a 63% sequence identity. The flexible loop in LT-I, ranging from residue 47 to 56, closes over the active site cleft. Previous studies have shown that point mutations in this loop have dramatic effects on the activity of LT-I. Yet, in LT-II the sequence of the equivalent loop differs at four positions from LT-I. Therefore five mutants were created by a stepwise replacement of the loop sequence in LT-I with virtually all the corresponding residues in LT-II. Since we discovered that LT-II had no activity versus the artificial substrate diethylaminobenzylidene-aminoguanidine (DEABA)G while LT-I does, our active site mutants most likely probe the NAD binding, not the arginine binding region of the active site. The five hybrid toxins obtained (Q49A, F52N, V53T, Q49V/F52 and Q45V/F52N/V53T) show (i) great differences in holotoxin assembly efficiency; (ii) decreased cytotoxicity in Chinese hamster ovary cells; and (iii) increased *in vitro* enzymatic activity compared with wild type LT-I. Specifically, the three mutants contain the F52N substitution display a greater V_{max} for NAD than wild type LT-I. The enzymatic activity of the V53T mutant is significantly higher than that of wild type LT-I. Apparently this subtle variation at position 53 is beneficial, in contrast to several other substitutions at position 53 which previously had been shown to be deleterious for activity. The most striking result of this study is that the active site loop of LT-I, despite great sensitivity for point mutations, can essentially be replaced by the active site loop of LT-II, yielding an active 'hybrid enzyme' as well as 'hybrid toxin'. Record Date Created: 19990308 Record Date Completed: 19990308

77/38 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

11626571 99060051 PMID: 9843379
Characterization of membrane translocation by anthrax protective antigen.

Wesche J, Elliott J L, Falnes P O, Olsnes S, Collier R J

Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.

Biochemistry (UNITED STATES) Nov 10 1998, 37 (45) p1573-46, ISSN 0006-2960 Journal Code: 0370623

Contract/Grant No.: A122021; AI; NIAID Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM

Record type: Completed

Solving the crystallographic structure of the ring-shaped heptamer formed by protective antigen (PA), the B moiety of anthrax toxin, has focused attention on understanding how this oligomer mediates membrane translocation of the toxin's A moieties. We have developed an assay for translocation in which radiolabeled ligands are bound to proteolytically activated PA (PA63) at the surface of CHO or 6 cells, and translocation across the plasma membrane is induced by lowering the pH. The cells are then treated with Pronase E to degrade residual surface-bound material, and protected ligands are quantified after fractionation by SDS-PAGE. Translocation was most efficient (35%-50%) with LFN, the N-terminal PA binding domain of the anthrax lethal factor (LF). Intact LF, edema factor (EF), or fusion proteins containing LFN fused to certain heterologous proteins [the diphtheria toxin (A chain (DTA)) or dihydrofolate reductase (DHFR)] were less efficiently translocated (15%-20%); and LFN fusions to several other proteins were not translocated at all. LFN with different N-terminal residues was found to be degraded according to the N

protected cells from the effects of MTX. Both results are consistent with a cytosolic location of protected proteins. Evidence that a protein must unfold to be translocated was obtained in experiments showing that (i) translocation of LFNDHTA was blocked by introduction of an artificial disulfide into the DTA moiety, and (ii) translocation that the acid-induced translocation by anthrax toxin closely resembles that of diphtheria toxin, despite the fact that these two toxins are unrelated and form pores by different mechanisms.

Record Date Created: 19981221 Record Date Completed: 19981221

777539 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.
1606274 99039034 PMID: 9821593

Positive selection vectors to generate fused genes for the expression of his-tagged proteins.

Universite Libre de Bruxelles, Rhode-Saint-Genese, Belgium.

BioTechniques (UNITED STATES) Nov 1998 , 25 (5) p889-904, ISSN 0736-6205 Journal Code: 8306785

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Epitope tagging simplifies detection, characterization and purification of proteins. Gene fusion to combine the coding region of a well-characterized epitope with the coding region for a protein of interest, generally requires several subcloning steps. Alternatively, a PCR strategy can be used to generate such a chimeric gene. In addition to its simplicity, this approach allows one to limit the size of the multiple cloning sites present in conventional expression vectors, thus reducing the introduction of artificial amino-acid sequences into the fused protein. In this communication, we describe new vectors that allow PCR cloning and selection of chimeric genes coding for N- or C-terminal His-tagged proteins. These vectors are based on the control of cell death CodB direct selection technology and are well adapted to the cloning of blunt-ended PCR products that were generated by using the thermostable polymerases that provide proofreading activity. Record Date Created: 19980119 Record Date Completed: 19980119

77552 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

1368068 98248937 PMID: 9587386

Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology

Immunotoxines recombinantes et toxines chimériques pour une thérapie ciblée en oncologie.

Chiron MF

Rhone-Poulenc Rorer Genecell, Centre de recherche de Vitry-Alfortville, France.

Bulletin du cancer (FRANCE) Dec 1997 , 84 (12) p1135-40, ISSN 0007-4551 Journal Code: 0072416

Document type: Journal Article; Review; Review; Tutorial; English Abstract Languages: FRENCH

Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

Immunotoxins and chimeric toxins are hybrid molecules constituted of antibodies, growth factor or cytokines coupled to peptide toxins. They are designed to selectively eliminate tumor cells. Some of these chimeric have been shown to induce complete tumor regressions of human tumor xenografts in immunodeficient mice. In clinical trials, higher anti tumor response were observed in lymphoma, brain tumor, breast and colon cancers. Problems arose with normal tissue toxicity and the production of neutralising antibodies. Should the latest recombinant toxins conceived by rationale design, solved these problems, chimeric toxins would be an alternative approach to target tumor cells and vascular endothelial cells in solid tumors. (37 Refs.)

Tags: Animal; Human; Descriptors: Antigen-Presenting Cells; -angi effects; -DE; *immunotoxins; -therapeutic use; -TU; *Neoplasms; Experimental-therapY; -TH; *Recombinant Fusion Proteins; -therapeutic use; -TU; Antibodies; Monoclonal; pharmacology -PC; Antibodies; Monoclonal; therapeutic use; -TU; Bacterial Toxins; -pharmacology -PD; Bacterial Toxins; -therapeutic use; -TU; Cytotoxicity; Immunologic; Exotoxins; -pharmacology -PD; Exotoxins; -therapeutic use; -TU; Immunotherapy; -methods; -MF; Immunotoxins; -pharmacology -PD; Immunotoxins; -toxicity; -TO; Mice; Recombinant Fusion Proteins; -toxicity; -TO C4S Registry No.: 0 (Antibodies; Monoclonal); 0 (Bacterial Toxins); 0 (Exotoxins); 0 (Immunotoxins); 0 (Recombinant Fusion Proteins); Record Date Created: 19980602 Record Date Completed: 19980602

77552 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

13537192 98217769 PMID: 9558086

Increasing immunogenicity of antigens fused to Ig-binding proteins by cell surface targeting.

Leonetti M; Thao R; Cotton J; Leroy S; Drewe P; Ducanell F; Boulain J C; Menez A

Departement d'ingénierie et d'Etudes des Protéines, C. E. Saday, Gil-Sur-Yvette, France leonetti@cea.fr

Journal Code: 2085117R Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM

Record type: Completed Subfile: AIM; INDEX MEDICUS

Fusion of antigenic proteins to Ig-binding proteins such as protein A from *Staphylococcus aureus* and its derived ZZ fragment is known to increase immunogenicity of the fused Ag *in vivo*. To shed light on the origin of this effect, we used snake toxins as Ags

and observed that 1) fusion of toxins to ZZ enhanced their presentation to a toxin-specific T cell hybridoma (T1B2), using A20 B lymphoma cells, splenocytes, or peritoneal exudate cells as APCs; 2) this enhancement further increased when the number of fused Ig-binding domains varied from two with ZZ to five with protein A; and 3) the phenomenon vanished when the fusion protein was preincubated with an excess of free ZZ or when P388D1 myeloma cells were used as APCs. Therefore, ZZ-fused toxins are likely to be targeted to surface IgGs of APCs by their ZZ moiety. Furthermore, ZZ-alpha and toxin alpha stimulated similar profiles of toxin-specific T cells in BALB/c mice, suggesting a comparable processing and presentation *in vivo* for both

toxin forms. To improve the targeting efficiency, ZZ-alpha was noncovalently complexed to various IgGs directed to different cell surface components of APCs. The resulting complexes were up to 10(3)-fold more potent than the free toxin at stimulating T1B cells. They elicited both a T cell and an Ab response in BALB/c mice, without the need of any adjuvant. This simple approach may find practical applications by increasing the immunogenicity of recombinant proteins without the use of adjuvant.

*Immunoglobulins; -metabolism-ME; *Recombinant Fusion Proteins; -immunology-M; *Recombinant Fusion Proteins; -metabolism-ME; Antibody Formation; Antigen Presentation; Antigen-Presenting Cells; -immunology-M; Cell Membrane; -immunology-M; Erabutoxins; Immunology-M; Hydrides; Immunization; Lymphocyte Activation; Mice; Mice; Inbred BALB C; Peptide Fragments; -immunology-M; Peptides; -metabolism-ME; Staphylococcal Protein A; -immunology-M; Staphylococcal Protein A; -metabolism-ME; T-lymphocytes; -IM C4S Registry No.: 0 (Antigens); 0 (Carrier Proteins); 0 (Fabtoxins); 0 (Immunoglobulins); 0 (Peptide Fragments); 0 (Recombinant Fusion Proteins); 0 (Staphylococcal Protein A); 1194-61-4 (erabutoxin A)

Record Date Created: 19980504 Record Date Completed: 19980504

77763 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

11274724 98153210 PMID: 94-85477

Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1.

Landgraf R; Pegram M; Stiamon D J; Eisenberg D

Department of Chemistry and Biochemistry and Division of Hematology-Oncology, University of California-Los Angeles, Box 951570, Los Angeles, California 90095-1570, USA.

Biochemistry (UNITED STATES) Mar 3 1998 , 37 (9) p3220-8, ISSN 0006-2960 Journal Code: 0375623

Contract/Grant No.: 1K12 CA01714; CA; NCI; GM31299 GM; NIGMS Document type: Journal Article

Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

As a step in the design of directed toxins, aimed at cells that overexpress HER receptors, particularly breast carcinoma cells, we studied the properties of a chimera of diphtheria toxin (DT) and heregulin beta1. The EGF-like growth hormone heregulin is ligand for the HER3 and HER1 receptors and their heterodimers with HER2. The 60-residue EGF-like domain (hrg) of heregulin exhibits a biological response and binds to these receptors primarily through its N terminus. We tested a fusion protein in which replaces the C-terminal receptor-binding domain of DT (DT(389)hrg) and an alternative design in which this domain is fused to the N terminus of DT(389). Of those two constructs, the N-terminal fusion was not active as a directed toxin but elicited a growth response. The C-terminal fusion of hrG to DT(389) yielded a functional toxin and showed cell line specific cytotoxicity that is consistent with heregulin specificity. The binding of hrG to its cognate receptor is not impaired as shown by receptor activation direct binding, and competition with free hrG. Cytotoxicity is dependent on high-affinity binding of DT(389)hrG to HER3 and HER receptors and is not mediated by HER2 overexpression alone. For those cell lines exhibiting high-affinity binding sites, the level of cytotoxicity correlates with the rate of internalization. Thus DT(389)hrG chimeras offer a possible avenue toward directed toxins against cells that overexpress HER receptors. Record Date Created: 19980403 Record Date Completed: 19980403

77765 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

11269315 98147722 PMID: 9488398

Chimeric clostridial cytotoxins: identification of the N-terminal region involved in protein substrate recognition.

Hofmann F; Busch C; Aktories K

Institut für Pharmakologie und Toxikologie der Albert-Ludwigs-Universität Freiburg, Germany.

Infection and immunity (UNITED STATES) Mar 1998 , 66 (3) p1076-81, ISSN 0019-9567 Journal Code: 0246127

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Clostridium sordellii lethal toxin is a member of the family of large clostridial cytotoxins that glucosylate small GTPases. In

contrast to Clostridium difficile toxins A and B, which exclusively modify Rho subfamily proteins, C. sordellii lethal toxin also glucosylates Ras subfamily proteins. By deletion analysis and construction of chimeric fusion proteins of C. sordellii lethal toxin and C. difficile toxin B, we localized the enzymatic activity of the lethal toxin to the N terminus of the holotoxin and identified the region involved in protein substrate specificity. The toxin fragment of the N-terminal 56 amino acid residues of C. sordellii leth

toxin glucosylated Rho and Ras subfamily proteins, as the holotoxin did. Deletion of a further 30 amino acid residues from the terminus of this active fragment drastically reduced glucotransferase activity and blocked glucuronylase activity. Exchange of amino acid residues 364 through 516 of lethal toxin for those in the active toxin B fragment [1 to 546] allowed glucosylation of Ras subfamily proteins. In contrast, the chimera with amino acids 1 to 364 from toxin B, 365 to 468 from lethal toxin, and 469 to 546 from toxin B exhibited markedly reduced modification of Ras subfamily proteins, whereas modification of Rac and Cdc42 was hardly changed. The data indicate that the region of amino acid residues 364 through 516 primarily defines the substrate specificity of C. sordellii lethal toxin. Record Date Created: 19980312 Record Date Completed: 19980312

77792 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

10866676 97218154 PMID: 9055815

In vitro effects of a recombinant toxin, mSCF-PE40, targeting c-kit receptors ectopically expressed in small cell lung cancers.

Nishida K; Seio M; Takahashi T; Oshima Y; Asano S; Tojo A; Ueda R

Laboratory of Chemotherapy, Aichi Cancer Center Research Institute, Nagoya, Japan.

Cancer letters (IRELAND) Feb 26 1997 , 13 (2) p153-8, ISSN 0304-3835 Journal Code: 7500053

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Most small cell lung cancers (SCLCs) ectopically express high levels of the c-kit receptor. We have examined if the receptor can serve as a target for a chimeric toxin, mSCF-PE40 composed of murine stem cell factor (SCF) genetically fused to the N terminus of a modified form of *Pseudomonas* exotoxin (PE) lacking its cell recognition domain. Selective Cytotoxicity was found for human c-kit receptor-negative cells. This agent thus warrants further evaluation for therapy of human SCLCs. Record Date Created: 1997/04/07 Record Date Completed: 1997/04/07

77/96 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.
108/9657 97/09543 PMID: 8951823
Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin.

Chitron M; Oqata M; FitzGerald DJ
Biotherapy Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20292, USA.

Molecular microbiology (ENGLAND) Nov 1996, 22 (4):769-78, ISSN 0950-382X Journal Code: 8712028

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

To be toxic for mammalian cells, *Pseudomonas* exotoxin (PE) requires proteolytic cleavage between Arg-279 and Gly-280. Cleavage, which is mediated by the cellular protease furin, generates an active C-terminal fragment which translocates to the cytosol and inhibits protein synthesis. *In vitro*, furin-mediated cleavage is optimal at pH 5.5 with a relatively slow turnover rate. Within cells, only 5-10% of cell-associated PE is cleaved. To investigate the reasons for this inefficient cleavage, the amino acid composition near the cleavage site was altered to resemble more closely the arginine-rich sequence from the functionally similar region of diphtheria toxin (DT). Four PE-DT mutants were generated, whereby 1, 5, 6 or 8 amino acids at the PE-cleavage site were changed to amino acids found at the DT-cleavage site. Mutant proteins were expressed in *Escherichia coli*, purified and then analysed for their susceptibility to cleavage by furin and trypsin, susceptibility to cell-mediated cleavage, and cytotoxic activity relative to wild-type PE. At pH 5.5, the rate of both furin-mediated cleavage and trypsin-mediated cleavage increased dramatically when amino acids in PE were altered to resemble the DT sequence. This increase did not alter the pH optimum for furin-mediated cleavage of PE toxins, which remained at pH 5.0-5.5. When radioactive versions of selected PE-DT proteins were added to intact cells, an increase in the percentage of molecules that were cleaved relative to wild-type PE was not seen. However, changes that favoured increased proteolysis apparently interfered with other important toxin functions because none of the PE-DT proteins exhibited enhanced toxicity for cells when compared with the activity of wild-type PE. Record Date Created: 1997/03/31 Record Date Completed: 1997/03/31

1/6/1 14405705 22309410 PMID: 12421321

SycE allows secretion of YopE-DtHFR hybrids by the *Yersinia enterocolitica* type III Ysc system. Nov 2002

1/6/2 1163391 99067023 PMID: 9851688

Determinants of the fidelity of processing glucosaminidase-lysozyme fusions by *Aspergillus niger*. Nov 16 1998

10/6/3 10701557 97/050825 PMID: 8895564

Status of YopM and YopN in the *Yersinia* Yop virulon. YopM of *Y. enterocolitica* is internalized inside the cytosol of PU5-1.8 macrophages by the YopB, D N delivery apparatus. Oct 1 1996

10/6/4 098559120 21671924 PMID: 11737648

Purification of recombinant human epidermal growth factor secreted from the methylotrophic yeast *Hansenula polymorpha*. Feb 2002

10/6/5 09795539 21602927 PMID: 11737648

The type III secretion chaperone LcrH co-operates with YopD to establish a negative, regulatory loop for control of Yop synthesis in *Yersinia* pseudotuberculosis. Nov 2001

10/6/6 08156965 94/22840 PMID: 8165210

The lcb (YscNLU) gene cluster of *Yersinia pseudotuberculosis* is involved in Yop secretion and shows high homology to the spa gene clusters of *Shigella flexneri* and *Salmonella typhimurium*. May 1994

10/6/7 07723384 93/78658 PMID: 8440333

Purification and characterization of the trefoil peptide human spasmodolytic polypeptide (hSP) produced in yeast. Mar 8 1993

10/6/8 07520216 92/383946 PMID: 1514325

Efficient secretion in yeast based on fragments from K1 killer preprotein. Apr 1 1992

10/6/9 07461533 93/26077 PMID: 1624459

Structure and regulation of the *Yersinia pestis* yscBCDEF operon. Jul 1992

1/6/10 0595728 91/20791 PMID: 1387012

Efficient KEX2-like processing of a glucanase-interleukin-6 fusion protein by *Aspergillus nidulans* and secretion of mature interleukin-6. Apr 1991

Regulation of alpha-factor production in *Saccharomyces cerevisiae*: alpha-factor pheromone-induced expression of the MF alpha 1 and STE13 genes. Oct 1989

10/5/7 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

07723394 93/178658 PMID: 8440393
Purification and characterization of the trefoil peptide human spasmolytic polypeptide (hSP) produced in yeast.

Thim L; Norris K; Nielsen P; Bjorn S; Christensen M; Petersen J
Department of Protein Chemistry, Pharmaceuticals Research, Novo Nordisk, Novo Alle, Bagsvaerd, Denmark.

FBS Letters (NETHERLANDS) Mar 8 1993, 318 (3): p345-52, ISSN 0014-5793 Journal Code: 0155157

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Suflife: INDEX MEDICUS

Recombinant human spasmolytic polypeptide (r-hSP) has been produced in relatively large amounts in *Saccharomyces cerevisiae*. The two intronless trefoil domains of the hSP-DNA were cloned separately by PCR from human genomic DNA, and the remaining parts of the gene synthesized. Recombinant plasmids were constructed to encode a fusion protein consisting of hybrid leader sequence and the hSP sequence. The leader sequence serves to direct the fusion protein into the secretory pathway of the cell and to expose it to the Kex 2 processing enzyme system. The secreted r-hSP was found in a glycosylated and an non-glycosylated form. The two forms of r-hSP were purified from the yeast fermentation broth by a combination of ion exchange chromatography and preparative HPLC. The overall yield from 8 litres of fermentation broth was 160 mg r-hSP and 219 mg glycosylated r-hSP corresponding to 50% and 34%, respectively. The structure of the r-hSP and the glycosylated r-hSP was determined by amino acid analysis and carbohydrate composition analysis as well as by peptide mapping, amino acid sequencing and mass spectrometric analysis.

Tags: Human Descriptors: Peptides-isolation and purification-IP; * Recombinant Fusion Proteins--isolation and purification-IP; * *Saccharomyces cerevisiae*-metabolism-ME; Amino Acid Sequence; Amino Acids--analysis-AN; Base Sequence; Carbohydrates--analysis AN; Chromatography; High Pressure Liquid; Chromatography; Ion Exchange; Cloning; Molecular; DNA; genetics-GE; Glycosylation; Growth Substances--chemistry-CH; Growth Substances--genetics-GE; Molecular Sequence Data; Peptide Mapping; Peptides--chemistry-CH; Peptides--genetics-GE; Plasmids; Polymerase Chain Reaction; Recombinant Fusion Proteins--biosynthesis-BI; Recombinant Fusion Proteins--chemistry-CH; *Saccharomyces cerevisiae*-genetics-GE; Spectrum Analysis; Mass CAS Registry No: 0 (Amino Acids); 0 (Carbohydrates); 0 (Growth Substances); 0 (Peptides); 0 (Plasmids); 0 (Recombinant Fusion Proteins); 146046-76-3 (trefoil factor); 8298 (77-7 (pancreatic spasmodolytic polypeptide)); 9007-49-2 (DNA); Record Date Created: 19930330 Record Date Completed: 19930330

Recombinant human spasmolytic polypeptide (r-hSP) has been produced in relatively large amounts in *Saccharomyces cerevisiae*. The two intronless trefoil domains of the hSP-DNA were cloned separately by PCR from human genomic DNA, and the remaining parts of the gene synthesized. Recombinant plasmids were constructed to encode a fusion protein consisting of hybrid leader sequence and the hSP sequence. The leader sequence serves to direct the fusion protein into the secretory pathway of the cell and to expose it to the Kex 2 processing enzyme system. The secreted r-hSP was found in a glycosylated and an non-glycosylated form. The two forms of r-hSP were purified from the yeast fermentation broth by a combination of ion exchange chromatography and preparative HPLC. The overall yield from 8 litres of fermentation broth was 160 mg r-hSP and 219 mg glycosylated r-hSP corresponding to 50% and 34%, respectively. The structure of the r-hSP and the glycosylated r-hSP was determined by amino acid analysis and carbohydrate composition analysis as well as by peptide mapping, amino acid sequencing and mass spectrometric analysis.

Tags: Human Descriptors: Peptides-isolation and purification-IP; * Recombinant Fusion Proteins--isolation and purification-IP;

**Saccharomyces cerevisiae*-metabolism-ME; Amino Acid Sequence; Amino Acids--analysis-AN; Base Sequence; Carbohydrates--analysis AN; Chromatography; High Pressure Liquid; Chromatography; Ion Exchange; Cloning; Molecular; DNA; genetics-GE; Glycosylation; Growth Substances--chemistry-CH; Growth Substances--genetics-GE; Molecular Sequence Data; Peptide Mapping; Peptides--chemistry-CH;

Peptides--genetics-GE; Plasmids; Polymerase Chain Reaction; Recombinant Fusion Proteins--biosynthesis-BI; Recombinant Fusion Proteins--chemistry-CH; *Saccharomyces cerevisiae*-genetics-GE; Spectrum Analysis; Mass CAS Registry No: 0 (Amino Acids); 0

(Carbohydrates); 0 (Growth Substances); 0 (Peptides); 0 (Plasmids); 0 (Recombinant Fusion Proteins); 146046-76-3 (trefoil factor); 8298 (77-7 (pancreatic spasmodolytic polypeptide)); 9007-49-2 (DNA); Record Date Created: 19930330 Record Date Completed: 19930330

Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Oct 2 1997

12/6/2 10729076 97/078529 PMID: 8919453
Identification and characterization of an extracellular protease activity produced by the marine *Vibrio* sp. 60. Feb 1 1996

12/6/3 09567217 95/55518 PMID: 773736
Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants. May 1995

12/6/4 08370202 95/051875 PMID: 7836513
Proteolytic cleavage at arginine residues within the hydrophilic disulphide loop of the *Escherichia coli* Shiga-like toxin I A subunit is not essential for cytotoxicity Oct 1993

12/6/5 08332655 95/020525 PMID: 7836510
Genetic identification of exported proteins in *Streptococcus pneumoniae*. Sep 1993

12/6/6 08171538 94/237439 PMID: 8181710
Efficient extracellular production of hybrid E. coli heat-labile enterotoxin B subunits in a marine *Vibrio*. Mar 15 1994

12/6/7 07905627 93/56458 PMID: 8355916
Expression of the *Pasteurella haemolytica* leukotoxin is inhibited by a locus that encodes an ATP-binding cassette homolog. Sep 1993

12/6/8 0748879 93/33425 PMID: 1629152
Secretion of CyaA-PrfB and HlyA-PrfB fusion proteins in *Escherichia coli*: involvement of the glycine-rich repeat domain of *Erwinia chrysanthemi* protease B. Aug 1992

12/6/9 05844070 88/39014 PMID: 3129403
Association of degradation and secretion of three chimeric polypeptides in *Escherichia coli*. May 1988

16/5/1 10054164 2/2001/09 PMID: 12011466
The gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits Notch signaling. Mar 14 2

16/5/2 08627536 93/316033 PMID: 7795711
SeCA-dependent translocation of a large periplasmic loop in the *Escherichia coli* MalF inner membrane protein is a function of sequence context. Apr-Jun 1995

16/5/3 0854296 93/23124 PMID: 7715449

186/11 15677795 2287043 PMID: 12853446 Caspase-activated PAK-2 is regulated by subcellular targeting and proteasomal degradation. Oct 09 2003
Why green fluorescent fusion proteins have not been observed in the vacuoles of higher plants. Aug 2003

186/13 14599955 2242374 PMID: 12535522 ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Jan 2003
Dissecting various ATP-dependent steps involved in proteasomal degradation. Jan 2003

186/14 14599946 22423765 PMID: 12535513 P97 domains facilitate binding of high temperature requirement protease A (HtrA) and tail-specific protease (Tsp) to heterologous substrates through recognition of the small stable RNA A (SSRA)-encoded peptide. Oct 18 2002

186/16 14104297 22297623 PMID: 12408819 Multiple associated proteins regulate proteasome structure and function. Sep 2002

186/17 13957875 22200655 PMID: 12234933 Alternating translocation of protein substrates from both ends of ClpXP protease. Sep 16 2002
Characterization of intermediates in the process of plant peroxisomal protein import. Dec 1 1998

186/18 13800699 99321840 PMID: 10393320 Multi-ubiquitination of a nascent membrane protein produced in a rabbit reticulocyte lysate. Jul 1999

186/19 11626266 99059723 PMID: 9943491 UDP-galactose:ceramide galactosyltransferase is a class I integral membrane protein of the endoplasmic reticulum. Oct 2 1998

186/20 11151647-1 98405098 PMID: 9733748 Protoplast-dependent nuclear localization of the caspase-2 (Nedd2) precursor. A novel function for a caspase prodomain. Sep 18 1998
Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Oct 28 1997

186/21 11130331 98004523 PMID: 9342622 Antennae phospholipids are determinants of membrane protein topology. Jul 16 1997

186/22 11038716 97392455 PMID: 9250669 Aromatic phospholipids are determinants of membrane protein topology. Jul 16 1997

186/23 10984612 97392455 PMID: 9250669 Regulation of the proteinase B structural gene PRB1 in *Saccharomyces cerevisiae*. Mar 1997

186/24 10417616 96223976 PMID: 8626744 Stabilization of a HspA-LaeZ hybrid protein against proteolysis during carbon starvation in *atp* mutants of *Salmonella typhimurium*. Apr 1996
Ricin A chain fused to a chloroplast-targeting signal is unfolded on the chloroplast surface prior to import across the envelope membranes. Feb 23 1996

186/25 10417427 96218725 PMID: 8636508 Properties of the protein encoded by the U1-32 open reading frame of herpes simplex virus 1. Jun 1996

186/26 10404174 96210138 PMID: 8635976 Proteasome inhibitors block VCAM-1 and ICAM-1 gene expression in endothelial cells without affecting nuclear translocation of nuclear factor-kappa B. Apr 1996

186/27 10395035 96202337 PMID: 8633590 Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Feb 20 1996
Rapid transmembrane movement of CG-NBD-labeled phospholipids across the inner membrane of *Escherichia coli*. Apr 3 1996

186/28 10394680 96200102 PMID: 8631709

186/29 09382476 21145823 PMID: 11248057 Forssman-specific transcription of the lfb gene during sporulation in *Bacillus subtilis*. May 2001

186/30 09374452 21137192 PMID: 1128807 The nucleoporin Nup88 associates with the intranuclear filamentous protein network of TPR. Mar 13 2001
Proteasome inhibition induces nuclear translocation and transcriptional activation of the dioxin receptor in mouse embryo primary fibroblasts

186/31 09186881 20493582 PMID: 10922368 The amino-terminal domain of apolipoprotein B does not undergo retrograde translocation from the endoplasmic reticulum to the cytosol. The proteasomal degradation of nascent apolipoprotein B begins at the carboxyl terminus of the protein, while apolipoprotein B is still in its original translocon. Oct 13 2000

186/32 09186894 20493281 PMID: 11038175 Characterization of the signal that directs Tom20 to the mitochondrial outer membrane. Oct 16 2000

186/33 085890412 95278726 PMID: 7755939 Proteasomal degradation of the outer membrane protein α ga beta of *Neisseria gonorrhoeae*. Apr 1 1995

186/34 08575242 95263544 PMID: 7744847 C-terminal glycine-histidine tagging of the outer membrane protein α ga beta of *Neisseria gonorrhoeae*. Apr 1 1995
Import of transcription factor MTF-1 into the yeast mitochondria takes place through an unusual pathway. May 19 1995

186/35 08370202 95058175 PMID: 7966513 Proteolytic cleavage at arginine residues within the hydrophobic disulphide loop of the *Escherichia coli* Shiga-like toxin 1 A subunit is not essential for cytotoxicity. Oct 1993

186/36 0838357435 95054506 PMID: 7957078 Molecular chaperones cooperate with PIM1 protease in the degradation of misfolded proteins in mitochondria. Nov 1 1994
Translocation of N-terminal tails across the plasma membrane. Oct 3 1994

186/37 08332655 95020625 PMID: 7934910 Genetic identification of exported proteins in *Streptococcus pneumoniae*. Sep 1993

186/38 08321998 95009598 PMID: 7925307 Translocation of N-terminal tails across the plasma membrane. Oct 3 1994

186/39 07392600 93394533 PMID: 8379852 Semliki Forest virus capsid protein expressed by a baculovirus recombinant. 1993

186/40 07556265 92404727 PMID: 2136629 Nuclear transport of plant polyviral proteins. Oct 1990

186/41 07501664 92365167 PMID: 1501298 Regulation of nuclear transport of a plant polyvirus protein by autoproteolysis. Sep 1992

186/42 07483840 92332466 PMID: 1321129 Carboxy-terminal sequences can influence the in vitro import and intraorganellar targeting of chloroplast protein precursors. Jul 15 1992

186/43 07453660 92317095 PMID: 1377688 Sequential translocation of an artificial precursor protein across the two mitochondrial membranes. Jul 5 1992

186/44 07426279 92289698 PMID: 1600950

186/23 10113842 22080058 PMID: 12065522 Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain. Jul 4 2002
Role for the adaptor protein Grb10 in the activation of Akt. Feb 2002

186/24 0986371 21666973 PMID: 11809791 Hypoxia-inducible factor-1 alpha (HIF-1 alpha) escapes O2-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. Jul 2001

186/26 09463802 21260031 PMID: 1135933 Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. May 2001

186/27 0946666 21234971 PMID: 1136669 The human peroxisomal targeting signal receptor, Pex5p, is translocated into the peroxisomal matrix and recycled to the cytosol. Apr 20 2001

186/28 09453302 21225521 PMID: 11325926 Forssman-specific transcription of the lfb gene during sporulation in *Bacillus subtilis*. May 2001

186/29 09382476 21145823 PMID: 11248057

186/30 09374452 21137192 PMID: 1128807

186/31 09186881 20493582 PMID: 10922368 The amino-terminal domain of apolipoprotein B does not undergo retrograde translocation from the endoplasmic reticulum to the cytosol. The proteasomal degradation of nascent apolipoprotein B begins at the carboxyl terminus of the protein, while apolipoprotein B is still in its original translocon. Oct 13 2000

186/32 09186894 20493281 PMID: 11038175 Characterization of the signal that directs Tom20 to the mitochondrial outer membrane. Oct 16 2000

186/33 085890412 95278726 PMID: 7755939 Proteasomal degradation of the outer membrane protein α ga beta of *Neisseria gonorrhoeae*. Apr 1 1995

186/34 08575242 95263544 PMID: 7744847 C-terminal glycine-histidine tagging of the outer membrane protein α ga beta of *Neisseria gonorrhoeae*. Apr 1 1995
Import of transcription factor MTF-1 into the yeast mitochondria takes place through an unusual pathway. May 19 1995

186/35 08370202 95058175 PMID: 7966513 Proteolytic cleavage at arginine residues within the hydrophobic disulphide loop of the *Escherichia coli* Shiga-like toxin 1 A subunit is not essential for cytotoxicity. Oct 1993

186/36 0838357435 95054506 PMID: 7957078 Molecular chaperones cooperate with PIM1 protease in the degradation of misfolded proteins in mitochondria. Nov 1 1994
Translocation of N-terminal tails across the plasma membrane. Oct 3 1994

186/37 08332655 95020625 PMID: 7934910 Genetic identification of exported proteins in *Streptococcus pneumoniae*. Sep 1993

186/38 08321998 95009598 PMID: 7925307 Translocation of N-terminal tails across the plasma membrane. Oct 3 1994

186/39 07392600 93394533 PMID: 8379852 Semliki Forest virus capsid protein expressed by a baculovirus recombinant. 1993

186/40 07556265 92404727 PMID: 2136629 Nuclear transport of plant polyviral proteins. Oct 1990

186/41 07501664 92365167 PMID: 1501298 Regulation of nuclear transport of a plant polyvirus protein by autoproteolysis. Sep 1992

186/42 07483840 92332466 PMID: 1321129 Carboxy-terminal sequences can influence the in vitro import and intraorganellar targeting of chloroplast protein precursors. Jul 15 1992

186/43 07453660 92317095 PMID: 1377688 Sequential translocation of an artificial precursor protein across the two mitochondrial membranes. Jul 5 1992

186/44 07426279 92289698 PMID: 1600950

Selective extracellular release of cholera toxin B subunit by *Escherichia coli*: dissection of *Neisseria* IgA beta-mediated outer membrane transport. Jun 1992

186/45 0741152 9227449 PMID: 1350514
Cytochromes c1 and b2 are sorted to the intermembrane space of yeast mitochondria by a stop-transfer mechanism. May 29 1992

186/46 077179659 92041980 PMID: 1657948
Protein import into the yeast mitochondrial matrix. A new translocation intermediate between the two mitochondrial membranes. Nov 5 1991

186/47 06973915 91214407 PMID: 215020
Aberrant mitochondrial processing of chimaeric import precursors containing subunits 8 and 9 of yeast mitochondrial ATP synthase. Dec 1990

186/48 06533875 90284273 PMID: 2108944
SeeY, a multispanning integral membrane protein, contains a potential leader peptidase cleavage site. Jun 1990

186/49 06019539 89034426 PMID: 3203734
Topogenic analysis of the human immunodeficiency virus type 1 envelope glycoprotein gp160, in microsomal membranes. Nov 1988

186/50 059202842 88257183 PMID: 3202020
Signal and membrane anchor functions overlap in the type II membrane protein I gamma CAT. Jun 1988

187/20 DIALOG(R)File 155 MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.
10396906 96202337 PMID: 8643690
Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain.

Kopan R, Schroeter EH, Weintraub H, Nye JS
Division of Dermatology, Department of Molecular Biology and Pharmacology, Washington University, St. Louis, MO 63110, USA.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Feb 20 1996, 93 (4) p1683-8, ISSN 0027-8424 Journal Code: 7505876 Document type: Journal Article Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed
Previous studies imply that the intracellular domain of Notch1 must translocate to the nucleus for its activity. In this study, we

demonstrate that a mNotch1 mutant protein that lacks its extracellular domain but retains its membrane-spanning region becomes proteolytically processed on its intracellular surface and, as a result, the activated intracellular domain (mNotchC) is released and can move to the nucleus. Proteolytic cleavage at an intracellular site is blocked by protease inhibitors. Intracellular cleavage is not seen in cells transfected with an inactive variant, which includes the extracellular In-Notch-gp repeats.

Collectively, the studies presented here support the model that mNotch1 is proteolytically processed and the cleavage product is translocated to the nucleus for mNotch1 signal transduction. Record Date Created: 19960717 Record Date Completed: 19960717

187/21 DIALOG(R)File 155 MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.
10394860 96200283 PMID: 8634315
Rapid transmembrane movement of C6-NBD-labeled phospholipids across the inner membrane of *Escherichia coli*.

Huibregts R, de Kroon A, de Kruijff B
Department Biochemistry of Membranes, Centre for Biomembranes, Institute of Biomembranes, University, The Netherlands.

Biochimica et biophysica acta (NETHERLANDS) Apr 3 1996, 1280 (1) p41-50, ISSN 0006-3002 Journal Code: 0217513 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

In this study we have investigated the transmembrane movement of short chain fluorescently labeled phospholipids across the inner membrane of *Escherichia coli*. Exogenously added C6-NBD-labeled phospholipids rapidly flip across the inner membrane of *E. coli*, as was shown by a ditritio-reduction assay applied to inverted inner membrane vesicles (IMV) isolated from wild type *E. coli* cells. The rate of transmembrane movement of the phospholipid probes incorporated into IMV is temperature dependent, and shows no phospholipid head group specificity. C6-NBD-labeled phospholipids translocate across the membrane of IMV incubated at 37 degrees C with a t1/2 of 7 min. After the incorporation into IMV C6-NBD-PG is partially converted to CL by CL-synthase. If IMV are pretreated with proteinase K, the conversion of this fluorescent probe to C6-NBD-CL is not observed anymore, suggesting that the catalytic domain of CL-synthase is at the cytoplasmic site of the plasma membrane of *E. coli*. Newly synthesized C6-NBD-CL also flips across the inner membrane although at a slower rate than the other phospholipid probes. The transmembrane movement occurs in both directions and is not influenced by treatment of the IMV with a sulphydryl reagent or a proteinase, nor by the presence of ATP, or a deatahp across the membrane of the IMV. However, the transmembrane movement of the C6-NBD-labeled phospholipid probes is not observed in LUVET's (large unilamellar vesicles made by extrusion technique) prepared of wild type *E. coli* lipids, indicating that the rapid transmembrane movement of phospholipids across the inner membrane of *E. coli* is a protein-mediated process. Record Date Created: 19960710 Record Date Completed: 19960710

Proteolytic cleavage at arginine residues within the hydrophilic disulphide loop of the *Escherichia coli* Shiga-like toxin I A Subunit is not essential for cytotoxicity. Jun 1992

186/51 16123668 PMID: 14642278
Regulating the conducting states of a mammalian serotonin transporter. Oct 30 2003

206/2 15440652 22793392 PMID: 12911311
Rho-specific *Bacillus cereus* ADP-ribosyltransferase C3αεr cloning and characterization. Aug 19 2003

206/3 15377227 22613949 PMID: 12722723
Expression, purification, and efficacy of the type A *botulinum* neurotoxin catalytic domain fused to two translocation domain variants. May 2003

206/4 15348059 22765599 PMID: 1275364
Entrapment of Rho ADP-ribosylated by *Clostridium botulinum* C3 exoenzyme in the Rho-guanine nucleotide dissociation inhibitor-1 complex. 05 2003

206/5 15311407 22758900 PMID: 12890769
Reversible suppression of glutamatergic neurotransmission of cerebellar granule cells *in vivo* by genetically manipulated expression of tetanus neurotoxin light chain. Jul 30 2003

206/6 15311407 22758900 PMID: 1285556
Interactions between synaptic vesicle fusion proteins explored by atomicforce microscopy. 07 09 2003

206/7 15120030 2238130 PMID: 12650831
Prostaglandin F(2α)pe stimulation of cyclooxygenase-2 promoter activity by the FP(B) prostaglandin receptor. Mar 28 2003

206/8 15004649 2017621 PMID: 12731878
Channel formation by the binding component of *Clostridium botulinum* C2 toxin: glutamate 307 of C2II affects channel properties *in vitro* a pH-dependent C2I translocation *in vivo*. May 13 2003

206/9 14937457 22435559 PMID: 12547349
A single dose of recombinant *Salmonella typhimurium* induces specific humoral immune responses against heterologous *Elmetia leonella* antigens in chicken. Jan 2003

206/10 14928003 22331471 PMID: 12444490
The uptake machinery of clostridial *α*toxin ADP-ribosylating toxins—a cell delivery system for fusion proteins and polypeptide drugs. 09 24 2002

206/11 14915304 22578820 PMID: 12691734
The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Mar 2003

206/12 14709045 22560265 PMID: 12672406
Characterization of antibody responses to endogenous and exogenous antigen in the nonobese diabetic mouse. Feb 2003

206/13 14712165 22483024 PMID: 12553658
Activation of phospholipase D1 by ADP-ribosylated RhoA. Feb 28 2003

206/14 14706307 22148892 PMID: 12154081
Leukotriene D4 induces stress-fibre formation in intestinal epithelial cells via activation of RhoA and PIKCeDelta. Sep 1 2002

206/15 14667953 22477381 PMID: 12558974
Inhibition and stimulatory regulation of Rac and cell motility by the G12/13-Rho and G1 pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mar 2003

187/35 DIALOG(R)File 155 MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.
08370202 95058175 PMID: 7988513

2005/16 1469818 22516246 PMID: 12659174
A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. Mar 1 2003

2006/18 1456728 22135753 PMID: 12140265
Tetanus toxin abolishes exocytosis of ROMK1 induced by inhibition of protein tyrosine kinase. 12 30 2002

2006/17 14554070 22443989 PMID: 12556363
Plasma membrane targeting of SNAP-25 increases its local concentration and is necessary for SNARE complex formation and regulated exocytosis. Aug 15 2002

2006/19 14464053 22127360 PMID: 12126902
Recombinant *Lactobacillus johnsonii* as a mucosal vaccine delivery vehicle. Jul 26 2002

2006/20 14187371 22012452 PMID: 12018391
Cdc42 antagonizes inductive action of cAMP on cell shape, via effects of the myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK) on myosin light chain phosphorylation. Apr 2002

2006/21 14128307 22323262 PMID: 1223798
Sarcoplasmic overexpression in rat slow twitch muscle inhibits sarcoplasmic reticulum Ca2+ uptake and impairs contractile function. 09 16 2002

2006/22 4236805 22313557 PMID: 12221101
Clostridium perfringens iota toxin Mapping of the Ia domain involved in docking with Iib and cellular internalization. 09 06 2002

2006/23 14150739 22278759 PMID: 12291613
Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine. Nov 1 2002

2006/24 14124259 22316781 PMID: 12429212
Hybrid tetanus toxin C fragment-diphtheria toxin translocation domain allows specific gene transfer into PC12 cells. Sep 2002

2006/25 14150775 21960967 PMID: 11956555
EphA4 catalytic activity causes inhibition of RhoA GTPase in *Xenopus laevis* embryos. Mar 2002

2006/26 13966482 22233515 PMID: 12296860
Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous Interleukin-12. Oct 2002

2006/27 13963781 22229551 PMID: 12244189
Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. Oct 1 2002

2006/28 13954466 22213398 PMID: 12228361
Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses. Sep 2002

2005/29 13949465 22202501 PMID: 12213444
In vivo neuronal tracing with GFP-ITC gene delivery. Aug 2002

2006/30 11981772 99426801 PMID: 10498833
Humoral and cellular immune responses in mice immunized with recombinant *Mycobacterium bovis* *Bacillus Calmette-Guerin* producing a pertussis toxin- tetanus toxin hybrid protein. Oct 1999

2006/31 11974144 99419034 PMID: 10488092
Gaiphaf(3) simulates Rho-dependent activation of the cyclooxygenase-2 promoter. Sep 24 1999

2006/32 11974124 99419014 PMID: 10488072
Necrosynthesis and activation of Rho by *Escherichia coli* cytotoxic necrolytic factor (CNF1) reverse cytopathic effects of ADP-ribosylated Rho. Sep 24 1999

2006/33 11956074 99410778 PMID: 10479698
Relative contribution of endogenous neurotrophins in hippocampal long-term potentiation. Sep 15 1999

2006/34 11962231 99406790 PMID: 10477566
Human dendritic cells very efficiently present a heterologous antigen expressed on the surface of recombinant gram-positive bacteria to CD4+ T lymphocytes. Sep 15 1999

2006/35 11948316 99392469 PMID: 10463173
Antigenic variants in *Bordetella pertussis* strains isolated from vaccinated and unvaccinated children. Aug 1999

2006/36 11945831 99389884 PMID: 10460261
Neuropil pattern formation and regulation of cell adhesion molecules in *Drosophila* optic lobe development depend on synaptobrevin. Sep 1 1999

2006/37 11942945 99388886 PMID: 10456940
Cell surface-exposed tetanus toxin fragment C produced by recombinant *Bacillus anthracis* protects against tetanus toxin. Sep 1999

2006/38 11925624 99365242 PMID: 10442633
The Src family tyrosine kinase is involved in Rho-dependent activation of c-Jun N-terminal kinase by Galpha12. Aug 5 1999

2006/39 11909165 99352288 PMID: 10423269
Rho-kinase (ROK) promotes CD44(3-8)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. 1999

2006/40 11853824 99294868 PMID: 10364548
Instruments for oral disease-intervention strategies. recombinant *Lactobacillus casei* expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. Apr 23 1999

2006/41 11853404 99294410 PMID: 10367944
Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Jun 11 1999

2006/42 11847720 99288017 PMID: 10359665
The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. Jun 1999

2006/43 11837792 99278136 PMID: 10346912
Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol. May 25 1999

2006/44 11803560 99242792 PMID: 10225867
Immunogenicity of a *Salmonella typhimurium* aroA toD vaccine expressing a nontoxic domain of *Clostridium difficile* toxin A. May 1999

2006/45 11759317 99160933 PMID: 10094832
Activation of protein kinase C by phorbol esters modulates alpha2beta1 integrin on MCF-7 breast cancer cells. Apr 10 1999

2006/46 11723601 99160489 PMID: 10049579
Recombinant and truncated tetanus neurotoxin light chain: cloning, expression, purification, and proteolytic activity. Mar 1999

2006/47 11704099 99140154 PMID: 10206702
Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii neurotoxin surface protein-1 in live attenuated *Salmonella* vaccine strains. Jan 1999

2006/48 11620461 99053660 PMID: 9839925
Monitoring of scFv selected by phage display using detection of scFv- μ II fusion proteins in a microtiter scale assay. Nov 1 1998

2006/49 11602353 99035056 PMID: 9816208
Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Mar 1996

2006/50 11593846 99026267 PMID: 9805880
Conjugative transfer of the *Escherichia coli*-*Clostridium perfringens* shuttle vector pJIR1457 to *Clostridium botulinum* type A strains. Nov 1 1995

2006/51 11592988 99025406 PMID: 9809552
DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nov 1995

2006/52 11497567 98381840 PMID: 9717740
Production of an expression system for a synaptobrevin fragment to monitor cleavage by botulinum neurotoxin B. Jul 1998

2006/53 11496293 98380521 PMID: 9712688
Ganglioside GT1b as a complementary receptor component for *Clostridium botulinum* neurotoxins. Aug 1998

2006/54 11438327 98321222 PMID: 9647788
Localization of RhoA GTPase to endothelial caveolae-enriched membrane domains. Jun 29 1998

2006/55 11425098 98307523 PMID: 965656
Soluble human lymphocyte activation gene-3 modulates allo-specific T cell responses. May 1998

2006/56 11415520 983297359 PMID: 965436
The small GTP-binding protein RhoA regulates a delayed rectifier potassium channel. Jun 12 1998

2006/57 11383536 98254620 PMID: 963457
MHC class II-associated invariant chain peptide replacement by T cell epitopes, engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation. May 1998

2006/58 11350223 98230504 PMID: 9570577
Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. Feb 1 1998

Rho-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin matrix assembly. Apr 20 1998

205660 11335865 98215714 PMID: 9548719

Association of the myosin-binding subunit of myosin phosphatase and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin. Apr 1998

205662 11272298 98066179 PMID: 9491802

The small GTP-binding protein Rho1 is a multifunctional protein that regulates actin localization, cell polarity, and septum formation in the fission yeast *Schizosaccharomyces pombe*. Nov 1997

205663 11209393 98066179 PMID: 9426210

Transient expression of botulinum neurotoxin C1 light chain differentially inhibits calcium and glucose induced insulin secretion in clonal beta-cells. Dec 8 1997

205664 1139735 98015419 PMID: 9353935

Recombinant SNAP-25 is an effective substrate for *Clostridium botulinum* type A toxin endopeptidase activity in vitro. Oct 1997

205665 11129343 98003598 PMID: 9343703

Temperature-induced expression of human-mouse chimeric Fab. 1997

205665 11120921 97415331 PMID: 9271130

Identification of a recombinant synaptobrevin-thioredoxin fusion protein by capillary zone electrophoresis using laser-induced fluorescence detection. Jul 18 1997

205667 11110175 97404407 PMID: 9256494

Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system. Aug 19 1997

205668 11106181 97400359 PMID: 9257553

DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. Aug 15 1997

205669 11067813 9742537 PMID: 9278305

Impaired class II expression and antigen uptake in monocytic cells after HIV-1 infection. Sep 1 1997

205670 11060921 97415331 PMID: 9271130

Identification of a recombinant synaptobrevin-thioredoxin fusion protein by capillary zone electrophoresis using laser-induced fluorescence detection. Jul 18 1997

205671 11050175 97404407 PMID: 9256494

Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system. Aug 19 1997

205672 11046181 97400359 PMID: 9257853

DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. Aug 15 1997

205673 11019008 97373354 PMID: 9229383

Heterologous expression of the cuticular-glycolipid peroxidase of lymphatic filariae in an attenuated vaccine strain of *Salmonella* typhimurium abrogates H-2 restriction of specific antibody responses. Jun 1996

205674 11005552 97361879 PMID: 9218840

Isolation of human anti-c-erbB-2 Fabs from a lymph node-derived phage display library. Jul 1997

205675 10594209 97347435 PMID: 9202074

Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. Jul 1 1997

205676 10561209 97313662 PMID: 9170263

Cleavage of the synaptobrevin/vesicle-associated membrane protein (VAMP) of the mouse brain by the recombinant light chain of *Clostridium botulinum* type B toxin. May 15 1997

205677 10560533 97313177 PMID: 9169781

Expression and immunogenicity of an *Echinococcus granulosus* fatty acid-binding protein in live attenuated *Salmonella* vaccine strains. Jun 1997

205678 10824716 97175716 PMID: 9023371

Binding of the synaptic vesicle t-SNARE, synaptogamin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at neurotoxin-treated synapses. Feb 4 1997

205679 10790005 97140301 PMID: 8986782

Insulin-stimulated translocation of GLUT4 glucose transporters requires SNARE-complex proteins. Dec 24 1996

205680 10662431 97011151 PMID: 8856161

Regulation mediated of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in *Salmonella typhi* vaccine strain CVD 908. Oct 1996

205682 10600306 960417858 PMID: 8820649

A *Salmonella typhimurium* htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Feb 1996

205683 10590509 960405413 PMID: 8809553

Factors affecting the immunogenicity of tetanus toxin fragment C expressed in *Lactococcus lactis*. Jun 1996

205684 10421671 96228050 PMID: 8647268

Botulinum neurotoxin light chains inhibit both Ca^{2+} -induced and GTP analogue-induced catecholamine release from permeabilised adenovirus. May 20 1996

205685 10389160 96194531 PMID: 8617948

Herpesvirus salmuri open reading frame 14, a protein encoded by T lymphotrophic herpesvirus, binds to MHC class II molecules and stimulates T cell proliferation. May 1 1996

205686 10369907 96174811 PMID: 8599934

Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. Feb 1 1996

205687 10362180 96165391 PMID: 8571127

Identification of a putative target for Rho as the serine-threonine kinase protein kinase N. Feb 2 1996

205688 10361266 96164477 PMID: 8578848

Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in *Salmonella typhi* CVD 908 vaccine strain Nov 1995

205689 10348836 96151333 PMID: 8599150

Expression of a large, non-toxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Oct 1995

205690 10310362 96112457 PMID: 8678289

Detection of arginine-ADP-ribosylated protein using recombinant ADP-ribosylarginine hydrolase. Oct 10 1995

205691 10271008 96072756 PMID: 7578132

Expression and purification of the light chain of botulinum neurotoxin A: a single mutation abolishes its cleavage of SNAP-25 and neurotoxic after reconstitution with the heavy chain. Nov 21 1995

205692 10248273 96039754 PMID: 748581

Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs. Sep 29 1995

205693 10228878 96030146 PMID: 7476431

Purification and assay of recombinant C3 transferase. 1995

205694 10149075 22140381 PMID: 12145319

Anisyn, a novel synapsin-binding protein that may regulate SNARE complex assembly. Aug 2 2002

205695 10149812 22140304 PMID: 12145398

Calmodulin and lipid binding to synaptobrevin regulates calcium-dependent exocytosis. Aug 1 2002

205696 10144623 221133754 PMID: 12145337

Retrograde trans-synaptic transfer of green fluorescent protein allows the genetic mapping of neuronal circuits in transgenic mice. Jul 23 2002

205697 10092697 2208404 PMID: 12052960

Trans-synaptic Eph receptor-ephrin signalling in hippocampal mossy fiber LTP. Jun 7 2002

205698 0983662 21909309 PMID: 11912151

Vaccination with DNA encoding a single-chain TCR fusion protein induces antiidiotypic immunity and protects against T-cell lymphoma. Mar 2002

205699 09916932 21826459 PMID: 11741886

The binary *Clostridium botulinum* C2 toxin as a protein delivery system: identification of the minimal protein region necessary for interaction with components. Feb 15 2002

The N-terminal part of the enzyme component (C2I) of the binary *Clostridium botulinum* C2 toxin interacts with the binding component C2II and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin.

Baith H; Hoffmann F; Olenik C; Just I; Aktories K
Institut für Pharmakologie und Toxikologie der Albert-Ludwigs-Universität Freiburg, Germany.

Infection and immunity (UNITED STATES) Apr 1998; 66 (4) p1364-9; ISSN 0019-5567. Journal Code: 0246127

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The binary actin-ADP-ribosylating *Clostridium botulinum* C2 toxin consists of the enzyme component C2I and the binding component C2II, which are separate proteins. The active component C2I enters cells through C2II by receptor-mediated endocytosis and membrane translocation. The N-terminal part of C2I (C2I_{IN}), which consists of 225 amino acid residues but lacks ADP-ribosyltransferase activity, was identified as the C2II contact site. A fusion protein (C2IN-C3) of C2I_{IN} and the full-length C3-like ADP-ribosyltransferase from *Clostridium limosum* was constructed. The fusion protein C2IN-C3 ADP-ribosylated Rho but not actin in CHO cell lysates. Together with C2II, C2IN-C3 induced complete rounding up of CHO and HeLa cells after incubation for 3 h. No cell rounding was observed without C2II or with the original C3-like transferase from *C. limosum*. The data indicate that the N-terminal 225 amino acid residues of C2I are sufficient to cause the cellular uptake of C. limosum transferase via the binding component of C2II thereby increasing the cytotoxicity of the C3-like exoenzyme several hundred-fold. Record Date Created: 19980409 Record Date Completed: 19980409

207767 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv. 1110175_97404407 PMID: 9256494

Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system.

Coen L; Osta R; Maury M; Brunet P
Unité d'Embryologie Moléculaire, Unité de Recherche Associate 1947, Centre National de la Recherche Scientifique, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Aug 19 1997; 94 (17) p9405-5; ISSN 0027-8424. Document type: Journal Article Languages: ENGLISH Main Citation

Owner: NLM Record type: Completed

The nontoxic proteolytic C fragment of tetanus toxin (TTT peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. We have investigated its potential use as an in vivo neurotropic carrier. In this work we show that a hybrid protein encoded by the lacZ-TTC gene fusion retains the biological functions of both proteins in vivo i.e., retrograde transsynaptic transport of the TTT fragment and beta-galactosidase enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy could also be used to map synaptic connections between neural cells. Record Date Created: 19970917 Record Date Completed: 19970917

207767 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

Chain of *Clostridium botulinum* type B toxin.

Rhee S D; Jung H H; Yang G H; Moon Y S; Yang K H
Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Taejon, South Korea.

FEBS microbiology letters (NETHERLANDS) May 15 1997; 150 (2) p203-8; ISSN 0378-1097. Journal Code: 7705721

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The light chain of *Clostridium botulinum* type B toxin was expressed in *Escherichia coli* using the expression vector pET-3a

proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Aug 19 1997; 94 (17) p9405-5; ISSN 0027-8424. Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The light chain of *Clostridium botulinum* type B toxin was expressed in *Escherichia coli* using the expression vector pET-3a chromatography and the proteolytic activity of the purified light chain was studied. The purified recombinant light chain cleaved synaptobrevin when mixed with the mouse brain microsome and the proteolytic activity of the light chain was inhibited if a metal chelating agent such as EDTA or 2,2'-dipyridyl was added. The recombinant light chain cleaved synaptobrevin more effectively than the native type B toxin. When the native toxin was tryptinized and was reduced with DTT, its proteolytic activity was similar to that of the recombinant light chain. Record Date Created: 19970714 Record Date Completed: 19970714

207768 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in *Salmonella typhi* CVD 98 vaccine strain.

Gomez-Duarte O G; Galen J; Chaffield S N; Rappuoli R; Eidels L; Levine M M
Department of Medicine, University of Maryland School of Medicine, Baltimore 21201 USA.

Vaccine (ENGLAND) Nov 1995; 13 (16) p1595-602; ISSN 0264-410X. Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

We report the expression of fragment C of tetanus toxin (FC) fused to the eukaryotic cell binding domain (the carboxyl-terminal of diphtheria toxin (FC-bD fusion) in attenuated *Salmonella typhi* live vector vaccine strain CVD 98. The FC-bD protein fusion was constructed using plasmid pETntr15 which carries the gene encoding FC under control of the ntrB promoter (ntrBp). The open reading frame for FC was modified to incorporate an in-frame glycine-proline hinge region and a set of four restriction sites at the 3' end of the modified FC gene to create an in-frame FC-bD fusion gene. The resulting plasmid, pG215, was able to express the FC-bD fusion protein in both *Escherichia coli* DH5 α and *S. typhi* CVD 98, as evidenced by Western immunoblots using anti-FC and anti-C-terminal diphtheria toxin monoclonal antibodies. Maximum expression of the FC-bD fusion protein was achieved by growing CVD 98(pG215) at the low oxidation-reduction potential of thioglycollate broth, i.e. conditions that activate ntrBp and drive transcription of the FC-bD fusion gene. Whereas maximum expression of FC alone was also observed using thioglycollate broth, expression of bD alone was unsuccessful using a variety of growth conditions. FC fusions constitute one strategy to "rescue" expression of proteins which are otherwise difficult to express. Record Date Created: 19960312 Record Date Completed: 19960312

207768 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection.

Chababogty J A; Khan C M; Nash A A; Hormaeche C E
Department of Microbiology, University of Newcastle, Newcastle upon Tyne, UK.

Molecular microbiology (ENGLAND) Feb 1996; 19 (4) p791-801; ISSN 0950-382X. Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

207771 DIALOG(R)File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

11050715_97404407 PMID: 9256494

Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system.

Coen L; Osta R; Maury M; Brunet P
Unité d'Embryologie Moléculaire, Unité de Recherche Associate 1947, Centre National de la Recherche Scientifique, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Aug 19 1997; 94 (17) p9405-5; ISSN 0027-8424. Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The nontoxic proteolytic C fragment of tetanus toxin (TTT peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. We have investigated its potential use as an in vivo neurotropic carrier. In this work we show that a hybrid protein encoded by the lacZ-TTC gene fusion retains the biological functions of both proteins in vivo i.e., retrograde transsynaptic transport of the TTT fragment and beta-galactosidase enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy could also be used to deliver a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein could also be used to map synaptic connections between neural cells. Record Date Created: 19970917 Record Date Completed: 19970917

Multiple tandem copies of an immunogenic epitope comprising amino acids 8-23 of glycoprotein D of herpes simplex virus (HSV) were expressed as C-terminal fusions to tetanus toxin fragment C (TeC) in different *Salmonella* typhimurium live vaccine strains. Expression of the longer fusions was best in strains harbouring a lesion in *htrA*, a stress protein gene. *S.3261*, an aroA strain, did not effectively express the longer fusions. Mice immunised with an *S. typhimurium* C3 *htrA* mutant expressing fusions with two or four copies of the peptide made an antibody response to both the peptide and TeC, whereas constructs expressing one copy of the peptide only elicited antibody to TeC. A non-immunogenic octameric fusion underwent rearrangements *in vivo* resulting in a predominantly monomeric fusion. In contrast, the *S. typhimurium* *S.3261* aroA vaccine expressing the TeC-tetrameric fusion did not elicit antibody to the peptide. Sera from mice immunised with a single dose of the dimer and tetramer fusions in the *htrA* strain neutralised HSV *in vitro* and the mice were protected from HSV infection as measured by a reduction in virus load in the ear pinna. We have previously shown that mice vaccinated with *salmonella* expressing TeC are protected against tetanus toxin and virulent *salmonella* challenge. These results suggest that it may be possible to develop a multivalent vaccine against salmonellosis, tetanus and HSV. Record Date Created: 19961216 Record Date Completed: 19961216

2007/88 DIALOG(R)File 155 MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

10361266 96164477 PMID: 8578848

Expression of fragment C of tetanus toxin fused to a carboxy-terminal fragment of diphtheria toxin in *Salmonella* typhi CVD 908

Vaccine strain.

Gomez-Duarte O G; Galen J; Chatfield S N; Rappuoli R; Eidele L; Levine M M

Department of Medicine, University of Maryland School of Medicine, Baltimore 21201 USA

Vaccine (ENGLAND) Nov 1995, 13 (16) p1595-602, ISSN 0264-410X, Journal Code: 8408899

Contract/Grant No.: NOT AL15096; AI; NIADDK; NOT AI4525; AI; NIADDK; RO1 A129471; PHS Document type: Journal Article

Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

We report the expression of fragment C of tetanus toxin (FC) fused to the eukaryotic cell binding domain (the carboxy-terminus) of diphtheria toxin (FC-bdT fusion) in attenuated *Salmonella* typhi live vector vaccine strain CVD 908. The FC-bdT protein fusion was constructed using plasmid pTE1115 which carries the gene encoding FC under control of the *ntrB* promoter (*ntrB*). The open reading frame for FC was modified to incorporate an in-frame glycine-proline hinge region and a set of four restriction sites at the 3' end of the FC gene. A 482 bp DNA fragment encoding the eukaryotic cell binding domain of diphtheria toxin was then inserted at the 3' end of the modified FC gene to create an in-frame FC-bdT fusion gene. The resulting plasmid, pOG215, was able to express the FC-bdT fusion protein in both *Escherichia coli* Dh5α and *S. typhi* CVD 908, as evidenced by Western immunoblots using anti-FC and anti-C-terminal diphtheria toxin monoclonal antibodies. Maximum expression of the FC-bdT fusion protein was achieved by growing CVD 908(pOG215) at the low oxidation-reduction potential of thioglycollate broth, i.e. in conditions that activate ntrB and drive transcription of the FC-bdT fusion gene. Whereas maximum expression of FC alone was also observed using thioglycollate broth, expression of bD alone was unsuccessful using a variety of growth conditions. FC fusions constitute one strategy to "rescue" expression of proteins which are otherwise difficult to express. Record Date Created: 19960312 Record Date Completed: 19960312

2007/89 DIALOG(R)File 155 MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

10348836 96151333 PMID: 8599190

Expression of a large, non-toxic fragment of botulinum neurotoxin serotype A and its use as an immunogen.

LaPenotiere H F; Clayton M A; Middlebrook J L

Toxicology Division, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702-5011, USA.

Toxicon - official journal of the International Society on Toxicology (ENGLAND) Oct 1995, 33 (10) p1383-6, ISSN 0041-1010, Journal Code: 1307333 Document type: Journal Article; Review; Review, Tutorial Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

Using the polymerase chain reaction, a large fragment of botulinum toxin was placed in two expression systems, one designed to produce a fusion protein product and another designed to produce only the toxin fragment. Expression of the fragment in the latter system was inconsistent. Expression of the fusion protein was easily measurable by ELISA. Mice were vaccinated with crude fusion protein, then challenged with native toxin. Mice receiving two immunizations were partially protected from up to 1200 LD50, suggesting that this toxin fragment may be a good vaccine candidate to replace the currently used toxoid. (8 Refs.) Record Date Created: 19960419 Record Date Completed: 19960419

2007/99 DIALOG(R)File 155 MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

09916932 21826459 PMID: 1741886

The binary Clostridium botulinum C2 toxin as a protein delivery system: identification of the minimal protein region necessary for interaction of toxin components.

Barth Holger; Roebling Robert; Fritz Michael; Aktories Klaus

Institut für Experimentelle und Klinische Pharmakologie und Toxikologie der Albert-Ludwigs-Universität Freiburg, Albertstrasse 25, D-7911 Freiburg Germany; barth@uni-freiburg.de

Journal of biological chemistry (United States) Feb 15 2002, 277 (7) p5074-81, ISSN 0021-9258, Journal Code: 2985121R

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The binary Clostridium botulinum C2 toxin is composed of the enzyme component C2I and the binding component C2II, which are individual and non-linked proteins. Activated C2IIa mediates cell binding and translocation of C2I into the cytoplasm. C2I

ADP-ribosylates G-actin at Arg-177 to depolymerize actin filaments. A fusion toxin containing the N-terminal domain of C2I (residues 1-225) transports C3 ADP-ribosyltransferase from *Clostridium limosum* into cells (Barth, H.; Hofmann, F.; Olenik, C. Just, I., and Aktories, K. (1998) Infect. Immun. 66, 1364-1369). We characterized the adaptor function of C2I and its interaction with C2IIa. The fusion toxin C2I-C3 was efficiently transported by C2IIa, indicating that C2IIa translocates C2I (but not further truncated C2I fragments) competed with Alexa488-labeled C2I for binding to C2IIa. Also, the fragment C2I(343-1) and the fusion toxin C2I(30-225)-C3 competed with C2I-Alexa488 for binding to C2IIa. C2I(30-225)-C3 did not induce cytotoxic effects on cells when applied together with C2IIa, indicating that amino acid residues 1-29 are involved in translocation of C2I but are not absolutely essential for binding to C2IIa. Record Date Created: 20020111 Record Date Completed: 2002032 Recombinant *Lactobacillus johnsonii* as a mucosal vaccine delivery vehicle. Jul 26 2002

21612 11139735 98015419 PMID: 9353935

Recombinant SNAP-25 is an effective substrate for *Clostridium botulinum* type A toxin endopeptidase activity *in vitro*. Oct 1997

21613 10600306 96417658 PMID: 8820649

Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Feb 1996 Expression and purification of the light chain of botulinum neurotoxin A: a single mutation abolishes its proteolytic activity and removes the toxicity seen after reconstitution with the heavy chain. Nov 7 1996

21614 10277008 96072756 PMID: 7578132

A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with the heavy chain. Nov 7 1996

2006101 0938673 21503241 PMID: 1175697

New strategies for vaccination and immunomodulation in NHL. 2001

2006102 09784644 2150899 PMID: 1173320

DNA fusion vaccines against B-cell tumors. Dec 2001

2006103 09784045 21500233 PMID: 1173060

Remodeling of synaptic actin induced by photoconductive stimulation. Nov 30 2001

2005104 09694092 21486508 PMID: 11507098

Activation of protein kinase D by signalling through Rho and the alpha subunit of the heterotrimeric G protein G13. Oct 19 2001

2005105 09683906 21475804 PMID: 11591816

Rho-dependent transfer of Citron-kinase to the cleavage furrow of dividing cells Sep 2001

2005106 09683875 21475773 PMID: 11591573

Surface display of recombinant proteins on *Bacillus subtilis* spores. Nov 2001

2005107 09683871'15 21372433 PMID: 11479570

Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Aug 2001

2005108 09576600 21359546 PMID: 11465377

DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. Aug 1 2001

2006109 09574549 21357442 PMID: 11464916

Lytic acid bacteria as live vaccines. Jan 2000

2006110 09570545 21353021 PMID: 11447282

Antibodies with infinite affinity. Jul 17 2001

2006111 09564048 21324877 PMID: 11431570

Conditional restoration of hippocampal synaptic potentiation in GluR-A-deficient mice. Jun 29 2001

2006112 09551250 21260769 PMID: 11397774

Human urokinase II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Jun 8 2001

2006113 09490505 21267040 PMID: 11358871

A common exocytic mechanism mediates axonal and dendritic outgrowth. Jun 1 2001

205/11/4 0948:983 21258150 PMID: 11358482
Neuronal targeting of catenolophin-1 by coupling with tetanus toxin C fragment. May 2001

205/11/5 09445538 21214571 PMID: 11321160
Heterologous gene expression in bacterial systems under reduced oxygen tensions. Small-scale optimization precedes industrial fermentation. Feb 2001

205/11/6 093414709 21181853 PMID: 11265284
Restriction of secretory granule motion near the plasma membrane of chromaffin cells. Apr 2 2001

205/11/7 093410039 21176902 PMID: 11261322
Sub35p yeast protein-like protein as an adapter for production of the Gag-p55 antigen of HIV-1 and the L-chain of botulinum neurotoxin in *Saccharomyces cerevisiae*. Jan-Feb 2001

205/11/8 09384540 21148517 PMID: 11253870
Recombinant vaccines against infectious hemopoietic necrosis virus: production by the *Caulobacter crescentus* S-layer protein secretion system and evaluation in laboratory trials. Jan 26 2001

205/11/9 09382538 21145885 PMID: 11248119
Genetically altered AMPA-type glutamate receptor kinematics in interneurons disrupt long-range synchrony of gamma oscillation. Mar 13 2001

205/11/10 09355316 21119888 PMID: 1119324
Efficacy of two alternate vaccines based on *Plasmodium falciparum* merozoite surface protein 1 in an *Aotus* challenge trial. Mar 2001

205/11/21 093421013 21101372 PMID: 11165271
Assessment of a vaccinia virus vectored multi-epitope live vaccine candidate for *Plasmodium falciparum*. Jan 2001

205/11/22 093417772 21100916 PMID: 11168632
Low concentrations of lipopolysaccharide synergize with peptides to augment human T-cell proliferation and can prevent the induction of non-responsiveness by CTLA4:9. Jan 2001

205/11/23 09292031 21029392 PMID: 11191108
Rho GTPase overexpression modulates induction of angiogenic factors in breast cells. Sep-Oct 2000

205/11/24 09182865 20489211 PMID: 11036618
Rho GTPases: secretion and actin dynamics in permeabilized mast cells. 2000

205/11/25 09149087 20451085 PMID: 1095446
205/11/26 09112657 20411243 PMID: 10954418
Membrane localization and biological activity of SNAP-25 cysteine mutants in insulin-secreting cells. Sep 2000

205/11/27 09104452 20402597 PMID: 10944231
Ca²⁺-dependent regulation of synaptic SNARE complex assembly via a calmodulin- and phospholipid-binding domain of synaptobrevin. Aug 15 2000

205/11/28 09092184 20389730 PMID: 10930694
Cloning, expression and evaluation of a recombinant sub-unit vaccine against *Clostridium botulinum* type F toxin. Sep 15 2000

205/11/29 09030890 20324939 PMID: 10865133
Measurement of exocytosis by amperometry in adrenal chromaffin cells: effects of clostridial neurotoxins and activation of protein kinase C on fusion pore kinetics. May 2000

205/11/30 09002386 20294906 PMID: 10833399
Cloning, expression, and one-step purification of the minimal essential domain of the light chain of botulinum neurotoxin type A. Jun 2000

205/11/31 08996880 20289121 PMID: 10830309
The activation of phospholipase D by endothelin-1, angiotensin I, and platelet-derived growth factor in vascular smooth muscle A10 cells is mediated by small G proteins of the ADP-ribosylation factor family. Jun 2000

205/11/32 08990056 20281858 PMID: 10820215
Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to neurons. Jun 2000

205/11/33 08953915 20243570 PMID: 10779774
Characterization of human inducible costimulator ligand expression and function. May 1 2000

205/11/34 08942669 20231879 PMID: 10759020
Ephrin-A5 induces collapse of growth cones by activating Rho and Rho kinase. Apr 17 2000

205/11/35 08942573 20231782 PMID: 10769337
Tetanus toxin fragment C expressed in live *Salmonella* vaccines enhances antibody responses to its fusion partner *Schistosoma haemacanthum* glutathione S-transferase. May 2000

205/11/36 08922959 20211255 PMID: 10744952
High-level expression of tetanus toxin fragment C-thiotoxin fusion protein in *Escherichia coli*. Apr 2000

205/11/37 08915837 20203748 PMID: 1074704
Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Mar 2000

205/11/38 08914955 20202758 PMID: 10736202
Rho family proteins modulate rapid apoptosis induced by cytotoxic T-lymphocytes and Fas. Mar 31 2000

205/11/40 08900434 20187498 PMID: 1072622
Immunogenicity and efficacy in acus monkeys of four recombinant *Plasmodium falciparum* vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Apr 2000

205/11/41 08900479 20187483 PMID: 1072607
Linkage of exogenous T-cell epitopes to 19-kilodalton region of *Plasmodium yoelii* merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19). Apr 2000

205/11/42 08883909 20170179 PMID: 10707906
A somatic gene transfer approach using recombinant fusion proteins to map muscle-motoneuron projections in *Xenopus* spinal cord. Nov 1999

205/11/43 08873157 20158951 PMID: 10692440
G protein modulation of N-type calcium channels is facilitated by physical interactions between syntaxin 1A and Gbetagamma. Mar 3 2000

205/11/44 08856185 20141225 PMID: 10675534
Identification and characterization of functional subunits of *Clostridium botulinum* type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. Feb 11 2000

205/11/45 08765143 20047427 PMID: 10582602
Botulinum neurotoxin E-insensitive mutants of SNAP-25 fail to bind VAMP but support exocytosis. Dec 1999

205/11/46 08715029 95403634 PMID: 7673393
Generation of an expression library in the baculovirus expression vector system. Jun 1995

205/11/47 08655250 95447847 PMID: 7522252
Characterization of recombinant tetanus toxin derivatives suitable for vaccine development. Aug 1995

205/11/48 08649251 95337845 PMID: 7613218
Cloning of human anti-IgE autoantibodies and their role in the regulation of IgE synthesis. May-Jun 1995

205/11/49 08639422 9526951 PMID: 7603339
Engineering human monoclonal antibody fragments: a recombinant enzyme-linked Fab. Apr 1995

205/11/50 08621485 95310012 PMID: 7790070
Influence of preimmunization with tetanus toxoid on immune responses to tetanus toxin fragment C-quest antigen fusions in a *Salmonella* vaccine carrier. Jul 1995

205/11/51 08548161 95236461 PMID: 7720079
Utilization of soluble fusion proteins for induction of T cell proliferation. Feb 1995

205/11/52 08509092 9519778 PMID: 7534271
Immunogenic combinations of HIV-1 B and heterologous T-cell epitopes. Oct 1994

205/11/53 0849053 95179179 PMID: 7874174
Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nov 1994

205/11/54 08393632 95081611 PMID: 7527446
Construction, expression, and immunogenicity of multiple tandem copies of the *Schistosoma mansoni* peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live attenuated vaccine strain of *Salmonella*. Dec 15 1994

205/11/55 08363150 95051122 PMID: 7562205
Probing the action of *Clostridium difficile* toxin B in *Xenopus laevis* oocytes. Jun 1994

205/157 08323681 95011651 PMID: 7925831

Phage display of a human antibody against *Clostridium tetani* toxin. Oct 11 1994

205/158 08289739 94255662 PMID: 8075633

Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. May 1994

205/159 08248894 94283656 PMID: 8013871

Cloning, sequencing and expression in *Escherichia coli* of the gene encoding component S of the coenzyme B12-dependent glutamate mutase from *Clostridium cocleum*. May 1 1994

205/161 08224919 94280660 PMID: 8011337

A post-docking role for synaptobrevin in synaptic vesicle fusion. Jun 7 1994

205/162 08198098 94264020 PMID: 7911329

Assays for adjuvanticity of new formulations and of carrier proteins for inducing antibody responses to selected immunogens in the squirrel monkey. *Science*. Apr 1994

205/163 08193553 94259475 PMID: 8206992

A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with native heavy chain. Jun 7 1994

205/164 08055830 94131577 PMID: 7507893

Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein. *Feb* 1994

205/165 08043965 94100700 PMID: 8282204

Cloning in a bacteriophage lambda vector for the display of binding proteins on filamentous phage. Dec 27 1993

205/166 0790760 93368431 PMID: 8361360

Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Jun 1993

205/167 07862039 93342856 PMID: 8593605

Comparison of the effects of adjuvants and adjuvant doses on the quantitative and qualitative antibody response to selected antigens in New World squirrel monkeys. *Science*. Jun 1993

205/168 07845929 93301597 PMID: 7688212

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. Jul 1 1993

205/169 07843212 93298860 PMID: 8518367

Recombinant human antibodies: linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture. Apr 1993

205/170 07829910 93285459 PMID: 8508952

A bacteriophage lambda vector for the cloning and expression of immunoglobulin Fab fragments on the surface of filamentous phage. Jun 15 1993

205/171 07753752 93205239 PMID: 8458345

A chimeric toxin to study the role of the 21 kDa GTP binding protein rho in the control of actin microfilament assembly. Mar 1993

205/172 07070744 93162704 PMID: 1286873

Therapeutic human antibodies derived from PCR amplification of B-cell variable regions. Dec 1992

205/173 07366559 92249751 PMID: 1577256

Cloning of a *Clostridium botulinum* type B toxin gene fragment encoding the N-terminus of the heavy chain. Feb 1 1992

205/174 07351758 92214927 PMID: 1806685

Effects of a soluble CD4 and CD4-Pseudomonas exotoxin A chimeric protein on human peripheral blood lymphocytes: lymphocyte activation and anti-HIV activity in vitro. Oct 1991

205/175 07134855 91376059 PMID: 1896445

Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Sep 15 1991

205/176 07131767 91372981 PMID: 1910014

Characterization of the C3 gene of *Clostridium botulinum* types C and D and its expression in *Escherichia coli*. Oct 1991

205/177 06865780 91105879 PMID: 1988163

Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein. Feb 1994

205/178 06410889 90035423 PMID: 2478475

Expression of tetanus toxin subfragments in vitro and characterization of epitopes. Nov 1989

207/136 DIALOG(R)File 155 MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

08922959 20211225 PMID: 10744982

High-level expression of tetanus toxin fragment C-thioredoxin fusion protein in *Escherichia coli*.

Ribeiro A V; Ho P L; Tanizaki M M; Rawi I; Nascimento A L

Center of Biotechnology, Instituto Butantan, Av. Vital Brasil, 1500, CEP 05033-900, São Paulo, SP, Brazil.

Biotechnology and applied biochemistry (ENGLAND) Apr 2000; 31 (Pt 2): p91-4. ISSN 0885-4513. Journal Code: 869946

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

An insert of *Clostridium tetani* DNA corresponding to fragment C of tetanus toxin was amplified by PCR. This 1.4 Kb fragment was cloned into the high-expression vector pET32a, under control of the T7 promoter. Expression of this plasmid in *Escherich coli* BL21(DE3) resulted in the production of a fusion protein (~approximately 62 kDa) consisting of 112 amino acids of thioredoxin and approximately 450 amino acids of fragment C. This fusion protein was recognized by anti-tetanus toxin antiserum in an ELISA and on immunoblots. The recombinant fragment-C-thioredoxin protein was purified significantly in one step by Ni(2+)-chelate Sepharose, the final yield being approximately 35 mg/l. Immunization of animals with the recombinant protein produced antibodies that were able to recognize the tetanus toxin. By using this gene-fusion expression system we produced soluble fragment C of tetanus toxin in a high yield, preventing many problems inherent in the use of other expression systems that produce either insoluble fragment C in inclusion bodies, or a soluble form, but in low yield, using *E. coli* as the expression host

Record Date Created: 20000525 Record Date Completed: 20000525

207/132 DIALOG(R)File 155 MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

08950056 20281888 PMID: 10820215

Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: potential vector for delivering heterologous proteins to neurons.

Francis J W; Brown R H; Figueiredo D; Remington M P; Castillo O; Schwarzschild M A; Fishman P S; Murphy J R; VandeSpak J C

Cecil B; Day Center for Neuromuscular Research, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA. francis@helix.mgh.harvard.edu

Journal of neurochemistry (UNITED STATES) Jun 2000; 74 (6): p2528-36. ISSN 0022-3342. Journal Code: 2985190R Contract/Grant No.: 1P01NS31248-02; NS; NINDS; 5F32NS10064; HS; AHCPR; R01NS38679-01; NS; NINDS

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

This study describes the expression, purification, and characterization of a recombinant fusion toxin, DAB(389)TTC, composed of the catalytic and membrane translocation domains of diphtheria toxin (DAB(389)) linked to the receptor binding fragment of tetanus toxin (C-fragment). As determined by its ability to inhibit cellular protein synthesis in primary neuron cultures, DAB(389)TTC was approximately 1,000-fold more cytotoxic than native diphtheria toxin or the previously described fusion toxin DAB(389)MSH. The cytotoxic effect of DAB(389)TTC on cultured cells was specific toward neuronal-type cells and was blocked by coincubation of the chimeric toxin with tetanus antitoxin. The toxicity of DAB(389)TTC, like that of diphtheria toxin, was dependent on passage through an acidic compartment and ATP-ribosyltransferase activity of the DAB(389) catalytic fragment. These results suggest that a catalytically inactive form of DAB(389)TTC may be useful as a nonviral vehicle to deliver exogenous proteins to the cytosolic compartment of neurons. Record Date Created: 20000602 Record Date Completed: 20000602

207/134 DIALOG(R)File 155 MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

09481983 21258150 PMID: 11358482

Neuronal targeting of cardiotrophin-1 by coupling with tetanus toxin C fragment.

Bordet T; Castelnau-Plakhtine L; Fauchereau F; Riocourt G; Kahn A; Haase G

INSERM U729, Institut Cochin de Génétique Moléculaire, 24, Rue du Faubourg St Jacques, 75014 Paris, France.

Molecular and cellular neurosciences (United States) May 2001; 17 (5): p842-54. ISSN 1044-7431. Journal Code: 910009

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Cardiotrophin-1 (CT-1) is a potent neurotrophic factor for motoneurons but its clinical use in motor neuron diseases is precluded by side effects on the heart and liver. We explored the possibility of targeting CT-1 to neurons by coupling with the tetanus toxin fragment TTC. Genetic fusion proteins between CT-1 or GFP and TTC were produced in *Escherichia coli* and assayed in vitro contrast to uncoupled CT-1 or GFP. TTC-coupled proteins bind with high affinity to cerebral neurons and spinal cord motoneurons and were rapidly internalized. Glia, hepatocytes, or cardiomyocytes did not show detectable binding or uptake of TTC-proteins. Similar to CT-1, TTC-coupled CT-1 induced IL-6 secretion by KB cells, activated Reg-2 gene expression and promoted motoneuron survival in a dose-dependent manner. In vivo studies will test whether TTC-coupled CT-1 might be targeted to degenerating spinal cord or brain-stem motoneurons and migrate trans-synaptically to cortical motoneurons, which are also affected in amyotrophic lateral sclerosis. Copyright 2001 Academic Press. Record Date Created: 20010518 Record Date Completed: 20010809

Tags: Animal; Human; Support, Non-U.S. Gov't Descriptors: Cells, Cultured-drug effects-DE; Cytokines-pharmacology-DE; Peptide Fragments-DE; Disease-drug therapy-DE; Motor Neurons-drug effects-DE; Nerve Growth Factors-pharmacology-DE; Peptide Fragments-pharmacology-DE; Recombinant Fusion Proteins-pharmacology-DE; Tetanus Toxin-pharmacology-DE; Brain-cytochemistry-CV; Brain-

drug effects-DE; Brain-metabolism-ME; Cell Survival-drug effects-DE; Cell Survival-physiology-PI; Cells, Cultured-cytology-CY; Cells, Cultured-metabolism-ME; Cytokines-genetics-GE; Dose-Response Relationship, Drug-PI; Escherichia coli-Genetics-GE; Feius, Gene Expression-drug effects-DE; Gene Expression-physiology-PI; Heart-drug effects-DE; Heart-physiology-PI; Hepatocytes-metabolism-ME; Interleukin-6--metabolism-ME; Interleukin-6--metabolism-ME; Interleukin-6-secretion-SE; Luminescent Proteins--analyses-AT; Luminescent Proteins-genetics-GE; Mice, Motor Neuron Disease-metabolism-ME; Motor Neuron Disease-physiology-PI; Motor Neurons-cytology-CY; Motor Neurons-metabolism-ME; Nerve Growth Factors--genetics-GE; Peptide Fragments-genetics-GE; Protein Engineering--methiods-MI; Recombinant Fusion Proteins--chemical synthesis-CS; Recombinant Fusion Proteins--genetics-GE; Signal Transduction-drug effects-DE; Signal Transduction-genetics-GE; Spinal Cord-cytology-CY; Spinal Cord-drug effects-DE; Spinal Cord-metabolism-ME; Tetanus Toxin-genes-GE; CAS Registry No.: 0 (Cytokines); 0 (Peptide Fragments); 0 (Recombinant Fusion Proteins); 0 (Tetanus Toxin); 0 (cardiotrophin-1); 0 (tetanus toxin fragment C); 14736-22-9 (green fluorescent protein)

2077151 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rs. reserv.

005548161 95236461 PMID: 7720079

Utilization of soluble fusion proteins for induction of T cell proliferation.
Kirschmann D A; De Groot P A; Bono C P; Zacheis M L; Schwartz B D; Woulfe S L

Department of Immunology and Glycobiology, Monsanto Corporate Research, D. Seare, St. Louis, Missouri 63198, USA.

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

A peptide display library was evaluated as a means to identify peptide binding motifs for class II molecules. Peptides expressed as part of a soluble fusion protein with a maltose binding protein (maltE) were produced by *Escherichia coli* Constructs containing the high-affinity binding influenza hemagglutinin peptide 307W319 (maltHA) or the low-affinity binding tetanus toxoid peptide 830-843 (malt-TT) were used as controls. malt-HA, but not malt-TT, inhibited synthetic biotinylated-HA peptide from binding to purified DR4 D_{w4} molecules in a dose-dependent manner. The fusion-peptide presentation system was also evaluated to its ability to induce antigen-specific T cell proliferation. DR4 D_{w4+} B cells pulsed with malt-HA, but not malt-TT, induced dose-dependent proliferation of an HA-specific DR4 D_{w4}-restricted T cell line to the same extent as synthetic HA peptide. Using this type of peptide display library, it may be possible to determine the antigenic specificity of T cell clones isolated from patients with autoimmune diseases. Record Date Created: 19950522 Record Date Completed: 19950522

2077164 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rs. reserv.

08065830 94131577 PMID: 7507693

Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin- tetanus toxin fusion protein.
Boucher P; Sato H; Sato Y; Locht C

Laboratoire de Microbiologie Génétique et Moléculaire, Institut Pasteur de Lille, France.

Infection and immunity (UNITED STATES) Feb 1994; 62 (2) p449-56; ISSN 0019-9567 Journal Code: 0246127

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The currently available diphtheria- tetanus whole-cell pertussis (DTP) vaccines are associated with a variety of problems, including undesirable side effects and inconsistent efficacy. These problems are probably related to the poor definition of such vaccines, especially with respect to the whole-cell component against pertussis. Ideal vaccines should include only immunoprotective antigens with no toxin activity. As an initial step towards obtaining a well-defined and simplified DTP vaccine, a pertussis toxin- tetanus toxin chimeric protein was constructed. A soluble form of the pertussis toxin S1 subunit was fused to the protective fragment C of tetanus toxin, and the recombinant hybrid protein was produced in *Escherichia coli*. The 75-kDa fusion protein (p75) was overexpressed as a soluble molecule and purified to near homogeneity by two consecutive chromatographic steps. Purified p75 retained its ability to bind to ganglioside G1b, the receptor for tetanus toxin and to be recognized by protective and neutralizing anti-pertussis toxin antibodies specific for conformational epitopes. When administered to mice, the hybrid protein was found to be nontoxic but immunogenic. In addition, it was capable of inducing strong protection against tetanus and some protection against pertussis, as well as eliciting a pertussis toxin-neutralizing antibody response. Although the levels of anti-pertussis toxin antibodies were rather low, neutralizing titers of the immunized mice correlated well with anti-pertussis toxin titers, indicating that protective epitopes are conserved in the recombinant protein. Record Date Created: 19940304 Record Date Completed: 19940304

237711 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rs. reserv.

11119318 974 3668 PMID: 9270054
Postischemic infusion of Cu/Zn superoxide dismutase or SOD1:Te451 reduces cerebral infarction following focal ischemia/reperfusion in rats.

Francis J W; Rein J; Warren L; Brown R H; Finklestein S P

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The currently available diphtheria- tetanus whole-cell pertussis (DTP) vaccines are associated with a variety of problems, including undesirable side effects and inconsistent efficacy. These problems are probably related to the poor definition of such vaccines, especially with respect to the whole-cell component against pertussis. Ideal vaccines should include only immunoprotective antigens with no toxin activity. As an initial step towards obtaining a well-defined and simplified DTP vaccine, a pertussis toxin- tetanus toxin chimeric protein was constructed. A soluble form of the pertussis toxin S1 subunit was fused to the protective fragment C of tetanus toxin, and the recombinant hybrid protein was produced in *Escherichia coli*. The 75-kDa fusion protein (p75) was overexpressed as a soluble molecule and purified to near homogeneity by two consecutive chromatographic steps. Purified p75 retained its ability to bind to ganglioside G1b, the receptor for tetanus toxin and to be recognized by protective and neutralizing anti-pertussis toxin antibodies specific for conformational epitopes. When administered to mice, the hybrid protein was found to be nontoxic but immunogenic. In addition, it was capable of inducing strong protection against tetanus and some protection against pertussis, as well as eliciting a pertussis toxin-neutralizing antibody response. Although the levels of anti-pertussis toxin antibodies were rather low, neutralizing titers of the immunized mice correlated well with anti-pertussis toxin titers, indicating that protective epitopes are conserved in the recombinant protein. Record Date Created: 19940304 Record Date Completed: 19940304

hybrid protein SOD1:Te451, composed of hSOD-1 linked to the neuronal binding fragment of tetanus toxin (TTx-C), following ischemic/reperfusion in rats.

Francis J W; Rein J; Warren L; Brown R H; Finklestein S P

Cecil B; Day Laboratory for Neuromuscular Research, Massachusetts General Hospital, Charlestown 02129 USA.

Experimental neurology (UNITED STATES) Aug 1997; 146 (2) p435-43; ISSN 0014-4886 Journal Code: 0370712

ContractGrant No.: IPO1AG 2292-01; AG; NIA; IPO1NS31248-04; NS; NINDS; P01 NS 10828; NS; NINDS

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Oxygen-free radicals play a major role in neuronal cell injury following cerebral ischemia/reperfusion. The free-radical scavenging enzyme, Cu/Zn superoxide dismutase (SOD-1), ameliorates various types of brain injury resulting from temporary CNS ischemia. We have compared the cerebroprotective properties of human SOD-1 (hSOD-1) with a novel recombinant SOD-1 hybrid protein, SOD1:Te451, composed of hSOD-1 linked to the neuronal binding fragment of tetanus toxin (TTx-C). Following temporary middle cerebral artery occlusion, rats infused with equivalent activities of either hSOD-1 or SOD1:Te451 for the initial 3 h of reperfusion showed reductions in cerebral infarct volume of 43 and 57%, respectively, compared to saline-treated controls ($P < 0.01$). Serum hSOD-1 concentrations in rats receiving SOD1:Te451 were seven-fold higher than those in rats receiving the native enzyme. Animals treated with SOD1:Te451 also demonstrated an extended persistence of hSOD-1 in the bloodstream during drug washout as compared to animals given free enzyme. Immunohistochemical examination of brain sections from an SOD1:Te451-treated ischemic rat showed positive immunoreactivity in the ipsilateral cerebral cortex using either hSOD-1 or anti-human SOD-1 antibodies. Our results document that both hSOD-1 and SOD1:Te451 for the initial 3 h of reperfusion showed reductions in cerebral infarct volume of 43 and 57%, respectively, compared to saline-treated controls ($P < 0.01$). Serum hSOD-1 concentrations in rats receiving SOD1:Te451 were seven-fold higher than those in rats receiving the native enzyme. Animals treated with SOD1:Te451 also demonstrated an extended persistence of hSOD-1 in the bloodstream during drug washout as compared to animals given free enzyme. Immunohistochemical examination of brain sections from an SOD1:Te451-treated ischemic rat showed positive immunoreactivity in the ipsilateral cerebral cortex using either hSOD-1 or anti-human SOD-1 antibodies. Our results document that both hSOD-1 and SOD1:Te451 significantly reduce brain infarct volume in a model of transient focal ischemia/reperfusion in rats. Additionally, our findings suggest that the cerebroprotective effects of SOD-1 may be enhanced by neuronal targeting as seen with the hybrid protein SOD1:Te451. Record Date Created: 19970919 Record Date Completed: 19970919

237712 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rs. reserv.

11059318 97413668 PMID: 9270054

Postischemic infusion of Cu/Zn superoxide dismutase or SOD1:Te451 reduces cerebral infarction following focal ischemia/reperfusion in rats.

Francis J W; Rein J; Warren L; Brown R H; Finklestein S P

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Enthargement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: potential vector for delivering heterologous proteins to neurons.

Francis J W; Brown R H; Figueiredo D; Remington M P; Castillo O; Schwartzschild M A; Fishman P S; Murphy J R; vanderSpek J C

Cecil B, Day Center for Neuromuscular Research, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA; Francis@heijx.mgh.harvard.edu

Journal of neurochemistry (UNITED STATES) Jun 2000; 74 (6) p2528-36; ISSN 0022-3042 Journal Code: 2985190R

ContractGrant No.: IPO1NS31248-02; NS; NINDS; 5F32HS1064; HS; AHCPR; R01 NS38679-01; NS; NINDS

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

This study describes the expression, purification, and characterization of a recombinant fusion toxin, DAB(389)TTC, composed of the catalytic and membrane translocation domains of diphtheria toxin (DAB(389)) linked to the receptor binding fragment of tetanus toxin (C-fragment). As determined by its ability to inhibit cellular protein synthesis in primary neuron cultures, DAB(389)TTC was approximately 1,000-fold more cytotoxic than native diphtheria toxin or the previously described fusion toxin DAB(389)MSH. The cytotoxic effect of DAB(389)TTC on cultured cells was specific toward neuronal-type cells and was blocked by coimmunization of the chimeric toxin with tetanus toxin antitoxin. The toxicity of DAB(389)TTC, like that of diphtheria toxin, was dependent on passage through an acidic compartment and ADP-ribosyltransferase activity of the DAB(389) catalytic fragment proteins to the cytosolic compartment of neurons. Record Date Created: 20000602 Record Date Completed: 20000602

Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, Non-H.S.; Support, U.S. Gov't, H.S.; Supports: Hippocampus-metabolism-ME; Immunodominance-ME; *Neurons-metabolism-ME; Peptide Fragments-metabolism-ME; *Superoxide Dismutase-metabolism-ME; *Tetanus Toxin-metabolism-ME; Base Sequence; Biological Transport; Blotting, Western; Cell Line; Cells, Cultured; Cloning Molecular; DNA Primers; Electrophoresis; Polycrylamide Gel Immunoblotting; Immunotoxins-Administration and dosage-AD; Kinetics Molecular Sequence Data; Peptide Fragments-administration and dosage-AD; Peptide Fragments-biosynthesis-BI; Polymerase Chain Reaction; Protein Hybridization; Rats; Restriction Mapping; Superoxide Dismutase-administration and dosage-AD; Superoxide Dismutase-

09jan04 12:55:17 User2018600 Session D1604.3
File 34:SciSearch(R) Cited Ref Sci 1990-2004 Jan W1 (c) 2004 Inst
for Sci Info
Set Items Description

Ref	Items	Index-term
E11	CR=FRANCIS J, 1994, V40, P829, J AM GERIATR SOC	
E11	CR=FRANCIS J, 1994, V99, P395, J GEOPHYS RES	
E21	CR=FRANCIS J, 1994, V99, P395, J GEOPHYS RES	
E30	*CR=FRANCIS J, 1995	
E41	CR=FRANCIS J, 1995, BERICHT KARZFEHN	
E51	CR=FRANCIS J, 1995, BLOOD CONSERVATION	
E61	CR=FRANCIS J, 1995, P26, WORLD INGRED MAR	
E71	CR=FRANCIS J, 1995, P34, WORLD INGREDIENT SEP	
E82	CR=FRANCIS J, 1995, P7, TRANSFORMATION TROP	
E91	CR=FRANCIS J, 1995, V19, P383, J ACCOUNT ECON	
E101	CR=FRANCIS J, 1995, V329, P208, NEW ENGL J MED	
E114	CR=FRANCIS J, 1995, V43, P585, J AM GERIATR SOC	
Ref	Items	Index-term
E13	CR=FRANCIS JW, 1996, V112, P317, J MOL CATAL A-CH	
E21	CR=FRANCIS JW, 1996, V26, P192, J COLL SCI TEACH	
E30	*CR=FRANCIS JW, 1997	
E42	CR=FRANCIS JW, 1997, V146, P435, EXP NEUROL	
E51	CR=FRANCIS JW, 1997, V23, SOC NEUR ABSTR	
E629	CR=FRANCIS JW, 1998, V95, P6492, P NATL ACAD SCI	
E72	CR=FRANCIS JW, 2000, V62, P90, AM BIOL TEACH	
E87	CR=FRANCIS JW, 2000, V74, P2528, J NEUROCHEM	
E91	CR=FRANCIS K, UNPUB	
E101	CR=FRANCIS K, V92, P3616, BLOOD	
E111	CR=FRANCIS K, 1995, V45, AM J PUBLIC HLTH 2 S	
E121	CR=FRANCIS K, 1971, NZ KIWI	
E221	CR=FRANCIS K, 1979, V35, P23, EXPERIMENTA	
E231	CR=FRANCIS K, 1982, V52, P11, P NATL ACAD SCI IND	
E246	CR=FRANCIS K, 1985, V26, P1195, PLANT CELL PHYSIO	

3/6/11 11:08:03 555 Genuine Article#: 602XU Number of References: 129 Title: Clostridial neurotoxins (ABSTRACT AVAILABLE) Publication date: 2002/200000	3/6/2 09/10/099 Genuine Article#: 437QX Number of References: 58 Title: Neuronal targeting of cardiotrophin-1 by coupling with tetanus toxin C fragment (ABSTRACT AVAILABLE) Publication date: 2010/50	3/6/3 08/93/0221 Genuine Article#: 345QX Number of References: 46 Title: Protective effect of supplemental superoxide dismutase on survival of neuronal cells during starvation - Requirement for cytosolic distribution (ABSTRACT AVAILABLE) Publication date: 2000/600
3/6/4 08/65/93 Genuine Article#: 312XG Number of References: 52 Title: Enhancement of cипthiota toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: A potential vector for delivering heterologous proteins to neurons (ABSTRACT AVAILABLE) Publication date: 2000/600	3/6/5 08/03/6308 Genuine Article#: 360GP Number of References: 26 Title: High-level expression of tetanus toxin fragment C-thioredoxin fusion protein in <i>Escherichia coli</i> (ABSTRACT AVAILABLE) Publication date: 2000/400	3/6/5 08/34/6824 Genuine Article#: 274MM Number of References: 41 Title: A somatic gene transfer approach using recombinant fusion proteins to map muscle-motoneuron projections in <i>Xenopus</i> spinal cord (ABSTRACT AVAILABLE) Publication date: 1999/1100
3/6/7 07/48/2407 Genuine Article#: 171LB Number of References: 149 Title: Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses (ABSTRACT AVAILABLE) Publication date: 1999/0228	3/6/7 07/19/9828 Genuine Article#: 135NO Number of References: 42 Title: Tracing axons (ABSTRACT AVAILABLE) Publication date: 1998/1000	3/6/9 05/17/475 Genuine Article#: YA203 Number of References: 30 Title: Structure of the receptor binding fragment H-C of tetanus neurotoxin (ABSTRACT AVAILABLE) Publication date: 1997/1000
3/7/1 11/06/55012 Genuine Article#: X7765 Number of References: 41 Title: Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system (ABSTRACT AVAILABLE) Publication date: 1997/0819	3/7/1 11/06/55012 Genuine Article#: X7765 Number of References: 41 Title: Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system (ABSTRACT AVAILABLE) Publication date: 1997/0819	3/7/11 05/09/6700 Genuine Article#: X1537 Number of References: 50 Title: Delivery of recombinant tetanus-superoxide dismutase proteins to central nervous system neurons by retrograde axonal transport (ABSTRACT AVAILABLE) Publication date: 1997/0600
3/7/7 DIALOG(R)File 34 SciSearch(R) Cited Ref Sci (C) 2004 Inst for Sci Info. All rts. reserv.	3/7/8 02/40/7 Genuine Article#: 171LB Number of References: 49 Title: Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses (ABSTRACT AVAILABLE)	3/7/9 11/03/8111 P259-268 ISSN: 0962-8436 Publication date: 1999/0228 Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/ (REPRINT); UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/; UNIV PADUA,DIPARTIMENTO SCI BIOMED/IT/35100 PADUA/ITALY/; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOL/ LONDON WC2A 3PX/ENGLAND/
3/7/9 11/03/8111 P259-268 ISSN: 0962-8436 Publication date: 1999/0228 Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/ (REPRINT); UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/; UNIV PADUA,DIPARTIMENTO SCI BIOMED/IT/35100 PADUA/ITALY/; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOL/ LONDON WC2A 3PX/ENGLAND/	3/7/9 11/03/8111 P259-268 ISSN: 0962-8436 Publication date: 1999/0228 Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/ (REPRINT); UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/; UNIV PADUA,DIPARTIMENTO SCI BIOMED/IT/35100 PADUA/ITALY/; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOL/ LONDON WC2A 3PX/ENGLAND/	3/7/9 11/03/8111 P259-268 ISSN: 0962-8436 Publication date: 1999/0228 Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/ (REPRINT); UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/; UNIV PADUA,DIPARTIMENTO SCI BIOMED/IT/35100 PADUA/ITALY/; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOL/ LONDON WC2A 3PX/ENGLAND/
3/7/9 11/03/8111 P259-268 ISSN: 0962-8436 Publication date: 1999/0228 Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/ (REPRINT); UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/; UNIV PADUA,DIPARTIMENTO SCI BIOMED/IT/35100 PADUA/ITALY/; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOL/ LONDON WC2A 3PX/ENGLAND/	3/7/9 11/03/8111 P259-268 ISSN: 0962-8436 Publication date: 1999/0228 Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/ (REPRINT); UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/; UNIV PADUA,DIPARTIMENTO SCI BIOMED/IT/35100 PADUA/ITALY/; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOL/ LONDON WC2A 3PX/ENGLAND/	3/7/9 11/03/8111 P259-268 ISSN: 0962-8436 Publication date: 1999/0228 Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/ (REPRINT); UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/; UNIV PADUA,DIPARTIMENTO SCI BIOMED/IT/35100 PADUA/ITALY/; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOL/ LONDON WC2A 3PX/ENGLAND/
3/7/9 11/03/8111 P259-268 ISSN: 0962-8436 Publication date: 1999/0228 Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/ (REPRINT); UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/; UNIV PADUA,DIPARTIMENTO SCI BIOMED/IT/35100 PADUA/ITALY/; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOL/ LONDON WC2A 3PX/ENGLAND/	3/7/9 11/03/8111 P259-268 ISSN: 0962-8436 Publication date: 1999/0228 Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/ (REPRINT); UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/; UNIV PADUA,DIPARTIMENTO SCI BIOMED/IT/35100 PADUA/ITALY/; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOL/ LONDON WC2A 3PX/ENGLAND/	3/7/9 11/03/8111 P259-268 ISSN: 0962-8436 Publication date: 1999/0228 Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/ (REPRINT); UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/; UNIV PADUA,DIPARTIMENTO SCI BIOMED/IT/35100 PADUA/ITALY/; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOL/ LONDON WC2A 3PX/ENGLAND/
3/7/9 11/03/8111 P259-268 ISSN: 0962-8436 Publication date: 1999/0228 Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/ (REPRINT); UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/; UNIV PADUA,DIPARTIMENTO SCI BIOMED/IT/35100 PADUA/ITALY/; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOL/ LONDON WC2A 3PX/ENGLAND/	3/7/9 11/03/8111 P259-268 ISSN: 0962-8436 Publication date: 1999/0228 Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/ (REPRINT); UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/; UNIV PADUA,DIPARTIMENTO SCI BIOMED/IT/35100 PADUA/ITALY/; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOL/ LONDON WC2A 3PX/ENGLAND/	3/7/9 11/03/8111 P259-268 ISSN: 0962-8436 Publication date: 1999/0228 Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/ (REPRINT); UNIV PADUA,CTR BIOMEMBRANE, CNR/IT/35100 PADUA/ITALY/; UNIV PADUA,DIPARTIMENTO SCI BIOMED/IT/35100 PADUA/ITALY/; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOL/ LONDON WC2A 3PX/ENGLAND/

Author(s): Figueiredo DM; Halewell RA (REPRINT); Chen LL; Fairweather NF; Dougan G; Savitt M; Parks DA; Fishman PS
Corporate Source: UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED DEPT BIOCHEM LONDON SW7 2AZ/ENGLAND/ (REPRINT); UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED DEPT BIOCHEM LONDON SW7 2AZ/ENGLAND/; UNIV MARYLAND, SCH MED, VAMC, NEUROL SERV BALTIMORE/MD/21201; UNIV MARYLAND, SCH MED, VAMC, DEPT NEUROL BALTIMORE/MD/21201
Journal: EXPERIMENTAL NEUROLOGY 1997, V145, N2 (JUN), P56-59 ISSN: 0014-4886 Publication date: 19970600
Publisher: ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
Language: English Document Type: ARTICLE

Abstract: The nontoxic C fragment of tetanus toxin (TC) can transport other proteins from the circulation to central nervous system (CNS) motor neurons. Increased levels of Cu/Zn superoxide dismutase (SOD) are protective in experimental models of stroke and Parkinson's disease, whereas mutations in SOD can cause motor neuron disease. We have linked TC to SOD and purified the active recombinant proteins in both the TC-SOD and SOD-TC orientations. Light microscopic immunohistochemistry and quantitative enzyme-linked immunosorbent assays (ELISA) of mouse brainstem, after intramuscular injection, demonstrate that the fusion proteins undergo retrograde axonal transport and transsynaptic transfer as efficiently as TC alone. (C) 1997 Academic Press.

5/6/1 09361245 Genuine Article#: 3963M Number of References: 39
Title: Interaction of tetanus toxin derived hybrid proteins with neuronal cells (ABSTRACT AVAILABLE) Publication date: 200001100

5/6/2 07912310 Genuine Article#: 169FN Number of References: 43
Title: Hybrid enzymes (ABSTRACT AVAILABLE) Publication date: 19990800

5/6/3 07467070 Genuine Article#: 169FN Number of References: 35
Title: Non-viral neuronal gene delivery mediated by the H-C fragment of tetanus toxin

5/6/4 06042440 Genuine Article#: XRG56 Number of References: 47
Title: Postischemic infusion of Cu/Zn superoxide dismutase or SOD Tel451 reduces cerebral infarction following focal ischemia/reperfusion in rats (ABSTRACT AVAILABLE) Publication date: 19970800

5/7/2 DIALOG(R)File 34-SciSearch(R) Cited Ref Sci(c) 2004 Inst for Sci Info, All rights reserved
Title: Hybrid enzymes
Author(s): Beguin P (REPRINT)

Corporate Source: INST PASTEUR,DEPT BIOTECHNOL, UNITE PHYSIOL CELLULARE, 28 RUE DR ROUX/F-75724 PARIS/FRANCE (REPRINT)
Journal: CURRENT OPINION IN BIOTECHNOLOGY, 1999 V10, N4 (AUG) P336-340 ISSN: 0958-1669 Publication date: 19990800 Publisher: CURRENT BIOLOGY LTD, 34-42 CLEVELAND STREET, LONDON W1P 6LE, ENGLAND
Language: English Document Type: REVIEW

Abstract: Combining structural elements belonging to different proteins is a powerful method for generating proteins with new properties. Progress based on detailed structural and functional analysis enables a better integration of the elements to be fit together while preserving or creating functional interactions between them.

5/7/3 DIALOG(R)File 34-SciSearch(R) Cited Ref Sci(c) 2004 Inst for Sci Info, All rights reserved
Title: Non-viral neuronal gene delivery mediated by the H-C fragment of tetanus toxin

Author(s): Knight A (REPRINT); Canvala J; Schneider H; Couteille C; Chamberlain S; Fairweather N
Corporate Source: UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED SCH MED CYST FIBROSIS GENE THERAPY RES GRP/LONDON SW7 2AZ/ENGLAND/ (REPRINT); UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED SCH MED GENE THERAPY RES GRP, SECT MOL GENET/LONDON/ENGLAND/; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED SCH MED, ATAXIA GRP, SECT MOL GENET/LONDON/ENGLAND/; UNIV LONDON IMPERIAL COLL SCI/LONDON/ENGLAND/; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED DEPT BIOCHEM/LONDON/ENGLAND/; UNIV LONDON IMPERIAL COLLEGE SCIENCES, LONDON/ENGLAND/

Journal: EUROPEAN JOURNAL OF BIOCHEMISTRY 1999 V259 N3 (FEB) P762-769 ISSN: 0014-2956 Publication date: 19990200 Publisher: SPRINGER VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010 Language: English Document Type: ARTICLE
Abstract: Many inherited neurological diseases and cancers could potentially benefit from efficient targeted gene delivery to neurons of the central nervous system. The nontoxic fragment C (H-C) of tetanus toxin retains the specific nerve cell binding and transport properties of tetanus holotoxin. The H-C fragment has previously been used to promote the uptake of attached proteins such as horseradish peroxidase, beta-galactosidase and superoxide dismutase into neuronal cells *in vitro* and *in vivo*. We report the use of purified recombinant H-C fragment produced in yeast and covalently bound to polylysine [poly(Lys)] to enable binding of DNA. We demonstrate that when used to transfect cells, this construct results in nonviral gene delivery and marker gene expression *in vitro* in N18 RE 105 cells (a neuroblastoma x glioma mouse/rat hybrid cell line) and F98 (a glioma cell line). Transfection was dependent on H-C and was neuronal cell type specific. H-C may prove a useful targeting ligand for future neuronal gene therapy

Mark a special word or phrase in this record: All organism
Clostridium tetaniSelect one or more organism in this record:

EC NUMBER COMMENTARY

3.4.24.68

RECOMMENDED NAME GeneOntology No.

Tentoxilysin

GO:0000000

SYSTEMATIC NAME

No entries in this field

SYNONYMS ORGANISM COMMENTARY LITERATURE

More

cf. EC 3.4.24.69

Tentoxilysin

SwissProt

Tetanus neurotoxin

CAS REGISTRY NUMBER COMMENTARY

107231-12-9

REACTION COMMENTARY

Synaptobrevin + H₂O = hydrolyzed synaptobrevin Clostridium tetani: structure and mechanism <2, 5, 6>

REACTION TYPE ORGANISM COMMENTARY LITERATURE

hydrolysis of peptide bond

ORGANISM COMMENTARY

Clostridium tetani toxicogenic strains N3911 <1>; E 88 (non-sporulating) <3>; Harvard <6>; all toxicogenic strains synthesize only one type of neurotoxin <5, 6>

LITERATURE

1-6

SUBSTRATE	PRODUCT	REACTION DIAGRAM	ORGANISM	COMMENTARY/ Substrate r:=reversible ir:=irreversible	LITERATURE/ COMMENTARY/ Substrate	Product	LITERATURE/ COMMENTARY/ Product
More	?		Clostridium tetani	no substrates are rat <4,5>; or chicken <5>; synaptobrevin-1 (with Val76 instead of Gln76) or short peptides containing the cleavage site of the target protein <5,6>; catalytic activity requires reduction of the single interchain disulfide bond of the neurotoxin <4> i.e. VAMP <5,6>; neuronal vesicle-associated	4, 5, 6		

Synaptobrevin + H ₂ O	Hydrolyzed synaptobrevin		Clostridium tetani	membrane protein, MW 19000 <4>; with 2 isoforms in human <4>; chicken <5>; or rat brain <4,5>; synaptobrevin/VAMP-1 and synaptobrevin/VAMP-2, cleaves at Gln76-Phe77, the same site as botulin neurotoxin B <5,6>	<u>1</u> , <u>2</u> , <u>3</u> , <u>4</u> , <u>5</u> , <u>6</u>	2 peptide fragments, MW 12000 and MW 7000	4
----------------------------------	--------------------------	---	--------------------	---	---	---	----------

NATURAL SUBSTRATE	NATURAL PRODUCT	REACTION DIAGRAM	ORGANISM	COMMENTARY SUBSTRATE	LITERATURE (Substrate)	COMMENTARY PRODUCT	LITERATURE (Product)	ORGANISM (Product)
Synaptobrevin + H ₂ O			Clostridium tetani	i.e. VAMP, neuronal vesicle-associated membrane protein, predominantly exposed to cytosol <5>; neurotoxin blocks neurotransmitter release in Aplysia neurons <4>; tetanus neurotoxin receptors are located on the motor neuron plasmalemma at neuromuscular junction, after binding the toxin is internalized inside vesicles of unknown nature and then translocated across the vesicle membrane <5>; enzyme disables neuroexocytosis apparatus, acts at spinal inhibitory interneurons, blocking release of various neurotransmitters to produce spastic paralysis, clostridial neurotoxins are described as the most toxic substances known	<u>4</u> , <u>5</u> , <u>6</u>	-	-	-

COFACTOR ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

METAL IONS	ORGANISM	COMMENTARY	LITERATURE
Cobalt	Clostridium tetani	zinc-dependent endoproteinase, can replace zinc	5
Nickel	Clostridium tetani	zinc-dependent endoproteinase, can replace zinc	5
Zinc	Clostridium tetani	zinc-dependent endoproteinase <2,4,5,6>; L-chain: form of zinc-endopeptidase, 0.8-1 gatom zinc/mol toxin, bound to light or L-chain <6>; 1 atom zinc per molecule toxin, zinc-binding motif: His-Glu-X-X-His, nickel or cobalt can replace zinc <5>; toxin surface topography of His-residues <2>	2 , 4 , 5 , 6

INHIBITORS	ORGANISM	COMMENTARY	LITERATURE	IMAGE
Ala-Ser-Gln-Phe-Glu-Thr-Ser	Clostridium tetani	synthetic peptide containing cleavage site of synaptobrevin, inhibits toxin action on buccal ganglion of <i>Aplysia californica</i>	4	

Clostridium



Captopril	tetani	-	<u>4</u> , <u>5</u>	image
EDTA	Clostridium tetani	-	<u>4</u> ,	2D-image
Gln-Phe-Glu-Thr	Clostridium tetani	synthetic peptide containing cleavage site of synaptobrevin, inhibits toxin action on buccal ganglion of <i>Aplysia californica</i>	<u>4</u>	2D-image
NaOCl	Clostridium tetani	inactivation	<u>6</u>	2D-image

ACTIVATING COMPOUND	ORGANISM	COMMENTARY	LITERATURE	IMAGE
Proteases	Clostridium tetani	activation by rapid cleavage within an exposed loop of the single inactive MW 150000 polypeptide chain and generation of active di-chain neurotoxin <5,6>; bacterial <5,6>; or tissue proteases <5>	<u>5</u> , <u>6</u>	-

KM VALUE [mM] KM VALUE [mM] Maximum SUBSTRATE ORGANISM COMMENTARY LITERATURE IMAGE
 No entries in this field

Ki VALUE [mM] Ki VALUE [mM] Maximum INHIBITOR ORGANISM COMMENTARY LITERATURE IMAGE
 No entries in this field

TURNOVER NUMBER TURNOVER NUMBER MAXIMUM SUBSTRATE ORGANISM COMMENTARY LITERATURE IMAGE
 No entries in this field

SPECIFIC ACTIVITY [μ M/min/mg]	SPECIFIC ACTIVITY MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
additional information	-	Clostridium tetani	in neurotoxin-injected <i>Aplysia</i> neurons 4-10 molecules of L-chains are sufficient to cause blockade of neurotransmitter release with a t _{1/2} of 20-40 min at 20°C	<u>5</u>

pH OPTIMUM pH MAXIMUM ORGANISM COMMENTARY LITERATURE
 No entries in this field

pH RANGE pH RANGE MAXIMUM ORGANISM COMMENTARY LITERATURE
 No entries in this field

TEMPERATURE OPTIMUM TEMPERATURE OPTIMUM MAXIMUM ORGANISM COMMENTARY LITERATURE
 37 Clostridium tetani assay at 4 , 6

TEMPERATURE RANGE TEMPERATURE MAXIMUM ORGANISM COMMENTARY LITERATURE
 No entries in this field

SOURCE TISSUE ORGANISM COMMENTARY LITERATURE
 culture supernatant Clostridium tetani - 6

LOCALIZATION ORGANISM COMMENTARY GeneOntology No. LITERATURE
 cytosol Clostridium tetani accumulates until bacterial lysis [GO:0005829](#) 5 , 6

ACCESSION CODE ENTRY NAME ORGANISM NO. OF AA MOLECULAR WEIGHT[Da] SOURCE Sequence
 No entries in this field

PDB ORGANISM
[1A8D](#), [download](#) Clostridium tetani

1AF9, [download](#) Clostridium tetani
1DFQ, [download](#) Clostridium tetani
1DIW, [download](#) Clostridium tetani
1DLL, [download](#) Clostridium tetani
1FV2, [download](#) Clostridium tetani

MOLECULAR WEIGHT	MOLECULAR WEIGHT MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
150700	-	Clostridium tetani	Clostridium tetani, calculated from amino acid sequence	<u>6</u>
additional information	-	Clostridium tetani	amino acid sequence homologies between tetanus toxin TeNT and botulinum toxins BoNT/A, B and E	<u>3</u>
SUBUNITS	ORGANISM	COMMENTARY		LITERATURE
More	Clostridium tetani	the enzyme consists of a heavy (H) chain and a light (L) chain <2,3>; held together by a single disulfide bond and non-covalent forces <2>; MW 52288 (L-chain) and MW 98300 (H-chain), calculated from amino acid sequence <3>		<u>2</u> , <u>3</u>

POSTTRANSLATIONAL MODIFICATION ORGANISM COMMENTARY LITERATURE

No entries in this field

Crystallization/COMMENTARY ORGANISM LITERATURE

No entries in this field

pH STABILITY pH STABILITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

TEMPERATURE STABILITY TEMPERATURE STABILITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

GENERAL STABILITY ORGANISM LITERATURE

No entries in this field

ORGANIC SOLVENT ORGANISM COMMENTARY LITERATURE

No entries in this field

OXIDATION STABILITY ORGANISM LITERATURE

Clostridium tetani 6

STORAGE STABILITY

-80°C, in 10 mM HEPES buffer, pH 7.2, 50 mM NaCl, after freezing in liquid N₂, stable

ORGANISM COMMENTARY LITERATURE
Clostridium tetani 6

Purification/COMMENTARY

single-chain, two-chain and L-chain form <6>; very toxic! Booster injection of tetanus toxoid before starting research with tetanus toxin advisable, human anti-tetanus neurotoxin antibodies available <6>

ORGANISM LITERATURE
Clostridium tetani 2 , 6

Cloned/COMMENTARY

Clostridium tetani <1,3>; expressed in Escherichia coli JM101 using three different plasmid vectors <3>

ORGANISM LITERATURE
Clostridium tetani 1 , 3

ENGINEERING ORGANISM COMMENTARY LITERATURE

No entries in this field

Renatured/COMMENTARY ORGANISM LITERATURE

No entries in this field

APPLICATION ORGANISM COMMENTARY LITERATURE

No entries in this field

DISEASE TITLE OF PUBLICATION LINK TO PUBMED

No entries in this field

REF.	AUTHORS	TITLE	JOURNAL	VOL.	PAGES	YEAR	ORGANISM	COMMENTARY	LINK TO PUBMED
1	Fairweather, N.F.; Lyness, V.A.	The complete nucleotide sequence of tetanus toxin	Nucleic Acids Res.	14	7809-7813	1986	Clostridium tetani	-	PubMed
2	Rossetto, O.; Schiavo, G.; Polverino de Laureto, P.; Fabbiani, S.; Montecucco, C.	Surface topography of histidine residues of tetanus toxin probed by immobilized-metal-ion affinity chromatography	Biochem. J.	285	9-12	1992	Clostridium tetani	-	PubMed
3	Eisel, U.; Jarusch, W.; Goretzki, K.; Henschen, A.; Engels, J.; Weller, U.; Hudel, M.; Habermann, E.; Niemann, H.	Tetanus toxin: primary structure, expression in <i>E. coli</i> , and homology with botulinum toxins	EMBO J.	5	2495-2502	1986	Clostridium tetani	-	PubMed
4	Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; Polverino de Laureto, P.; DasGupta, B.R.; Montecucco, C.	Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin [see comments]	Nature	359	832-835	1992	Clostridium tetani	-	PubMed
5	Montecucco, C.; Schiavo, G.	Mechanism of action of tetanus and botulinum neurotoxins	Mol. Microbiol.	13	1-8	1994	Clostridium tetani	review	PubMed
6	Schiavo, G.; Montecucco, C.	Tetanus and botulism neurotoxins: isolation and assay	Methods Enzymol.	248	643-652	1995	Clostridium tetani	review	PubMed

LINKS TO OTHER DATABASES (specific for EC-Number 3.4.24.68)

[ExPASy](#)

[Online Mendelian Inheritance in Man](#)

[KEGG](#)

NCBI: [PubMed](#), [Protein](#), [Nucleotide](#), [Structure](#), [Genome](#), [OMIM](#), [Domains](#)

[IUBMB Enzyme Nomenclature](#)

[WIT database](#)

[EMP Project](#)

[PDB database\(3D structure\)](#)

[PROSITE Database of protein families and domains](#)

[SYSTERS](#)

[Protein Mutant Database](#)

Mark a special word or phrase in this record:

All organism
Clostridium barati
Clostridium botulinum
Clostridium butyricum
Clostridium sp.

Select one or more organism in this record:

EC NUMBER COMMENTARY

3.4.24.69

RECOMMENDED NAME GeneOntology No.

Bontoxilysin

GO:0000000

SYSTEMATIC NAME

No entries in this field

SYNONYMS ORGANISM COMMENTARY LITERATURE

BoNT	-	-	-
BoNT/B	-	SwissProt	-
BoNT/C1	-	SwissProt	-
BoNT/D	-	SwissProt	-
BoNT/E	-	SwissProt	-
BoNT/F	-	SwissProt	-
BoNT/G	-	SwissProt	-
Bontoxilysin C1	-	SwissProt	-
Botulinum neurotoxin	-	-	-
More	-	cf. EC 3.4.24.68	-

CAS REGISTRY NUMBER COMMENTARY

107231-12-9

REACTION COMMENTARY

Protein + H ₂ O = hydrolyzed protein	Clostridium botulinum: mechanism <4>; Clostridium botulinum, Clostridium barati, Clostridium butyricum: structure/function relationship <5>
	-

REACTION TYPE ORGANISM COMMENTARY LITERATURE

hydrolysis of peptide bond -

ORGANISM	COMMENTARY	LITERATURE
Clostridium barati	-	5
<u>Clostridium botulinum</u>	strains 62A (serotype A) or Beluga (serotype E) <10>; type G strain <15>; 7 serologically different neurotoxin types: BoNT/A-G <2, 3, 5, 6>; serotypes BoNT/A, BoNT/B <1, 4, 8, 15>; BoNT/C, BoNT/D <15>; BoNT/E <1, 4, 8>	<u>1-10</u> , <u>12</u> , <u>15</u>
<u>Clostridium butyricum</u>	-	5
<u>Clostridium sp.</u>	serotypes BoNT/A, B, D, E <13>; F <13, 14>	<u>6</u> , <u>11</u> , <u>13</u> , <u>14</u>

SUBSTRATE	PRODUCT	REACTION DIAGRAM	ORGANISM	Substrate r=reversible ir=irreversible	LITERATURE/ Substrate	COMMENTARY/ Product	LITERATU Product
More	?	?	Clostridium botulinum	catalytic activity requires reduction of the single interchain disulfide bond of the neurotoxin <4,15>; activating protease activity is localized on light or L-chain of neurotoxin <4>; the clostridial neurotoxins differ from other proteases in the recognition of the	1, 4, 5, 6, 15	-	-
More	?	?	Clostridium barati	tertiary structure of the target rather than the sequence of the peptide bond to be cleaved <15>; neuroparalytic activity tested by intravenous injection into Balb/c mice <1>; no hydrolysis of short peptides spanning the respective cleavage sites of the target proteins <5,6>; synaptotagmin, synaptophysin <15>	5	-	-
More	?	?	Clostridium butyricum	no hydrolysis of short peptides spanning the respective cleavage sites of the target proteins <5>	5	-	-
More	?	?	Clostridium sp.	no hydrolysis of short peptides spanning the respective cleavage sites of the target proteins <5>	6, 13	-	-
Proteins of neuroexocytosis apparatus + H ₂ O	?	?	Clostridium botulinum	-	2, 3, 5, 6	-	-
Proteins of neuroexocytosis apparatus + H ₂ O	?	?	Clostridium barati	-	5	-	-
Proteins of neuroexocytosis apparatus + H ₂ O	?	?	Clostridium butyricum	-	5	-	-
Proteins of neuroexocytosis apparatus + H ₂ O	?	?	Clostridium sp.	-	6	-	-
Recombinant glutathione S-methyltransferase	Hydrolyzed recombinant glutathione S-	?	Clostridium	-	15	2 proteolytic fragments. MW	15

VAMP-2 fusion protein + H2O	methyltransferase VAMP-2 fusion protein		botulinum		36000 and MW 6000
			i.e. VAMP <5,6,12,15>; synaptic vesicle- associated membrane protein <4,6,15>; MW 19000 <4>; two isoforms in human <4>; chicken <5>; or rat brain <4,5>; synaptobrevin/VAMP-1 (VAMP-1 from chicken, #Clostridium botulinum,5#Clostridium barati,o#Clostridium butyricum# <5> or rat brain, #Clostridium botulinum,n#Clostridium barati,l#Clostridium butyricum# <4, 5> carrying Val76 instead of Gln76 is not hydrolyzed by serotype BoNT/B, #Clostridium botulinum,off#Clostridium barati,i#Clostridium butyricum# <4, 5>) <4,5,15>; and synaptobrevin/VAMP-2 <4,5,6,15>; both isoforms are cleaved at the same rate <15>; highly specific neurotoxins <4,5,6,15>; serotype BoNT/B: cleavage at Ser-Gln-+- Phe-Glu (at the same site as the tetanus neurotoxin) <5>; or Gln76-Phe77 <4>; or Gln-Lys-+-Leu-Ser <5>; or-Asp-Gln-+-Lys-Leu- serotype BoNT/G: cleavage at Ala83- Ala84 (VAMP-1), Ala81- Ala82 (VAMP-2) <15>; or Ser-Ala-+-Ala-Lys <5>; hydrolyzed by serotypes BoNT/B <4,5,6>; D, F or G <5,6>; in vitro, in synaptosomes and in injected Aplysia neurons <5>; no substrate of serotype BoNT/A or E <4,12>; the term -+- depicts the points of cleavage	2 proteolytic fragments, MW 12000 and MW 7000 <4>; MW 13000 and MW 6000 <15>	
Synaptobrevin + H2O	Hydrolyzed synaptobrevin		Clostridium botulinum	4 , 5 , 6 , 15	4 , 15

Synaptobrevin + H2O	Hydrolyzed synaptobrevin	█	Clostridium sp.	<p>of Gln76 is not hydrolyzed by serotype BoNT/B, #Clostridium botulinum, #Clostridium barati, #Clostridium butyricum# <4, 5> <13>; and synaptobrevin/VAMP-2 <6,13>; both isoforms are cleaved at the same rate <13,14>; highly specific neurotoxins <6,13,14>; serotype BoNT/D: cleavage at Lys61-Leu62 <13>; serotype BoNT/F: cleavage at Gln-Lys <14>; hydrolyzed by serotypes BoNT/B <6>; D, F or G <6>; the term -+- depicts the points of cleavage</p> <p>i.e. VAMP <5>; chicken <5>; or rat brain <5>; synaptobrevin/VAMP-1 (VAMP-1 from chicken, #Clostridium botulinum, k#Clostridium barati, #Clostridium butyricum# <5> or rat brain, #Clostridium botulinum, o#Clostridium barati, m#Clostridium butyricum# <4, 5> carrying Val76 instead of Gln76 is not hydrolyzed by serotype BoNT/B, #Clostridium botulinum, >#Clostridium barati, e#Clostridium butyricum# <4, 5>) <5>; and</p>	<u>6</u> , <u>13</u> , <u>14</u>	MW 8000 and MW 9000 <13>	<u>13</u>
Synaptobrevin + H2O	Hydrolyzed synaptobrevin	█	Clostridium barati	<p>synaptobrevin/VAMP-2 <5>; highly specific neurotoxins <5>; serotype BoNT/B: cleavage at Ser-Gln-+-Phe-Glu (at the same site as the tetanus neurotoxin) <5>; or Gln-Lys-+-Leu-Ser <5>; or Ser-Ala-+-Ala-Lys <5>; hydrolyzed by serotypes BoNT/B <5>; D, F or G <5>; in vitro, in synaptosomes and in injected Aplysia neurons <5>; the term -+- depicts the points of cleavage</p> <p>i.e. VAMP <5>; chicken <5>; or rat brain <5>; synaptobrevin/VAMP-1 (VAMP-1 from chicken, #Clostridium botulinum, d#Clostridium barati, d#Clostridium butyricum# <5> or rat brain, #Clostridium botulinum, i#Clostridium barati, i#Clostridium butyricum# <4, 5> carrying Val76 instead</p>	5		

Synaptobrevin + H ₂ O	Hydrolyzed synaptobrevin		Clostridium butyricum	<p>of Gln76 is not hydrolyzed by serotype BoNT/B, #Clostridium botulinum, u#Clostridium barati, u#Clostridium butyricum# <4, 5> <5>; and synaptobrevin/VAMP-2 <5>; highly specific neurotoxins <5>; serotype BoNT/B: cleavage at Ser-Gln-+-Phe-Glu (at the same site as the tetanus neurotoxin) <5>; or Gln-Lys-+-Leu-Ser <5>; or Ser-Ala-+-Ala-Lys <5>; hydrolyzed by serotypes BoNT/B <5>; D, F or G <5>; in vitro, in synaptosomes and in injected Aplysia neurons <5>; the term -+- depicts the points of cleavage</p> <p>i.e. SNAP 25, protein of presynaptic membrane <5>; MW 25000 <5>; native and recombinant protein <12>; highly specific neurotoxins <12>; serotype BoNT/A: cleavage at Gln197-Arg198 <12>; or Asn-Gln-+-Arg-Ala <5>; serotype BoNT/E: cleavage at Arg180-Ile181 <12>; or Asp-Arg-+-Ile-Met <5>; serotype BoNT/A and E <5,6,12>; in vitro, in isolated synaptosomes <5,12>; and in injected Aplysia neurons <5>; no substrate of serotype BoNT/G <15>; the term -+- depicts the points of cleavage</p> <p>i.e. SNAP 25, protein of presynaptic membrane <5>; MW 25000 <5>; or Asn-Gln-+-Arg-Ala <5>; or Asp-Arg-+-Ile-Met <5>; serotype BoNT/A and E <5>; in vitro, in isolated synaptosomes <5>; and in injected Aplysia neurons <5>; the term -+- depicts the points of cleavage</p> <p>i.e. SNAP 25, protein of presynaptic membrane <5>; MW 25000 <5>; or Asn-Gln-+-Arg-Ala <5>; or Asp-Arg-+-Ile-Met <5>; serotype BoNT/A and E <5>; in vitro, in isolated synaptosomes <5>; and in injected Aplysia neurons <5>; the term -+- depicts the points of cleavage</p>	5
Synaptosome-associated protein + H ₂ O	Hydrolyzed synaptosome-associated protein		Clostridium botulinum	<p>i.e. SNAP 25, protein of presynaptic membrane <5>; MW 25000 <5>; or Asn-Gln-+-Arg-Ala <5>; serotype BoNT/E: cleavage at Arg180-Ile181 <12>; or Asp-Arg-+-Ile-Met <5>; serotype BoNT/A and E <5,6,12>; in vitro, in isolated synaptosomes <5,12>; and in injected Aplysia neurons <5>; no substrate of serotype BoNT/G <15>; the term -+- depicts the points of cleavage</p>	5 , 6 , 12
Synaptosome-associated protein + H ₂ O	Hydrolyzed synaptosome-associated protein		Clostridium barati	<p>i.e. SNAP 25, protein of presynaptic membrane <5>; MW 25000 <5>; or Asn-Gln-+-Arg-Ala <5>; or Asp-Arg-+-Ile-Met <5>; serotype BoNT/A and E <5>; in vitro, in isolated synaptosomes <5>; and in injected Aplysia neurons <5>; the term -+- depicts the points of cleavage</p>	5
Synaptosome-associated protein + H ₂ O	Hydrolyzed synaptosome-associated protein		Clostridium butyricum	<p>i.e. SNAP 25, protein of presynaptic membrane <5>; MW 25000 <5>; or Asn-Gln-+-Arg-Ala <5>; or Asp-Arg-+-Ile-Met <5>; serotype BoNT/A and E <5>; in vitro, in isolated synaptosomes <5>; and in injected Aplysia neurons <5>; the term -+- depicts the points of cleavage</p>	5

2 proteolytic fragments, MW 20500 and MW 3000 (serotype BoNT/E) or MW 22500 and MW 1000 (serotype BoNT/A)

12

2 proteolytic fragments, MW 20500 and MW 3000 (serotype BoNT/E) or MW 22500 and MW 1000 (serotype BoNT/A)

2 proteolytic fragments, MW 20500 and MW 3000 (serotype BoNT/E) or MW 22500 and MW 1000 (serotype BoNT/A)

Synaptosome-associated protein + H ₂ O	Hydrolyzed synaptosome-associated protein		Clostridium sp.	i.e. SNAP 25, protein of presynaptic membrane <13>; serotype BoNT/A and E <6,13>; the term -+ depicts the points of cleavage	6, 13	2 proteolytic fragments, MW 20500 and MW 3000 (serotype BoNT/E) or MW 22500 and MW 1000 (serotype BoNT/A)
Syntaxin + H ₂ O	?		Clostridium botulinum	serotype BoNT/C <5,6>; in vitro, in synaptosomes and in injected Aplysia neurons <5>; no substrate of serotype BoNT/G <15>	5, 6	-
Syntaxin + H ₂ O	?		Clostridium baratti	serotype BoNT/C <5>; in vitro, in synaptosomes and in injected Aplysia neurons <5>	5	-
Syntaxin + H ₂ O	?		Clostridium butyricum	serotype BoNT/C <5>; in vitro, in synaptosomes and in injected Aplysia neurons <5>	5	-
Syntaxin + H ₂ O	?		Clostridium sp.	serotype BoNT/C <6>	6	-
NATURAL SUBSTRATE	NATURAL PRODUCT	REACTION DIAGRAM	ORGANISM	COMMENTARY SUBSTRATE	LITERATURE (Substrate)	COMMENTARY PRODUCT
Neuroexocytosis multi-subunit complex + H ₂ O	-		Clostridium botulinum	involved in limited hydrolysis of proteins of the neuroexocytosis apparatus, blocks release of neurotransmitter acetylcholine at neuromuscular junction <5>; causing flaccid paralysis, in contrast to spastic paralysis caused by EC 3.4.24.68, three functionally distinct domains: domain L blocks neuroexocytosis, domain HN governs cell penetration, domain HC responsible for neurospecific binding <5,6>; neurotoxin binds specifically to nerve cells, botulin neurotoxin-receptors are located on the motor neuron plasmalemma at neuromuscular junctions, neurotoxin binds via protein and lipid interaction, after binding it is internalized inside vesicles of unknown nature	5, 6	LITERATURE (Product) ORGANISM (Product)

**Neuroexocytosis
multi-subunit
complex + H₂O**



involved in limited hydrolysis of proteins of the neuroexocytosis apparatus, blocks release of neurotransmitter acetylcholine at neuromuscular junction <5>; causing flaccid paralysis, in contrast to spastic paralysis caused by EC
3.4.24.68, three functionally distinct domains: domain L blocks neuroexocytosis, domain HN governs cell penetration, domain HC responsible for neurospecific binding <5>; neurotoxin binds specifically to nerve cells, botulin neurotoxin-receptors are located on the motor neuron plasmalemma at neuromuscular junctions, neurotoxin binds via protein and lipid interaction, after binding it is internalized inside vesicles of unknown nature

5

**Neuroexocytosis
multi-subunit
complex + H₂O**



involved in limited hydrolysis of proteins of the neuroexocytosis apparatus, blocks release of neurotransmitter acetylcholine at neuromuscular junction <5>; causing flaccid paralysis, in contrast to spastic paralysis caused by EC
3.4.24.68, three functionally distinct domains: domain L blocks neuroexocytosis, domain HN governs cell penetration, domain HC responsible for neurospecific binding <5>; neurotoxin binds specifically to nerve cells, botulin neurotoxin-receptors are located on the motor neuron plasmalemma at neuromuscular junctions, neurotoxin

5

Neuroexocytosis multi-subunit complex + H ₂ O		Clostridium sp.	binds via protein and lipid interaction, after binding it is internalized inside vesicles of unknown nature	
			causing flaccid paralysis, in contrast to spastic paralysis caused by EC 3.4.24.68, three functionally distinct domains: domain L blocks neuroexocytosis, domain HN governs cell penetration, domain HC responsible for neurospecific binding <6>; neurotoxin binds specifically to nerve cells, botulin neurotoxin-receptors are located on the motor neuron plasmalemma at neuromuscular junctions, neurotoxin binds via protein and lipid interaction, after binding it is internalized inside vesicles of unknown nature	6
Synaptobrevin + H ₂ O		Clostridium botulinum	i.e. VAMP <5,6,12>; synaptic vesicle- associated membrane protein, neurotoxin responsible for human and animal botulism <12>	4 , 5 , 6 , 12
Synaptobrevin + H ₂ O		Clostridium barati	i.e. VAMP <5>	5
Synaptobrevin + H ₂ O		Clostridium butyricum	i.e. VAMP <5>	5
Synaptobrevin + H ₂ O		Clostridium sp.	i.e. VAMP <6>	6
Synaptosome- associated protein + H ₂ O		Clostridium botulinum	i.e. SNAP 25, protein of presynaptic membrane	5
Synaptosome- associated protein + H ₂ O		Clostridium barati	i.e. SNAP 25, protein of presynaptic membrane	5
Synaptosome- associated protein + H ₂ O		Clostridium butyricum	i.e. SNAP 25, protein of presynaptic membrane	5
Synaptosome- associated protein + H ₂ O		Clostridium sp.	i.e. SNAP 25, protein of presynaptic membrane	13

COFACTOR ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

METAL IONS	ORGANISM	COMMENTARY	LITERATURE
More	<i>Clostridium botulinum</i>	no involvement of cobalt, copper, iron, manganese or nickel, atomic absorption spectroscopy	<u>1</u>
More	<i>Clostridium</i> sp.	no involvement of cobalt, copper, iron, manganese or nickel, atomic absorption spectroscopy	<u>14</u>
Zinc	<i>Clostridium botulinum</i>	zinc-dependent endopeptidase (serotype BoNT/B, # <i>Clostridium botulinum</i> ,# <i>Clostridium</i> sp.# <4, 6> <4,6,12,15>; atom absorption spectroscopy <1,5,6>; 1 atom of zinc per molecule botulinum neurotoxin (MW 150000, of serotypes A, B and E, each in 2-chain form, # <i>Clostridium botulinum</i> # <1>, bound to light chain (i.e. L-chain) <5>; the L-chain of BoNT/B is a form of zinc-endopeptidase <6>; 0.8-1 gatom zinc/mol neurotoxin <6>; contains zinc binding motif of metalloendopeptidases His-Glu-X-X-His <1,5,15>; or His223-Glu-Leu-Ile-His-X-X-His230 <10>; activation requires reduction of interchain disulfide bond <4,15>	<u>1, 4, 5, 6, 10, 12, 15</u>
Zinc	<i>Clostridium barati</i>	atom absorption spectroscopy <5>; 1 atom of zinc per molecule botulinum neurotoxin (MW 150000, of serotypes A, B and E, each in 2-chain form, # <i>Clostridium botulinum</i> # <1>), bound to light chain (i.e. L-chain) <5>; contains zinc binding motif of metalloendopeptidases His-Glu-X-X-His <5>	<u>5</u>
Zinc	<i>Clostridium butyricum</i>	atom absorption spectroscopy <5>; 1 atom of zinc per molecule botulinum neurotoxin (MW 150000, of serotypes A, B and E, each in 2-chain form, # <i>Clostridium botulinum</i> # <1>), bound to light chain (i.e. L-chain) <5>; contains zinc binding motif of metalloendopeptidases His-Glu-X-X-His <5>	<u>5</u>
Zinc	<i>Clostridium</i> sp.	zinc-dependent endopeptidase (serotype BoNT/B, # <i>Clostridium botulinum</i> ,# <i>Clostridium</i> sp.# <4, 6> <6,13,14>; atom absorption spectroscopy <6,14>; 1 atom of zinc per molecule botulinum neurotoxin (MW 150000, of serotypes A, B and E, each in 2-chain form, # <i>Clostridium botulinum</i> # <1>), bound to light chain (i.e. L-chain) <14>; the L-chain of BoNT/B is a form of zinc-endopeptidase <6>; 0.8-1 gatom zinc/mol neurotoxin <6>	<u>6, 13, 14</u>

INHIBITORS	ORGANISM	COMMENTARY	LITERATURE	IMAGE
1,10-Phenanthroline	<i>Clostridium botulinum</i>		<u>1, 15</u>	2D-image
1,10-Phenanthroline	<i>Clostridium</i> sp.	r, Zn2+ restores <14>	<u>14</u>	2D-image
Ala-Ser-Gln-Phe-Glu-Thr-Ser	<i>Clostridium botulinum</i>	synthetic peptide containing cleavage site of synaptobrevin, inhibits toxin action on buccal ganglion of <i>Aplysia californica</i> , serotype BoNT/B, not A or E	<u>4</u>	2D-image
Captopril	<i>Clostridium botulinum</i>	serotype BoNT/B <4>	<u>4, 5, 15</u>	2D-image
Captopril	<i>Clostridium barati</i>	-	<u>5</u>	2D-image
Captopril	<i>Clostridium butyricum</i>	-	<u>5</u>	2D-image
Captopril	<i>Clostridium</i> sp.	-	<u>13, 14</u>	2D-image
Dipicolinic acid	<i>Clostridium botulinum</i>	-	<u>1</u>	2D-image
EDTA	<i>Clostridium botulinum</i>	r, Zn2+ restores <1>; serotype BoNT/B <4>	<u>1, 4, 15</u>	2D-image
EDTA	<i>Clostridium</i> sp.	r, Zn2+ restores <14>	<u>13, 14</u>	2D-image
Gln-Phe-Glu-Thr	<i>Clostridium botulinum</i>	synthetic peptide containing cleavage site of synaptobrevin, inhibits toxin action on buccal ganglion of <i>Aplysia californica</i> , serotype BoNT/B, not A or E	<u>4</u>	2D-image

ACTIVATING COMPOUND	ORGANISM	COMMENTARY	LITERATURE	IMAGE
Proteases	<i>Clostridium botulinum</i>	activation by rapid cleavage of MW 150000 polypeptide chain and generation of active di-chain neurotoxin <5,6>; bacterial or tissue proteases <5>	<u>5,6</u>	-
Proteases	<i>Clostridium barati</i>	activation by rapid cleavage of MW 150000 polypeptide chain and generation of active di-chain neurotoxin <5>; bacterial or tissue proteases <5>	<u>5</u>	-

Proteases	Clostridium butyricum	activation by rapid cleavage of MW 150000 polypeptide chain and generation of active di-chain neurotoxin <5>; bacterial or tissue proteases <5>	5
Proteases	Clostridium sp.	activation by rapid cleavage of MW 150000 polypeptide chain and generation of active di-chain neurotoxin <6>	6

KM VALUE [mM] KM VALUE [mM] Maximum SUBSTRATE ORGANISM COMMENTARY LITERATURE IMAGE
 No entries in this field

Ki VALUE [mM] Ki VALUE [mM] Maximum INHIBITOR ORGANISM COMMENTARY LITERATURE IMAGE
 No entries in this field

TURNOVER NUMBER TURNOVER NUMBER MAXIMUM SUBSTRATE ORGANISM COMMENTARY LITERATURE IMAGE
 No entries in this field

SPECIFIC ACTIVITY SPECIFIC ACTIVITY MAXIMUM ORGANISM COMMENTARY LITERATURE
 [μM/min/mg]

No entries in this field

pH OPTIMUM pH MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

pH RANGE pH RANGE MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

TEMPERATURE OPTIMUM	TEMPERATURE OPTIMUM	MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
37	-	-	Clostridium botulinum	assay at	<u>4, 6, 12, 15</u>
37	-	-	Clostridium sp.	assay at	<u>6, 13, 14</u>

TEMPERATURE RANGE TEMPERATURE MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

SOURCE TISSUE ORGANISM COMMENTARY LITERATURE

No entries in this field

LOCALIZATION	ORGANISM	COMMENTARY	GeneOntology No.	LITERATURE
cytosol	Clostridium botulinum	accumulates until bacterial lysis	<u>GO:0005829</u>	<u>5, 6</u>
cytosol	Clostridium barati	accumulates until bacterial lysis	<u>GO:0005829</u>	<u>5</u>
cytosol	Clostridium butyricum	accumulates until bacterial lysis	<u>GO:0005829</u>	<u>5</u>
cytosol	Clostridium sp.	accumulates until bacterial lysis	<u>GO:0005829</u>	<u>6</u>

ACCESSION CODE ENTRY NAME ORGANISM NO. OF AA MOLECULAR WEIGHT[Da] SOURCE Sequence
 No entries in this field

PDB ORGANISM

1E1H, download Clostridium botulinum

1EPW, download Clostridium botulinum

1F31, download Clostridium botulinum

1F82, download Clostridium botulinum

1F83, download Clostridium botulinum

1FQH, download Clostridium botulinum

1G9A, download Clostridium botulinum

[1G9B, download](#) Clostridium botulinum
[1G9C, download](#) Clostridium botulinum
[1G9D, download](#) Clostridium botulinum
[1I1E, download](#) Clostridium botulinum
[3BTA, download](#) Clostridium botulinum

MOLECULAR WEIGHT	MOLECULAR WEIGHT MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
155000	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/B, calculated from amino acid sequence	<u>8</u>
152000	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/E, calculated from amino acid sequence	<u>8</u>
150000	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/A, SDS-PAGE, calculated from amino acid sequence	<u>8</u>
149500	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/A, calculated from nucleotide sequence	<u>9</u>
149400	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/A, calculated from nucleotide sequence	<u>10</u>
148700	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/C1, calculated from nucleotide sequence	<u>3</u>
146900	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/D, calculated from nucleotide sequence	<u>2</u>
additional information	-	Clostridium botulinum	amino acid content <8>; comparison of amino acid sequences of H- and L-chains of serotypes A, B and E <8>; comparison of amino acid sequences of botulinum serotype BoNT/A and tetanus neurotoxin <9,10>; amino acid sequence similarity of clostridial neurotoxins	<u>8</u> , <u>9</u> , <u>10</u>
additional information	-	Clostridium sp.	amino acid content; comparison of amino acid sequences of H- and L-chains of serotypes A, B and E; comparison of amino acid sequences of botulinum serotype BoNT/A and tetanus neurotoxin; amino acid sequence similarity of clostridial neurotoxins <14>	<u>14</u>

SUBUNITS	ORGANISM	COMMENTARY	LITERATURE
Dimer	Clostridium botulinum	1 * 50000 + 1 * 102000, Clostridium botulinum, serotype BoNT/E, calculated from amino acid sequence, 1 * 51000 + 1 * 104000, Clostridium botulinum, serotype BoNT/B, calculated from amino acid sequence, 1 * 53000 + 1 * 97000, Clostridium botulinum, serotype BoNT/A, calculated from amino acid sequence	<u>8</u>
More	Clostridium botulinum	synthesized as single-chain polypeptide of about MW 150000, proteolytic activation yields 2-chain neurotoxin with N-terminal light (MW 50000) and C-terminal heavy chains (MW 100000) connected by single disulfide bonds <2,3,6>; serotype BoNT/E: single-chain polypeptide, serotype BoNT/B: mixture of single- and 2-chain molecules, serotype BoNT/A: 2-chain molecule <8>	<u>2</u> , <u>3</u> , <u>6</u> , <u>8</u>
More	Clostridium sp.	synthesized as single-chain polypeptide of about MW 150000, proteolytic activation yields 2-chain neurotoxin with N-terminal light (MW 50000) and C-terminal heavy chains (MW 100000) connected by single disulfide bonds <6>; serotype BoNT/E: single-chain polypeptide, serotype BoNT/B: mixture of single- and 2-chain molecules, serotype BoNT/A: 2-chain molecule	<u>6</u>

POSTTRANSLATIONAL MODIFICATION ORGANISM COMMENTARY LITERATURE

No entries in this field

Crystallization/COMMENTARY ORGANISM LITERATURE

No entries in this field

pH STABILITY pH STABILITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

TEMPERATURE STABILITY TEMPERATURE STABILITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

GENERAL STABILITY ORGANISM LITERATURE

No entries in this field

ORGANIC SOLVENT ORGANISM COMMENTARY LITERATURE

No entries in this field

OXIDATION STABILITY ORGANISM LITERATURE

Clostridium botulinum 6

STORAGE STABILITY

-80°C, in 10 mM HEPES buffer, pH 7.2, 50 mM NaCl, after freezing in liquid N2, stable

ORGANISMClostridium
botulinum**COMMENTARY LITERATURE****6****Purification/COMMENTARY**

serotypes BoNT/A to F

ORGANISM

Clostridium sp.

LITERATURE**11**serotypes BoNT/A, B, E (and their H-chain and L-chain <8> <6,8>; C, D, F <6> Clostridium botulinum **6, 8****Cloned/COMMENTARY**

Clostridium botulinum <2,3>; serotypes BoNT/A (3 fragments encompassing the structural gene <9> <9,10>; C1 <2,3>; or D <2>; expressed in Escherichia coli TG1 <9>

ORGANISMClostridium
botulinum**LITERATURE****2, 3, 9, 10****ENGINEERING ORGANISM COMMENTARY LITERATURE**

No entries in this field

Renatured/COMMENTARY ORGANISM LITERATURE

No entries in this field

APPLICATION ORGANISM COMMENTARY LITERATURE

No entries in this field

DISEASE**TITLE OF PUBLICATION****LINK TO PUBMED**

Blepharoptosis

[PubMed](#)

Blepharoptosis

[PubMed](#)

Botulism

[PubMed](#)

Botulism

[PubMed](#)

Botulism, Infantile

[PubMed](#)

Botulism, Infantile

[PubMed](#)

Nerve paralysis

[PubMed](#)

Nerve paralysis

[PubMed](#)Nystagmus, Pathologic Treatment of acquired nystagmus with botulinum neurotoxin A. [PubMed](#)**REF. AUTHORS****TITLE****JOURNAL****VOL.****PAGES****YEAR****ORGANISM****COMMENTARY****LINK TO PUBMED**

1 Schiavo, G.; Rossetto, O.; Santucci, A.; DasGupta, B.R.; Montecucco, C.

Botulinum neurotoxins are zinc proteins

J. Biol. Chem.

267

23479-
23483

1992

Clostridium
botulinum[PubMed](#)

2 Binz, T.; Kurazono, H.; Popoff, M.R.; Eklund, M.W.; Sakaguchi, G.; Kozaki, S.; Kriegstein, K.; Henschien, A.; Gill, D.M.; Niemann, H.

Nucleotide sequence of the gene encoding Clostridium botulinum neurotoxin type D

Nucleic
Acids Res.

18

5556

1990

Clostridium
botulinum[PubMed](#)

3	Hauser, D.; Eklund, M.W.; Kurazono, H.; Binz, T.; Niemann, H.; Gill, D.M.; Boquet, P.; Popoff, M.R.	Nucleotide sequence of Clostridium botulinum C1 neurotoxin	Nucleic Acids Res.	18	4924	1990	Clostridium botulinum	-	PubMed
4	Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; Polverino de Laureto, P.; DasGupta, B.R.; Montecucco, C.	Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin [see comments]	Nature	359	832-835	1992	Clostridium botulinum	-	PubMed
5	Montecucco, C.; Schiavo, G.	Mechanism of action of tetanus and botulinum neurotoxins	Mol. Microbiol.	13	1-8	1994	Clostridium botulinum, Clostridium barati, Clostridium butyricum	review	PubMed
6	Schiavo, G.; Montecucco, C.	Tetanus and botulism neurotoxins: isolation and assay	Methods Enzymol.	248	643-652	1995	Clostridium botulinum, Clostridium sp.	review	PubMed
7	Eisel, U.; Jarusch, W.; Goretzki, K.; Henschen, A.; Engels, J.; Weller, U.; Hudel, M.; Habermann, E.; Niemann, H.	Tetanus toxin: primary structure, expression in <i>E. coli</i>, and homology with botulinum toxins	EMBO J.	5	2495-2502	1986	Clostridium botulinum	-	PubMed
8	Saathyamoorthy, V.; DasGupta, B.R.	Separation, purification, partial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B, and E	J. Biol. Chem.	260	10461-10466	1985	Clostridium botulinum	-	PubMed
9	Thompson, D.E.; Brehm, J.K.; Oultram, J.D.; Swinfield, T.-J.; Shone, C.C.; Atkinson, T.; Mellings, J.; Minton, N.P.	The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene	Eur. J. Biochem.	189	73-81	1990	Clostridium botulinum	-	PubMed
10	Binz, T.; Kurazono, H.; Wille, M.; Frevert, J.; Wernars, K.; Niemann, H.	The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins	J. Biol. Chem.	265	9153-9158	1990	Clostridium botulinum	-	PubMed
11	Simpson, L.L.; Schmidt, J.J.; Middlebrook, J.L.	Isolation and characterization of the botulinum neurotoxins	Methods Enzymol.	165	76pp	1988	Clostridium sp.	-	-
12	Schiavo, G.; Santucci, A.; DasGupta, B.R.; Mehta, P.P.; Jontes, J.; Benfenati, F.; Wilson, M.C.; Montecucco, C.	Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds	FEBS Lett.	335	99-103	1993	Clostridium botulinum	-	PubMed
13	Schiavo, G.; Rossetto, O.; Catsicas, S.; Polverino de Laureto, P.; DasGupta, B.R.; Benfenati, F.; Montecucco, C.	Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E	J. Biol. Chem.	268	23784-23787	1993	Clostridium sp.	-	PubMed
14	Schiavo, G.; Shone, C.C.; Rossetto, O.; Alexander, F.C.G.; Montecucco, C.	Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin	J. Biol. Chem.	268	11516-11519	1993	Clostridium sp.	-	PubMed
15	Schiavo, G.; Malizio, C.; Trimble, W.S.; Polverino de Laureto, P.; Milan, G.	Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a	J. Biol.	269	20213-	1994	Clostridium	-	PubMed

Sugiyama, H.;
Johnson, E.A.;
Montecucco, C.

single Ala-Ala peptide
bond

Chem.

20216

botulinum

LINKS TO OTHER DATABASES (specific for EC-Number 3.4.24.69)

[ExPASy](#)

[Online Mendelian Inheritance in Man](#)

[KEGG](#)

NCBI: [PubMed](#), [Protein](#), [Nucleotide](#), [Structure](#), [Genome](#), [OMIM](#), [Domains](#)

[IUBMB Enzyme Nomenclature](#)

[WIT database](#)

[EMP Project](#)

[PDB database\(3D structure\)](#)

[PROSITE Database of protein families and domains](#)

[SYSTERS](#)

[Protein Mutant Database](#)